US20230287454A1 - Sequential gene editing in primary immune cells - Google Patents
Sequential gene editing in primary immune cells Download PDFInfo
- Publication number
- US20230287454A1 US20230287454A1 US18/303,080 US202318303080A US2023287454A1 US 20230287454 A1 US20230287454 A1 US 20230287454A1 US 202318303080 A US202318303080 A US 202318303080A US 2023287454 A1 US2023287454 A1 US 2023287454A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cell
- tcr
- gene
- neg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004990 primary immune cell Anatomy 0.000 title claims abstract description 49
- 238000010362 genome editing Methods 0.000 title description 110
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 80
- 108010042407 Endonucleases Proteins 0.000 claims abstract description 72
- 102000004533 Endonucleases Human genes 0.000 claims abstract description 21
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 115
- 238000010459 TALEN Methods 0.000 claims description 69
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims description 69
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 238000005520 cutting process Methods 0.000 claims description 15
- 239000000178 monomer Substances 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 10
- 210000000822 natural killer cell Anatomy 0.000 claims description 6
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 abstract description 260
- 108090000623 proteins and genes Proteins 0.000 abstract description 104
- 238000000034 method Methods 0.000 abstract description 100
- 238000011282 treatment Methods 0.000 abstract description 27
- 230000001225 therapeutic effect Effects 0.000 abstract description 26
- 238000009169 immunotherapy Methods 0.000 abstract description 11
- 230000005945 translocation Effects 0.000 abstract description 9
- 238000012239 gene modification Methods 0.000 abstract description 8
- 230000005017 genetic modification Effects 0.000 abstract description 7
- 235000013617 genetically modified food Nutrition 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 206010057248 Cell death Diseases 0.000 abstract description 3
- 230000003044 adaptive effect Effects 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract description 2
- 108091008874 T cell receptors Proteins 0.000 description 170
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 162
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 107
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 74
- 210000002865 immune cell Anatomy 0.000 description 71
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 68
- 102100031780 Endonuclease Human genes 0.000 description 51
- 238000004520 electroporation Methods 0.000 description 51
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 42
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 41
- 230000014509 gene expression Effects 0.000 description 41
- 239000000427 antigen Substances 0.000 description 40
- 108091007433 antigens Proteins 0.000 description 40
- 102000036639 antigens Human genes 0.000 description 40
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 37
- 108010065524 CD52 Antigen Proteins 0.000 description 37
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 34
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 34
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 34
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 31
- 230000026683 transduction Effects 0.000 description 30
- 238000010361 transduction Methods 0.000 description 30
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 25
- 230000007017 scission Effects 0.000 description 25
- 238000003776 cleavage reaction Methods 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 102000053602 DNA Human genes 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 22
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 22
- 108091030071 RNAI Proteins 0.000 description 21
- 230000009368 gene silencing by RNA Effects 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 21
- 102000040430 polynucleotide Human genes 0.000 description 20
- 108091033319 polynucleotide Proteins 0.000 description 20
- 239000002157 polynucleotide Substances 0.000 description 20
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 102100029198 SLAM family member 7 Human genes 0.000 description 18
- 230000004913 activation Effects 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- 230000010261 cell growth Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 102100025221 CD70 antigen Human genes 0.000 description 14
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 14
- 230000027455 binding Effects 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 description 13
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 description 13
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 description 13
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 description 13
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 230000002779 inactivation Effects 0.000 description 13
- 210000002751 lymph Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000000440 neutrophil Anatomy 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 108091028043 Nucleic acid sequence Proteins 0.000 description 11
- 230000004940 costimulation Effects 0.000 description 11
- 238000012217 deletion Methods 0.000 description 11
- 230000003394 haemopoietic effect Effects 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 10
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 10
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 10
- 101710163270 Nuclease Proteins 0.000 description 10
- 230000037430 deletion Effects 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000003780 insertion Methods 0.000 description 10
- 230000037431 insertion Effects 0.000 description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 9
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 9
- 230000000735 allogeneic effect Effects 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 9
- 238000010257 thawing Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 239000013603 viral vector Substances 0.000 description 9
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 8
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 8
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 8
- -1 OX-40 (CD134) Proteins 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 7
- 102100026008 Breakpoint cluster region protein Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 7
- 101000933320 Homo sapiens Breakpoint cluster region protein Proteins 0.000 description 7
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 7
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 7
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 description 7
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 7
- 101000874827 Thermus thermophilus (strain ATCC 27634 / DSM 579 / HB8) Dephospho-CoA kinase Proteins 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000001821 langerhans cell Anatomy 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 description 6
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 6
- 101001083151 Homo sapiens Interleukin-10 receptor subunit alpha Proteins 0.000 description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 6
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 6
- 102100030236 Interleukin-10 receptor subunit alpha Human genes 0.000 description 6
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 description 6
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 6
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 6
- 102100022748 Wilms tumor protein Human genes 0.000 description 6
- 101710127857 Wilms tumor protein Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000002659 cell therapy Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000003209 gene knockout Methods 0.000 description 6
- 210000005260 human cell Anatomy 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 108010025001 leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 210000004986 primary T-cell Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 6
- 230000009258 tissue cross reactivity Effects 0.000 description 6
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
- 239000013607 AAV vector Substances 0.000 description 5
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 5
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 5
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 description 5
- 102100032937 CD40 ligand Human genes 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 5
- 102100032768 Complement receptor type 2 Human genes 0.000 description 5
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 5
- 101000857740 Homo sapiens Probable G-protein coupled receptor 160 Proteins 0.000 description 5
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 5
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 5
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 5
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 5
- 102100024894 PR domain zinc finger protein 1 Human genes 0.000 description 5
- 102100025346 Probable G-protein coupled receptor 160 Human genes 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 108700019146 Transgenes Proteins 0.000 description 5
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 5
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 229940044683 chemotherapy drug Drugs 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000006495 integrins Human genes 0.000 description 5
- 108010044426 integrins Proteins 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 4
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 4
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 4
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 description 4
- 102100024263 CD160 antigen Human genes 0.000 description 4
- 102100038078 CD276 antigen Human genes 0.000 description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 108010007707 Hepatitis A Virus Cellular Receptor 2 Proteins 0.000 description 4
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 4
- 101000824278 Homo sapiens Acyl-[acyl-carrier-protein] hydrolase Proteins 0.000 description 4
- 101000761938 Homo sapiens CD160 antigen Proteins 0.000 description 4
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 4
- 101000884270 Homo sapiens Natural killer cell receptor 2B4 Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 4
- 101000596234 Homo sapiens T-cell surface protein tactile Proteins 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 108010043610 KIR Receptors Proteins 0.000 description 4
- 102000002698 KIR Receptors Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102100034256 Mucin-1 Human genes 0.000 description 4
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102100038081 Signal transducer CD24 Human genes 0.000 description 4
- 102100035268 T-cell surface protein tactile Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 210000003651 basophil Anatomy 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 210000003979 eosinophil Anatomy 0.000 description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000000415 inactivating effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 150000003212 purines Chemical class 0.000 description 4
- CDKIEBFIMCSCBB-UHFFFAOYSA-N 1-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-3-(1-methyl-2-phenylpyrrolo[2,3-b]pyridin-3-yl)prop-2-en-1-one;hydrochloride Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)C=CC(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-UHFFFAOYSA-N 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 3
- 102100036302 C-C chemokine receptor type 6 Human genes 0.000 description 3
- 102100037904 CD9 antigen Human genes 0.000 description 3
- 102100022436 CMRF35-like molecule 8 Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102100026549 Caspase-10 Human genes 0.000 description 3
- 102100029855 Caspase-3 Human genes 0.000 description 3
- 102100038918 Caspase-6 Human genes 0.000 description 3
- 102100038902 Caspase-7 Human genes 0.000 description 3
- 102100026548 Caspase-8 Human genes 0.000 description 3
- 108010078015 Complement C3b Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 3
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 102100026693 FAS-associated death domain protein Human genes 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 3
- 108010087819 Fc receptors Proteins 0.000 description 3
- 102000009109 Fc receptors Human genes 0.000 description 3
- 102100040754 Guanylate cyclase soluble subunit alpha-1 Human genes 0.000 description 3
- 102100040735 Guanylate cyclase soluble subunit alpha-2 Human genes 0.000 description 3
- 102100040739 Guanylate cyclase soluble subunit beta-1 Human genes 0.000 description 3
- 102100028963 Guanylate cyclase soluble subunit beta-2 Human genes 0.000 description 3
- 102100028008 Heme oxygenase 2 Human genes 0.000 description 3
- 102100035081 Homeobox protein TGIF1 Human genes 0.000 description 3
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 description 3
- 101000903742 Homo sapiens Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 3
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 description 3
- 101000868215 Homo sapiens CD40 ligand Proteins 0.000 description 3
- 101000901669 Homo sapiens CMRF35-like molecule 8 Proteins 0.000 description 3
- 101000983518 Homo sapiens Caspase-10 Proteins 0.000 description 3
- 101000741087 Homo sapiens Caspase-6 Proteins 0.000 description 3
- 101000741014 Homo sapiens Caspase-7 Proteins 0.000 description 3
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 3
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
- 101000911074 Homo sapiens FAS-associated death domain protein Proteins 0.000 description 3
- 101001038755 Homo sapiens Guanylate cyclase soluble subunit alpha-1 Proteins 0.000 description 3
- 101001038749 Homo sapiens Guanylate cyclase soluble subunit alpha-2 Proteins 0.000 description 3
- 101001038731 Homo sapiens Guanylate cyclase soluble subunit beta-1 Proteins 0.000 description 3
- 101001059095 Homo sapiens Guanylate cyclase soluble subunit beta-2 Proteins 0.000 description 3
- 101001079615 Homo sapiens Heme oxygenase 2 Proteins 0.000 description 3
- 101000596925 Homo sapiens Homeobox protein TGIF1 Proteins 0.000 description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 3
- 101001003149 Homo sapiens Interleukin-10 receptor subunit beta Proteins 0.000 description 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 3
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 3
- 101000692259 Homo sapiens Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Proteins 0.000 description 3
- 101001068027 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Proteins 0.000 description 3
- 101001068019 Homo sapiens Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Proteins 0.000 description 3
- 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 3
- 101000688930 Homo sapiens Signaling threshold-regulating transmembrane adapter 1 Proteins 0.000 description 3
- 101000863692 Homo sapiens Ski oncogene Proteins 0.000 description 3
- 101000688996 Homo sapiens Ski-like protein Proteins 0.000 description 3
- 101000740162 Homo sapiens Sodium- and chloride-dependent transporter XTRP3 Proteins 0.000 description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 101001135589 Homo sapiens Tyrosine-protein phosphatase non-receptor type 22 Proteins 0.000 description 3
- 101000617285 Homo sapiens Tyrosine-protein phosphatase non-receptor type 6 Proteins 0.000 description 3
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 description 3
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 description 3
- 102100020788 Interleukin-10 receptor subunit beta Human genes 0.000 description 3
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 3
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 3
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 3
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 3
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 3
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 3
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 3
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 3
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 3
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 102100026066 Phosphoprotein associated with glycosphingolipid-enriched microdomains 1 Human genes 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 102100034464 Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform Human genes 0.000 description 3
- 102100034470 Serine/threonine-protein phosphatase 2A catalytic subunit beta isoform Human genes 0.000 description 3
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 3
- 102100024453 Signaling threshold-regulating transmembrane adapter 1 Human genes 0.000 description 3
- 102100029969 Ski oncogene Human genes 0.000 description 3
- 102100024451 Ski-like protein Human genes 0.000 description 3
- 101000987219 Sus scrofa Pregnancy-associated glycoprotein 1 Proteins 0.000 description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 3
- 108091007178 TNFRSF10A Proteins 0.000 description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 3
- 102100024568 Tumor necrosis factor ligand superfamily member 11 Human genes 0.000 description 3
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 3
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 3
- 102100033138 Tyrosine-protein phosphatase non-receptor type 22 Human genes 0.000 description 3
- 102100021657 Tyrosine-protein phosphatase non-receptor type 6 Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960000390 fludarabine Drugs 0.000 description 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 229940125721 immunosuppressive agent Drugs 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000002213 purine nucleotide Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 3
- 229960003087 tioguanine Drugs 0.000 description 3
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 description 2
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 2
- 102100037982 Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Human genes 0.000 description 2
- 101100279855 Arabidopsis thaliana EPFL5 gene Proteins 0.000 description 2
- 102000008682 Argonaute Proteins Human genes 0.000 description 2
- 108010088141 Argonaute Proteins Proteins 0.000 description 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 102100034159 Beta-3 adrenergic receptor Human genes 0.000 description 2
- 108010051118 Bone Marrow Stromal Antigen 2 Proteins 0.000 description 2
- 101000964894 Bos taurus 14-3-3 protein zeta/delta Proteins 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100027138 Butyrophilin subfamily 3 member A1 Human genes 0.000 description 2
- 102100031172 C-C chemokine receptor type 1 Human genes 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 2
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 description 2
- 108700012439 CA9 Proteins 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 102100027221 CD81 antigen Human genes 0.000 description 2
- 102100029390 CMRF35-like molecule 1 Human genes 0.000 description 2
- 102100029382 CMRF35-like molecule 6 Human genes 0.000 description 2
- 101150031358 COLEC10 gene Proteins 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 102000004631 Calcineurin Human genes 0.000 description 2
- 108010042955 Calcineurin Proteins 0.000 description 2
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102100040835 Claudin-18 Human genes 0.000 description 2
- 108050009324 Claudin-18 Proteins 0.000 description 2
- 102100038449 Claudin-6 Human genes 0.000 description 2
- 108090000229 Claudin-6 Proteins 0.000 description 2
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 102100036466 Delta-like protein 3 Human genes 0.000 description 2
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 2
- 102100039673 Disintegrin and metalloproteinase domain-containing protein 10 Human genes 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102100038083 Endosialin Human genes 0.000 description 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 2
- 102000010451 Folate receptor alpha Human genes 0.000 description 2
- 108050001931 Folate receptor alpha Proteins 0.000 description 2
- 102000010449 Folate receptor beta Human genes 0.000 description 2
- 108050001930 Folate receptor beta Proteins 0.000 description 2
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 description 2
- 101710108873 G-protein coupled receptor 20 Proteins 0.000 description 2
- 102100031351 Galectin-9 Human genes 0.000 description 2
- 101710121810 Galectin-9 Proteins 0.000 description 2
- 102000010956 Glypican Human genes 0.000 description 2
- 108050001154 Glypican Proteins 0.000 description 2
- 108050007237 Glypican-3 Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 2
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 2
- 101000780539 Homo sapiens Beta-3 adrenergic receptor Proteins 0.000 description 2
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 description 2
- 101000984934 Homo sapiens Butyrophilin subfamily 3 member A1 Proteins 0.000 description 2
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 2
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 2
- 101100496086 Homo sapiens CLEC12A gene Proteins 0.000 description 2
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 description 2
- 101000990034 Homo sapiens CMRF35-like molecule 6 Proteins 0.000 description 2
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 2
- 101000959356 Homo sapiens Disintegrin and metalloproteinase domain-containing protein 10 Proteins 0.000 description 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 description 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 2
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 2
- 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 2
- 101001076642 Homo sapiens Inosine-5'-monophosphate dehydrogenase 2 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000971605 Homo sapiens Kita-kyushu lung cancer antigen 1 Proteins 0.000 description 2
- 101000958332 Homo sapiens Lymphocyte antigen 6 complex locus protein G6d Proteins 0.000 description 2
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 description 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 2
- 101000782865 Homo sapiens Neuronal acetylcholine receptor subunit alpha-2 Proteins 0.000 description 2
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 description 2
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000863882 Homo sapiens Sialic acid-binding Ig-like lectin 7 Proteins 0.000 description 2
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 description 2
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 2
- 101000610602 Homo sapiens Tumor necrosis factor receptor superfamily member 10C Proteins 0.000 description 2
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 2
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 2
- 101000662009 Homo sapiens UDP-N-acetylglucosamine pyrophosphorylase Proteins 0.000 description 2
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 102100034980 ICOS ligand Human genes 0.000 description 2
- 101710093458 ICOS ligand Proteins 0.000 description 2
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 2
- 102100020744 Immunoglobulin iota chain Human genes 0.000 description 2
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 description 2
- 101710107067 Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 description 2
- 102100025891 Inosine-5'-monophosphate dehydrogenase 2 Human genes 0.000 description 2
- 102100025390 Integrin beta-2 Human genes 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 102100020787 Interleukin-11 receptor subunit alpha Human genes 0.000 description 2
- 101710101479 Interleukin-11 receptor subunit alpha Proteins 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100021533 Kita-kyushu lung cancer antigen 1 Human genes 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 101000839464 Leishmania braziliensis Heat shock 70 kDa protein Proteins 0.000 description 2
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 description 2
- 101710196509 Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 102100038210 Lymphocyte antigen 6 complex locus protein G6d Human genes 0.000 description 2
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 2
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 2
- 101710157884 Lymphocyte antigen 75 Proteins 0.000 description 2
- 108010064171 Lysosome-Associated Membrane Glycoproteins Proteins 0.000 description 2
- 102000014944 Lysosome-Associated Membrane Glycoproteins Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 description 2
- 101710178381 Melanoma antigen preferentially expressed in tumors Proteins 0.000 description 2
- 102100039373 Membrane cofactor protein Human genes 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102100023123 Mucin-16 Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 2
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 102100035585 Neuronal acetylcholine receptor subunit alpha-2 Human genes 0.000 description 2
- 102100028762 Neuropilin-1 Human genes 0.000 description 2
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 description 2
- 102100032364 Pannexin-3 Human genes 0.000 description 2
- 101710165197 Pannexin-3 Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 102100026181 Placenta-specific protein 1 Human genes 0.000 description 2
- 108050005093 Placenta-specific protein 1 Proteins 0.000 description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 2
- 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 2
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 102100037686 Protein SSX2 Human genes 0.000 description 2
- 101710149284 Protein SSX2 Proteins 0.000 description 2
- 108010025832 RANK Ligand Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 102100027610 Rho-related GTP-binding protein RhoC Human genes 0.000 description 2
- 108010081734 Ribonucleoproteins Proteins 0.000 description 2
- 102000004389 Ribonucleoproteins Human genes 0.000 description 2
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 2
- 101150114242 SAMHD1 gene Proteins 0.000 description 2
- 102000014105 Semaphorin Human genes 0.000 description 2
- 108050003978 Semaphorin Proteins 0.000 description 2
- 102100029946 Sialic acid-binding Ig-like lectin 7 Human genes 0.000 description 2
- 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 2
- 102000012010 Sialomucins Human genes 0.000 description 2
- 108010061228 Sialomucins Proteins 0.000 description 2
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 description 2
- 101710176444 Sperm surface protein Sp17 Proteins 0.000 description 2
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- 102100024990 Tetraspanin-10 Human genes 0.000 description 2
- 101710133601 Tetraspanin-10 Proteins 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108090000253 Thyrotropin Receptors Proteins 0.000 description 2
- 102100029337 Thyrotropin receptor Human genes 0.000 description 2
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 description 2
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 2
- 102100040115 Tumor necrosis factor receptor superfamily member 10C Human genes 0.000 description 2
- 102000018594 Tumour necrosis factor Human genes 0.000 description 2
- 108050007852 Tumour necrosis factor Proteins 0.000 description 2
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 2
- 102100037921 UDP-N-acetylglucosamine pyrophosphorylase Human genes 0.000 description 2
- 102000013532 Uroplakin II Human genes 0.000 description 2
- 108010065940 Uroplakin II Proteins 0.000 description 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 102100039490 X antigen family member 1 Human genes 0.000 description 2
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 2
- 101710097851 Zinc transporter ZIP6 Proteins 0.000 description 2
- 238000010317 ablation therapy Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 108010034034 alpha-1,6-mannosylglycoprotein beta 1,6-N-acetylglucosaminyltransferase Proteins 0.000 description 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003432 anti-folate effect Effects 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 229940127074 antifolate Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 101150010487 are gene Proteins 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229940112129 campath Drugs 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 238000004163 cytometry Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012350 deep sequencing Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 2
- 239000004052 folic acid antagonist Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006028 immune-suppresssive effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010073531 rhoC GTP-Binding Protein Proteins 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 230000004572 zinc-binding Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 1
- 102000012758 APOBEC-1 Deaminase Human genes 0.000 description 1
- 108010079649 APOBEC-1 Deaminase Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102100022907 Acrosin-binding protein Human genes 0.000 description 1
- 101710107749 Acrosin-binding protein Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 101710096292 Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101710096294 Adhesion G protein-coupled receptor E5 Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 230000020955 B cell costimulation Effects 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 101710149814 C-C chemokine receptor type 1 Proteins 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 101710112613 C-C motif chemokine 13 Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 1
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 101710155834 C-C motif chemokine 7 Proteins 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 108010011491 CD11c Antigen Proteins 0.000 description 1
- 102100024210 CD166 antigen Human genes 0.000 description 1
- 102100021992 CD209 antigen Human genes 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- 102000013135 CD52 Antigen Human genes 0.000 description 1
- 108010084313 CD58 Antigens Proteins 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102000024905 CD99 Human genes 0.000 description 1
- 108060001253 CD99 Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100289995 Caenorhabditis elegans mac-1 gene Proteins 0.000 description 1
- 101100518995 Caenorhabditis elegans pax-3 gene Proteins 0.000 description 1
- 101100351961 Caenorhabditis elegans pgp-1 gene Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010083702 Chemokine CCL21 Proteins 0.000 description 1
- 108010083698 Chemokine CCL26 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010028777 Complement C8 Proteins 0.000 description 1
- 102000016916 Complement C8 Human genes 0.000 description 1
- 108010027644 Complement C9 Proteins 0.000 description 1
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 1
- 102100031037 Complement component C9 Human genes 0.000 description 1
- 102100025680 Complement decay-accelerating factor Human genes 0.000 description 1
- 101710143772 Complement receptor type 2 Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102000002427 Cyclin B Human genes 0.000 description 1
- 108010068150 Cyclin B Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 description 1
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 description 1
- 102100039061 Cytokine receptor common subunit beta Human genes 0.000 description 1
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102000050554 Eph Family Receptors Human genes 0.000 description 1
- 108091008815 Eph receptors Proteins 0.000 description 1
- 101000809594 Escherichia coli (strain K12) Shikimate kinase 1 Proteins 0.000 description 1
- 101000759376 Escherichia phage Mu Tail sheath protein Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 description 1
- 102000027583 GPCRs class C Human genes 0.000 description 1
- 108091008882 GPCRs class C Proteins 0.000 description 1
- 102100021260 Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Human genes 0.000 description 1
- 102100021023 Gamma-glutamyl hydrolase Human genes 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000006481 HIV Receptors Human genes 0.000 description 1
- 108010083930 HIV Receptors Proteins 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 description 1
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 description 1
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 1
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 description 1
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 description 1
- 101000894906 Homo sapiens Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 1 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101000604993 Homo sapiens Lysosome-associated membrane glycoprotein 2 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 description 1
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101100407307 Homo sapiens PDCD1LG2 gene Proteins 0.000 description 1
- 101000863978 Homo sapiens Protein downstream neighbor of Son Proteins 0.000 description 1
- 101001132524 Homo sapiens Retinoic acid early transcript 1E Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000612838 Homo sapiens Tetraspanin-7 Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102100027735 Hyaluronan mediated motility receptor Human genes 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102100022341 Integrin alpha-E Human genes 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000000426 Integrin alpha6 Human genes 0.000 description 1
- 108010041100 Integrin alpha6 Proteins 0.000 description 1
- 102100033016 Integrin beta-7 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 101710123866 Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 102100037363 Killer cell immunoglobulin-like receptor 2DL1 Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- 108010005832 Leukosialin Proteins 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 108010009489 Lysosomal-Associated Membrane Protein 3 Proteins 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102100026371 MHC class II transactivator Human genes 0.000 description 1
- 102100025136 Macrosialin Human genes 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 101710146216 Membrane cofactor protein Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100025825 Methylated-DNA-protein-cysteine methyltransferase Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 101100518997 Mus musculus Pax3 gene Proteins 0.000 description 1
- 101100351020 Mus musculus Pax5 gene Proteins 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 1
- 108091007369 NEUR proteins Proteins 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 241000169176 Natronobacterium gregoryi Species 0.000 description 1
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- KUIFHYPNNRVEKZ-VIJRYAKMSA-N O-(N-acetyl-alpha-D-galactosaminyl)-L-threonine Chemical compound OC(=O)[C@@H](N)[C@@H](C)O[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1NC(C)=O KUIFHYPNNRVEKZ-VIJRYAKMSA-N 0.000 description 1
- 102100037589 OX-2 membrane glycoprotein Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102100040891 Paired box protein Pax-3 Human genes 0.000 description 1
- 101710149060 Paired box protein Pax-3 Proteins 0.000 description 1
- 102100037504 Paired box protein Pax-5 Human genes 0.000 description 1
- 101710149067 Paired box protein Pax-5 Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 102100037891 Plexin domain-containing protein 1 Human genes 0.000 description 1
- 108050009432 Plexin domain-containing protein 1 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710094466 Proteasome subunit beta type-9 Proteins 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 238000012180 RNAeasy kit Methods 0.000 description 1
- 101150066681 Rae1 gene Proteins 0.000 description 1
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 description 1
- 101710138747 Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100033964 Retinoic acid early transcript 1E Human genes 0.000 description 1
- 101710083287 SLAM family member 7 Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 102100027744 Semaphorin-4D Human genes 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 description 1
- 102100032855 Sialoadhesin Human genes 0.000 description 1
- 102100034258 Sialomucin core protein 24 Human genes 0.000 description 1
- 102000008115 Signaling Lymphocytic Activation Molecule Family Member 1 Human genes 0.000 description 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 101710185775 Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100040952 Tetraspanin-7 Human genes 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100030859 Tissue factor Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 1
- 102100022405 Tripartite motif-containing protein 5 Human genes 0.000 description 1
- 101710130650 Tripartite motif-containing protein 5 Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- 101100351021 Xenopus laevis pax5 gene Proteins 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000004721 adaptive immunity Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 108010058061 alpha E integrins Proteins 0.000 description 1
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 108700010039 chimeric receptor Proteins 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000030414 genetic transfer Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000002602 induced regulatory T cell Anatomy 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 108010021315 integrin beta7 Proteins 0.000 description 1
- 230000005732 intercellular adhesion Effects 0.000 description 1
- 230000009319 interchromosomal translocation Effects 0.000 description 1
- 108040006856 interleukin-3 receptor activity proteins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 230000009320 intrachromosomal translocation Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000024631 kidney morphogenesis Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 108040008770 methylated-DNA-[protein]-cysteine S-methyltransferase activity proteins Proteins 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 108010066052 multidrug resistance-associated protein 1 Proteins 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 108091008800 n-Myc Proteins 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940002993 plasmanate Drugs 0.000 description 1
- 102000002022 plexin Human genes 0.000 description 1
- 108050009312 plexin Proteins 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000023999 pseudocleavage Effects 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 229960003452 romidepsin Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000034223 susceptibility to 2 systemic lupus erythematosus Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Definitions
- the invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci.
- the method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.
- TALE-nucleases which are fusions of a TALE binding domain with a cleavage catalytic domain have been successfully applied to primary immune cells, in particular T-cells from peripheral blood mononuclear cells (PBMC).
- TALE-nucleases are currently used to simultaneously inactivate gene sequences in T-cells originating from donors, in particular to produce allogeneic therapeutic T-Cells, in which the genes encoding TCR (T-cell receptor) and CD52 are disrupted. These cells can be endowed with chimeric antigen receptors (CAR) or recombinant TCR for treating cancer patients (US2013/0315884).
- TALE-nucleases are very specific reagents because they need to bind DNA by pairs under obligatory heterodimeric form to obtain dimerization of the cleavage domain Fok-1. Left and right heterodimer members each recognizes a different nucleic sequences of about 14 to 20 bp, together spanning target sequences of 30 to 50 bp overall specificity.
- RNA-guided nuclease system RNA-guided nuclease system [Gasiunas, Barrangou et al. (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria; PNAS 109(39):E2579-E2586]; Doudna, J. Charpentier E.
- Cpf1 is a single RNA-guided endonuclease that provides immunity in bacteria and can be adapted for genome editing in mammalian cells.
- Cell 163:759-771 endonuclease families coupled with a guide RNA molecules that have the ability to drive said nuclease to some specific genome sequences.
- Such programmable RNA-guided endonucleases are easy to produce because the cleavage specificity is determined by the sequence of the RNA guide, which can be easily designed and cheaply produced.
- the specificity of CRISPR/Cas9 although stands on shorter sequences than TAL-nucleases of about 10 pb, which must be located near a particular motif (PAM) in the targeted genetic sequence.
- PAM motif
- endonuclease systems derived from homing endonucleases (ex: I-Onul, or I-Crel), combined or not with TAL-nuclease (ex: MegaTAL) or zing-finger nucleases have also proven specificity, but with less efficiency so far.
- CARs transgenic T-cell receptors or so-called chimeric antigen receptors (CARs) (Jena et al. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 116:1035-1044).
- CARs are recombinant receptors comprising a targeting moiety that is associated with one or more signaling domains in a single fusion molecule.
- the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and heavy variable fragments of a monoclonal antibody joined by a flexible linker.
- scFv single-chain antibody
- Binding moieties based on receptor or ligand domains have also been used successfully.
- the signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains.
- First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo.
- Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), ICOS and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells.
- CARs, as well as the expression of recombinant TCRs have successfully allowed T cells to be redirected against antigens expressed by tumor cells from various malignancies including lymphomas and solid tumors.
- TCR T-cell receptor
- CAR chimeric antigen receptor
- UCART19 CD19 malignant antigen
- the TALE-nuclease was transiently expressed into the cells upon electroporation of capped mRNA to operate TCR gene disruption, whereas a cassette encoding the chimeric antigen receptor (CAR CD19) was introduced randomly into the genome using a retroviral vector.
- engineering primary immune cells is not without any consequences on the growth/physiology of such cells.
- one major challenge is to ovoid cells exhaustion/anergy that significantly reduces their immune reaction and life span. This is more likely to happen when the cells are artificially activated ahead of their infusion into the patient. It is also the case when a cell is endowed with a CAR that is too reactive.
- the inventors have explored safer means for ex-vivo delivery of endonucleases reagents into primary cells with the requirements that said cells (1) are modified at different genetic loci, (2) not bearing too many translocations, (3) produced in sufficient number to enable treating at least a hundred patients, and (4) produced in a limited time frame of less than 30 days to avoid exhaustion of the cells. They came up with the invention as described herein, where sequential gene editing is performed instead of multiplexing gene editing. Surprisingly, this occurred to be less destructive to the cells, resulting into higher quality primary immune cells.
- This invention paves the way to standard and affordable adoptive immune cell therapy treatments.
- the present invention is drawn to a method of sequential gene editing aiming to improve the genetic modification of primary human cells, especially immune cells originating from individual donors or patients.
- T-cells or NK cells have a limited life span, and although they can be expanded and activated ex-vivo by methods known in the art [Rasmussen A. M. et al. (2010) Ex-vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. Journal of Immunological Methods 355:52-60], their immune reactivity tends to reduce over time. They can also get exhausted from the moment they are collected from a donor to the moment they are reintroduced in-vivo to track down and eliminate malignant or infected cells into the patient.
- nucleotide sequence-specific reagents such as rare-cutting endonucleases
- endonucleases are used to cleave target sequences simultaneously at different loci, the risk of inter- or intra-chromosomal translocations increases significantly, which concur to a higher risk of unwanted genetic recombination or off-site mutations.
- the present invention thus primarily concerns a method comprising one or several steps of:
- the first, second and any subsequent sequence-specific reagents are introduced into said cell by electroporation, so that the method of the invention comprises:
- the first electroporation step can be performed in view of editing or modifying a gene, in such a way that the cell will better expand or get more permissive to the subsequent modification steps.
- the first step of gene editing can be performed on a receptor or surface protein, such as TCR.
- the TCR negative cells obtained by this first step can be purified by removal of the cells remaining TCR positive, such that said TCR negative cells can be cultivated and then subjected to a second step of gene editing, for instance to make them resistant to a chemotherapy drug.
- the resulting population of cells in which the second gene editing has been achieved can then be enriched in TCR negative drug resistant cells by culture in a medium containing said chemotherapy drug.
- the invention is drawn to the methods, but also to the new gene edited cells obtainable by these methods, especially new triple and quadruple gene inactivated immune cells, as well as the population of cells resulting thereof, which are useful for the preparation of therapeutic compositions.
- the present invention may be further summarized by the following items:
- FIG. 1 Examples of genes and cell functions which can be sequentially modified by gene editing according to the method of the present invention to produce engineered allogeneic primary immune T-cells. Arrows within the cell represents the various genetic loci that can be inactivated by the sequence specific nuclease reagent introduced into the T-cells.
- FIG. 2 Rationale for the sequential gene editing according to the present invention versus the multiplexing gene editing from the prior art in terms of yielding primary immune cells stacking mutations at three different loci, such as genes encoding TCR, PD1 and DCK.
- the method of the present invention ends up with a population of immune cells where at least 80% of the cells are triple mutants.
- simultaneous gene editing amounts about 50% of triple mutants. Upon cell expansion, this proportion should not much increase in the population, if not be decreasing.
- FIG. 3 Schematic representation of one embodiment of the method according to the invention, where a viral transduction step is performed between two electroporation gene editing steps.
- the viral transduction is preferably performed after a cell sorting step where the cells modified by the first gene editing modifications are purified.
- This cell sorting step reduces the overall number of cells, thereby reducing the number of viral particles to be used for the viral transduction. This can be advantageous, for instance, when TCR is first inactivated, to follow-up with stable viral transduction and expression of the CAR.
- Subsequent gene editing step can then be carried out to make the cells resistant to a drug. In such a situation, culturing or expanding the cells in a medium containing the drug allows the selection of the cells that are both TCR negative and drug resistant in view of their therapeutic use.
- FIG. 4 Schematic representation of one embodiment of the method of the invention, wherein a cell sorting step is performed between the two electroporation gene editing steps.
- FIG. 5 Schematic representation of one embodiment of the method of the invention, wherein a cell sorting step plus a viral transduction is performed between the two electroporation gene editing steps.
- FIG. 6 Schematic representation of one embodiment of the method according to the invention, where a culture step in a selective medium is performed between two electroporation gene editing steps, to select the cells that have been made resistant to a compound as per the first gene modification. This culture step increases the number of cells that are eventually modified at multiple loci after the second gene editing step.
- T-cells e.g.: Tumor Infiltrating Lymphocytes (TIL)
- TIL Tumor Infiltrating Lymphocytes
- FIG. 7 Schematic representation of one embodiment of the method according to the invention, where the first gene editing step is performed in a gene coding or regulating the expression of a surface antigen and the second gene editing step is performed in a gene coding or regulating the expression of a product that is not a surface antigen.
- a cell separation step is performed between the two gene editing steps to enrich the cells allowed to pass to the second gene editing step.
- the second gene editing step is followed by a culture step in a selective medium to favor/select expansion of the cells bearing the second gene editing.
- FIG. 8 Schematic representation of one embodiment wherein a cell sorting based on immune cells subtypes, for instance CD4+ and CD8+ cells is performed after the first gene editing step (ex: TCR inactivation) and before the second gene editing step.
- a different gene editing can be applied to the different subtypes respectively, such as for instance the inactivation of FOXP3 in CD4+ cells and the inactivation of PD1 in CD8+ cells.
- the gene edited cells from the separate batches (ex: CD8+ and CD4+) can be respectively mixed at a predetermined ratio (ex: 1 to 1) to produce more active therapeutic compositions.
- FIG. 9 Diagrams displaying the % number of cells TCR negative, CD52 negative and both TCR and CD52 negative after simultaneous gene editing (TALEN CD52 and TCR together) (see Example 1). Controls are untransfected cells, which results are represented the left columns of the diagrams
- FIG. 10 T-cell growth curve observed after the different electroporation strategies: simultaneous and sequential according to the invention (6, 20 and 40h interval between the two CD52 and TCR gene editing steps—see example 1).
- FIG. 11 Frequency of In-deletions (Indels) for 5 off-site targets (OFS1, OFS2, OFS3, OFS4 and OFS5) and TRAC and PD-1 on-site targets after simultaneous or sequential electroporation of TRAC and PD-1 TALEN®.
- Red stars highlight the abrogation of off-site 3 (OFS3) target cleavage by the method according to the invention (see example 2).
- FIG. 12 Diagrams showing the growth of the engineered cells populations overtime from Day 5 (D5) post thawing to Day 15 (D15) with respect to the different gene editing strategies detailed in Example 3 and Table 2.
- FIG. 13 Schematic representation of workflow for the generation of triple KO CAR T cells, as carried out in example 4.
- FIG. 14 Diagram displaying the triple KO efficacy (% number TCR/B2M and PD1 negative cells), in two different donors using indicated doses of mRNA enconding TRAC, ⁇ 2m and PD-1 TALEN®s that were electroporated either simultaneously (Sim.) or sequentially (Seq.), resulting into [TCR] neg [ ⁇ 2m] neg [PD1] neg therapeutically effective number of cells originating from donors, as explained in Example 4.
- FIG. 15 Diagrams showing cytotoxic activity on Raji cells at different effector to target ratios (E:T) of CD22 CAR-T cells that were either untransfected with TALEN® reagents (WT: black) or TALEN® transfected sequentially (dark grey) or TALEN® transfected simultaneously (light grey).
- Table 1 List of genes involved into immune cells inhibitory pathways
- Table 2 gene editing efficiency of various sequential gene editing strategies according to the invention as presented in Example 3 (percentage of gene edited cells based on numbers of CD38, TCR and/or CD52 negative cells; D4, D5 and D6 are the number of days after thawing frozen primary cells).
- Table 3 Sequence of TALEN® used in the examples.
- Table 4 Selection of antigen markers of various cancers found to be expressed on the surface of T-cells. The inactivation of the genes encoding these antigen markers is proposed as part of one of one of the gene editing steps according to the invention, especially when the engineered immune cells are endowed with chimeric antigen receptors targeting these very antigens.
- the present invention relates to methods to perform genome modification in multiple loci in primary cells through sequential electroporation steps, spaced by cell culture, sorting and/or expansion phase(s).
- these methods comprise the steps of:
- primary cell or “primary cells” are intended cells taken directly from living tissue (e.g. biopsy material) and established for growth in vitro for a limited amount of time, meaning that they can undergo a limited number of population doublings. Primary cells are opposed to continuous tumorigenic or artificially immortalized cell lines.
- Non-limiting examples of such cell lines are CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells; Molt 4 cells.
- Primary cells are generally used in cell therapy as they are deemed more functional and less tumorigenic.
- primary immune cells are provided from donors or patients through a variety of methods known in the art, as for instance by leukapheresis techniques as reviewed by Schwartz J. et al. (Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue (2013) J Clin Apher. 28(3):145-284).
- the primary immune cells according to the present invention can also be differentiated from stem cells, such as cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells (HSC) and induced pluripotent stem cells (iPS).
- stem cells such as cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells (HSC) and induced pluripotent stem cells (iPS).
- immune cell is meant a cell of hematopoietic origin functionally involved in the initiation and/or execution of innate and/or adaptive immune response, such as typically CD3 or CD4 positive cells.
- the immune cell according to the present invention can be a dendritic cell, killer dendritic cell, a mast cell, a NK-cell, a B-cell or a T-cell selected from the group consisting of inflammatory T-lymphocytes, cytotoxic T-lymphocytes, regulatory T-lymphocytes or helper T-lymphocytes.
- Cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and from tumors, such as tumor infiltrating lymphocytes.
- said immune cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection.
- said cell is part of a mixed population of immune cells which present different phenotypic characteristics, such as comprising CD4, CD8 and CD56 positive cells.
- nucleic acid reagent is meant a nucleic acid molecule that contributes to an endonuclease catalytic reaction in the target cell, itself or as a subunit of a complex, preferably leading to the cleavage of a nucleic acid sequence target.
- the endonuclease reagents of the invention are generally sequence-specific reagents, meaning that they can induce DNA cleavage in the cells at predetermined loci, referred to by extension as “gene targets”.
- the nucleic acid sequence which is recognized by the sequence specific reagents is referred to as “target sequence”. Said target sequence is usually selected to be rare or unique in the cell's genome, and more extensively in the human genome, as can be determined using software and data available from human genome databases, such as http://www.ensembl.org/index.html.
- “Rare-cutting endonucleases” are sequence-specific endonuclease reagents of choice, insofar as their recognition sequences generally range from 10 to 50 successive base pairs, preferably from 12 to 30 bp, and more preferably from 14 to 20 bp.
- the endonuclease reagent is transiently expressed into the cells, meaning that said reagent is not supposed to integrate into the genome or persist over a long period of time, such as be the case of RNA, more particularly mRNA, proteins or complexes mixing proteins and nucleic acids (e.g.: Ribonucleoproteins).
- RNA more particularly mRNA
- proteins or complexes mixing proteins and nucleic acids e.g.: Ribonucleoproteins.
- the endonuclease reagent is degraded by 30 hours, preferably by 24, more preferably by 20 hours after transfection.
- said endonuclease reagent is a nucleic acid encoding an “engineered” or “programmable” rare-cutting endonuclease, such as a homing endonuclease as described for instance by Arnould S., et al. (WO2004067736), a zing finger nuclease (ZFN) as described, for instance, by Urnov F., et al. (Highly efficient endogenous human gene correction using designed zinc-finger nucleases (2005) Nature 435:646-651), a TALE-Nuclease as described, for instance, by Mussolino et al.
- an “engineered” or “programmable” rare-cutting endonuclease such as a homing endonuclease as described for instance by Arnould S., et al. (WO2004067736), a zing finger nuclease (ZFN) as described, for instance, by Urnov F
- the endonuclease reagent is preferentially under RNA form to allow transient endonuclease activity of said reagent into the target cell and make the entire capsule biodegradable in-vivo.
- the endonuclease reagent is under the form of a mRNA for the expression of the rare cutting endonuclease into the cells.
- the endonuclease under mRNA form is preferably synthetized with a cap to enhance its stability according to techniques well known in the art, as described, for instance, by Kore A. L., et al. (Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization (2009) J Am Chem Soc. 131(18):6364-5).
- TALE-nuclease Due to their higher specificity, TALE-nuclease have proven to be particularly appropriate for therapeutic applications, especially under heterodimeric forms—i.e. working by pairs with a “right” monomer (also referred to as “5” or “forward”) and “left” monomer (also referred to as “3” or “reverse”) as reported for instance by Mussolino et al. (TALEN ⁇ facilitate targeted genome editing in human cells with high specificity and low cytotoxicity (2014) Nucl. Acids Res. 42(10): 6762-6773).
- the endonuclease reagent is a RNA-guide to be used in conjunction with a RNA guided endonuclease, such as Cas9 or Cpf1, as per, inter alia, the teaching by Doudna, J., and Chapentier, E., (The new frontier of genome engineering with CRISPR-Cas9 (2014) Science 346 (6213):1077), which is incorporated herein by reference.
- a RNA guided endonuclease such as Cas9 or Cpf1
- engineered rare-cutting endonuclease are sequence specific unique reagents, it cannot be excluded that, in some instances, they can promote or induce some chromosomal rearrangements, especially when several gene loci need to be cleaved in the same cell.
- the inventors have more particularly sought for lowering this risk without reducing the yield of the engineered cells when treated with any of the above endonuclease reagents (i.e. maintaining high gene KO efficacy and high cellular viability).
- the present invention thus provides a method allowing stacking gene editing in mammalian cells, while preventing undesirable genome deletions or translocations.
- genomic editing is meant, throughout the present specification, any methods by which a genomic sequence is modified by insertion, deletion or replacement at a selected locus by using at least an enzyme that cleaves phosphodiester bond within a polynucleotide chain.
- the method of the present invention can be associated with other methods involving physical of genetic transformations, such as a viral transduction or transfection using nanoparticles, in particular for transient expression of exogenous genetic sequences.
- the invention can be applied to human immune cells, in particular activated T-cells by alternating transfection (preferably by electroporation) and culture steps. Examples of such cycles as delineated below as examples:
- the above cycle may be combined with each other depending on the number of the different endonuclease reagents to be used sequentially.
- each gene editing step targets one locus at a time.
- sequence-specific endonuclease reagents can be combined with other types of cell transformation not involving sequence specific endonuclease reagents, such as a retroviral transduction.
- a retroviral transduction This is of particular interest, for instance, for the production of primary immune cells expressing a recombinant receptors, such as a chimeric antigen receptor (CAR) or a recombinant TCR.
- CAR chimeric antigen receptor
- TCR recombinant TCR
- Such chimeric antigen receptors are generally encoded by exogenous sequences which are introduced into cells by means of viral vectors, in particular lentiviral vectors. It is therefore advantageous to combine the sequential gene editing steps of the present invention with viral transduction steps, such as illustrated in FIGS. 3 , 5 , 6 and 7 .
- the transduction step may also take place prior to a gene editing step, when, for instance, vector introduces a template DNA into the primary cell to be integrated at a locus during the subsequent gene editing step.
- the sequence-specific endonuclease reagent is then introduced into the cell to promote the integration of said exogenous DNA at said locus.
- One preferred aspect is a method of the present invention comprising a first gene editing step, followed by a transduction step involving an AAV vector comprising an exogenous sequence to be integrated at a predetermined locus, prior to a second gene editing step wherein the exogenous DNA comprised in the AAV vector is integrated at said predetermined locus.
- the sequential gene editing method may combine single gene editing steps (TNx) with multiplexing gene editing steps (TNx/TNx).
- different endonuclease reagents may be used at different/multiple loci together.
- Endonucleases have different types of cleavage signatures: some of them can create “blunt ends”, such as CRISPR, 5′ “cohesive ends” such as zing Finger nucleases or TALE-nucleases or 3′ “cohesive ends” by using homing endonucleases. Combinations of endonuclease reagents can be made based on the type of cleavage sought.
- One preferred aspect of the invention is the combined use of endonuclease reagents creating different types of cleavage signatures to reduce the deletions or translocations occurring at/or between the different gene-edited loci.
- the primary immune cells are cultivated for an interval of time (h) as referred to above that is more than 10 hours, preferably from 12 to 72 hours and more preferably from 12 to 48 hours.
- a purification step can be performed between general step b) and c), as also illustrated in FIGS. 4 , 7 and 13 .
- This purification step can be performed for the sake of purity by any standard method known in the art.
- the purification step can help to select the cells which have undergone the gene editing achieved in step a).
- the purification can thus rely on the product resulting from the first gene editing reaction, such as a product resulting from the modification or insertion of a genetic sequence at said first locus, or the absence of a gene product in case of a deletion of such genetic sequence.
- the first gene editing step may help the expression of receptors or membrane proteins, which make the immune cells more receptive to the second gene editing step.
- the cells can also become more receptive to viral vectors transduction if genes involved into viral transformation are modified prior to the second gene editing.
- genes that can be targeted as part of the first gene editing step can be genes the modification of which will facilitate viral transduction or the realization of the second gene editing step or of any subsequent transduction or transfection step.
- genes can be, for instance, genes encoding cell restriction factors, such as TRIM5a (Uniprot Q9C035), APOBEC protein family (apolipoprotein B mRNA editing enzyme), and SAMHD1 (Uniprot Q9Y3Z3).
- cell restriction factors is meant molecules that directly and dominantly cause a significant decrease in viral infectivity.
- TRIM5a for instance, is a protein known to mediate/inhibit lentiviral, such as HIV, entry into immune cells (Stremlau M, et al.
- TRIM5a, SAMHD1 or proteins of APOBEC family as part of one of the gene editing steps of the present invention can increase the infectivity of primary cells to viral vectors during subsequent transduction steps.
- the invention provides that steps a) to d) of the general method are performed within 240 hours, preferably within 120 hours, more preferably within 96 hours, even more preferably within 72 hours.
- This limited period of time allows better recovery of the primary immune cells and limits their exhaustion.
- Limited exhaustion can be controlled at different steps during the process by one skilled in the art by using specific exhaustion markers such as reviewed by Wherry, J. A. (T cell exhaustion (2011) Nature Immunology 12:492-499).
- the transfection step T such as steps a) and c) in the general method previously described, as well as any further steps TN (where N is the number of gene editing steps) are performed by electroporation.
- the method according to the present invention can comprise at least one further step of submitting the primary immune cell to a third electroporation to introduce at least a third sequence-specific reagent into said cell.
- Such electroporation steps are typically performed in closed chambers comprising parallel plate electrodes producing a pulse electric field between said parallel plate electrodes greater than 100 volts/cm and less than 5,000 volts/cm, substantially uniform throughout the treatment volume such as described in WO/2004/083379, which is incorporated by reference, especially from page 23, line 25 to page 29, line 11.
- One such electroporation chamber preferably has a geometric factor (cm ⁇ 1 ) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm 3 ), wherein the geometric factor is less than or equal to 0.1 cm ⁇ 1 , wherein the suspension of the cells and the sequence-specific reagent is in a medium which is adjusted such that the medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens.
- the suspension of cells undergoes one or more pulsed electric fields.
- the treatment volume of the suspension is scalable, and the time of treatment of the cells in the chamber is substantially uniform.
- the sequence specific reagent is under the form of nucleic acids, more preferably under DNA or RNA form.
- the nucleic acids can either code for a polypeptide, typically a rare cutting endonuclease a subunit thereof, or a conjugate of both a polynucleotide and a polypeptide.
- the reagents can also be under the form RNA or DNA guides directing guided endonucleases such as Cas9 or Cpf1 (RNA-guided endonucleases) or Argonaute (DNA-guided endonucleases) as recently respectively described by Zetsche, B. et al.
- the sequence-specific reagent is under mRNA form and encodes a rare-cutting endonuclease, selected from programmable RNA or DNA guided endonuclease, TALE-nuclease, Zing-finger nuclease (ZFN), a megaTAL or a homing endonuclease.
- said first and/or second sequence-specific reagent is an interference RNA (RNAi) or a polynucleotide encoding same.
- RNAi interference RNA
- a transduction step can be introduced between steps b) and c) of the general method, especially an integrative lentiviral or retroviral vector for stable expression of a transgene.
- This is particularly adapted to express chimeric antigen receptors (CAR) at the surface of the primary immune cells modified as the present invention.
- CAR chimeric antigen receptors
- Non-integrative viral vectors can also be used, as also described by the applicant in WO2015028683.
- Non integrative viral vector can be used, inter alia, as a template or donor DNA for homologous recombination or NHEJ integration of transgene into the immune cell's genome as part of the second gene editing step as per the present invention.
- the steps of the present method are generally performed at mammalian cells physiological temperature (37° C. for human cells), but certain steps of the method may be performed at non-physiological temperatures, between 30 and 37° C., or even lower between 25 and 35° C., during a limited period of time, from 30 minutes to 12 hours, preferably from 1 to 10 hours, more preferably from 1 to 5, and even more preferably from 30 minutes to 2 hours.
- performing the electroporation steps at lower temperature e.g. below about 35° C., such as at about 30° C., favors transfection efficiency.
- the present method aims particularly at producing immune cells, preferably primary immune cells, genetically modified at multiple loci, especially by gene editing, for their subsequent use in cell therapy.
- Such immune cells are generally endowed with recombinant receptors, such as CAR or recombinant TCR, which confer them higher specificity toward malignant or infected cells.
- recombinant receptors such as CAR or recombinant TCR, which confer them higher specificity toward malignant or infected cells.
- These recombinant receptors are generally encoded by exogenous polynucleotides which are introduced into the cell using viral vectors as per one of the transduction steps referred to previously.
- the CARs expressed by these cells specifically target antigen markers at the surface of malignant or infected cells, which further help said immune cells to destroy these cells in-vivo as reviewed by Sadelain M. et al. [“The basic principles of chimeric antigen receptor design” (2013) Cancer Discov. 3(4):388-98].
- CAR polypeptides comprise an antigen binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and/or a primary signaling domain, wherein said antigen binding domain binds to the tumor antigen associated with the disease.
- CARs have been described in the art, which can be used to carry out the present method, which can bind tumor antigen as diverse as one selected from: CD19 molecule (CD19); membrane spanning 4-domains A1 (MS4A1 also known as CD20); CD22 molecule (CD22); CD24 molecule (CD24); CD248 molecule (CD248); CD276 molecule (CD276 or B7H3); CD33 molecule (CD33); CD38 molecule (CD38); CD44v6; CD70 molecule (CD70); CD72; CD79a; CD79b; interleukin 3 receptor subunit alpha (IL3RA also known as CD123); TNF receptor superfamily member 8 (TNFRSF8 also known as CD30); KIT proto-oncogene receptor tyrosine kinase (CD117); V-set pre-B cell surrogate light chain 1 (VPREB1 or CD179a); adhesion G protein-coupled receptor E5 (ADGRE5 or CD97); TNF receptor superfamily member 17
- CARs are those described in the examples, which more preferably comprise an extracellular binding domain directed against one antigen selected from CD19, CD22, CD33, 5T4, ROR1, CD38, CD52, CD123, CS1, BCMA, Flt3, CD70, EGFRvIII, WT1, HSP-70 and CCL1. Even more preferred are CARs directed against CD22, CD38, 5T4, CD123, CS1, HSP-70 and CCL1. Such CARs have preferably one structure as described in WO2016120216.
- Immune cells can also express recombinant T-Cell receptors.
- T cells recognise MHC-peptide conjugates on target cells through the paired a and 6 chains of the TCR. This pairing confers the antigen specificity of the immune cell.
- One gene therapy approach has involved the molecular cloning of the TCR genes known to be specific for an antigen of choice. These chains are then introduced into T cells usually by means of a retroviral vector in a similar way as with CAR. Consequently, expression of the cloned TCR ⁇ and TCR ⁇ genes endows the transduced immune cells with a functional specificity determined by the pairing of these new genes.
- TCRs recognize processed peptides presented on MHC
- targeted antigens can be derived from the entire protein composition of the tumor cells, including intracellular proteins
- CARs are generally designed to recognize molecules expressed on the surface of target cells.
- This quality also allows TCRs to target a large number of non-surface antigens of virally infected cells and tumors associated with viral infection, such as hepatitis-associated hepatocellular carcinoma, papilloma virus-associated cervical cancer, and Epstein-Barr virus-related malignancies (Spear, T. et al. (2016). Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunology Immunotherapy: 65(6):631-649).
- Preferred recombinant TCR to be used in the present invention are those directed against antigen specific of cancer cells, such as MART-1, MAGE-1, MAGE-2, MAGE-3 MAGE-12, BAGE, GAGE, NY-ESO-1, or overexpressed in cancer cells, such as a-Fetoprotein, Telomerase catalytic protein, G-250, MUC-1, CarcinoEmbryonic antigen (CEA), p53, Her-2/Neu and WT1 [Rosenberg S. A., (2001) Progress in human tumour immunology and immunotherapy Nature. 411(6835):380-4].
- cancer cells such as MART-1, MAGE-1, MAGE-2, MAGE-3 MAGE-12, BAGE, GAGE, NY-ESO-1
- overexpressed in cancer cells such as a-Fetoprotein, Telomerase catalytic protein, G-250, MUC-1, CarcinoEmbryonic antigen (CEA), p53, Her-2/Neu and WT1 [Rosenberg S. A.,
- exogenous polynucleotide sequence encoding the recombinant receptors are generally introduced by a transduction step, which can be performed in the course of the present invention as shown for instance in FIGS. 4 , 7 and 13 by using a viral vector, such as a lentiviral vector.
- AAV vectors can be used as a DNA template for gene targeted insertion of said polyncleotide sequence encoding a recombinant receptor at a desired locus by NHEJ or homologous recombination.
- the insertion locus may be selected to disrupt an endogenous gene present at this locus, such a gene encoding a component of TCR or ⁇ 2m as previously described.
- exogenous polynucleotide sequence can be integrated at a locus preferably encoding TCR, HLA, ⁇ 2m, HLA, PD1 or CTLA4, as part of the editing steps of the present invention.
- the inventors have significantly improved the rate of gene targeted insertion into human cells by using AAV vectors from the AAV6 family.
- the method of the invention can therefore comprise a step consisting in:
- the obtained insertion of the exogenous nucleic acid sequence may then result into the introduction of genetic material, correction or replacement of the endogenous sequence, more preferably “in frame” with respect to the endogenous gene sequences at that locus.
- the method according to the invention is particularly adapted to prepare primary immune cells for allogeneic therapeutic use.
- allogeneic therapeutic use is meant that the cells originate from a donor in view of being infused into patients having a different haplotype.
- the present invention provides with an efficient method for obtaining primary cells, which can be gene edited in various gene loci involved into host-graft interaction and recognition. Other loci may also be edited in view of improving the activity, the survival or the life-time of the engineered primary cells.
- engineered immune cells are preferably primary T cells.
- FIG. 1 maps the main cell functions that can be modified by gene editing according to the present invention to improve the efficiency of the engineered immune cells. Any gene inactivation listed under each function can be combined with another to obtain a synergistic effect on the overall therapeutic potency of the immune cells.
- the present method is particularly useful for developing engineered non-alloreactive T-cells for immunotherapy and more specifically to methods for increasing the persistence and/or the engraftment of allogeneic immune cells by proceeding with at least one step of inactivation, preferably permanently, of a gene implicated in the self/non-self recognition, using preferably specific rare-cutting endonuclease.
- one of the gene editing steps aims to reduce host versus graft disease (GVHD) reaction or immune rejection upon introduction of the allogeneic cells into the recipient patient.
- GVHD host versus graft disease
- one of the sequence-specific reagents used in the method can reduce or prevent the expression of TCR in primary T-cells, such as the genes encoding TCR-alpha or TCR-beta.
- one gene editing step is to reduce or prevent the expression of the 2m protein and/or another protein involved in its regulation such as C2TA (Uniprot P33076) or in MHC recognition, such as HLA proteins. This permits the engineered immune cells to be less alloreactive when infused into patients.
- TCR and B12m are gene editing of both TCR and B12m as part of the sequential gene editing method of the present invention into T-cells or precursor cells thereof, which method can comprise the steps of introducing an exogenous polynucleotide encoding recombinant receptors, such as CARs or recombinant TCR previously mentioned, and more preferably at the TCRalpha or TCRbeta locus.
- one of the gene editing steps aims to disrupt the expression of a protein involved in immune cells inhibitory pathways, in particular those referred to in the literature as “immune checkpoint” (Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, 12:252-264).
- immune cells inhibitory pathways means any gene expression in immune cells that leads to a reduction of the cytotoxic activity of the lymphocytes towards malignant or infected cells. This can be for instance a gene involved into the expression of FOXP3, which is known to drive the activity of Tregs upon T cells (moderating T-cell activity).
- Immuno checkpoints are molecules in the immune system that either turn up a signal (co-stimulatory molecules) or turn down a signal of activation of an immune cell.
- immune checkpoints more particularly designate surface proteins involved in the ligand-receptor interactions between T cells and antigen-presenting cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide-major histocompatibility complex (MHC) molecule complexes that are recognized by the T cell receptor (TCR)).
- APCs antigen-presenting cells
- MHC peptide-major histocompatibility complex
- TCR T cell receptor
- TNF tumor necrosis factor
- activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on APCs.
- A2aR adenosine A2a receptor
- B7RP1 B7-related protein 1
- BTLA B and T lymphocyte attenuator
- GAL9 galectin 9
- HVEM herpesvirus entry mediator
- ICOS inducible T cell co-stimulator
- IL interleukin
- KIR killer cell immunoglobulin-like receptor
- TGF ⁇ transforming growth factor- ⁇
- TIM3 T cell membrane protein 3.
- one of the sequence-specific reagents used in the method can reduce or prevent the expression by the immune cell of at least one protein selected from PD1 (Uniprot Q15116), CTLA4 (Uniprot P16410), PPP2CA (Uniprot P67775), PPP2CB (Uniprot P62714), PTPN6 (Uniprot P29350), PTPN22 (Uniprot Q9Y2R2), LAG3 (Uniprot P18627), HAVCR2 (Uniprot Q8TDQ0), BTLA (Uniprot Q7Z6A9), CD160 (Uniprot 095971), TIGIT (Uniprot Q495A1), CD96 (Uniprot P40200), CRTAM (Uniprot 095727), LAIR1 (Uniprot Q6GTX8), SIGLEC7 (Uniprot Q9Y286), SIGLEC9 (Uniprot Q9Y336), CD244 (Unipro
- Preference is given to inactivation of PP1 and CTLA4, in combination with TR.
- the steps of the present method using sequence-specific endonuclease reagents can be followed by a step of contacting said engineered immune cells with at least one non-endogenous immunosuppressive polypeptide, such as a PD-L1 ligand and/or CTLA-4 Ig.
- at least one non-endogenous immunosuppressive polypeptide such as a PD-L1 ligand and/or CTLA-4 Ig.
- the gene editing step concerns genes encoding or positively regulating suppressive cytokines or metabolites or receptors thereof, in particular TGFbeta (Uniprot P01137), IL10R (Uniprot Q13651 and/or Q08334), A2aR (Uniprot P29274), GCN2 (Uniprot P15442) and PRDM1 (Uniprot 075626).
- TGFbeta Uniprot P01137
- IL10R Uniprot Q13651 and/or Q08334
- A2aR Uniprot P29274
- GCN2 Uniprot P15442
- PRDM1 Uniprot 075626
- one gene editing step is performed into a locus responsible for the sensitivity of the immune cells to compounds used in standard of care treatments for cancer or infection, such as drugs purine nucleotide analogs (PNA) or 6-Mercaptopurine (6MP) and 6 thio-guanine (6TG) commonly used in chemotherapy. Reducing or inactivating the genes involved into the mode of action of such compounds (referred to as “drug sensitizing genes”) improves the resistance of the immune cells to same.
- PNA drugs purine nucleotide analogs
- 6MP 6-Mercaptopurine
- 6TG 6 thio-guanine
- Examples of drug sensitizing gene are those encoding DCK (Uniprot P27707) with respect to the activity of PNA, such a clorofarabine et fludarabine, HPRT (Uniprot P00492) with respect to the activity of purine antimetabolites such as 6MP and 6TG, and GGH (Uniprot Q92820) with respect to the activity of antifolate drugs, in particular methotrexate.
- DCK Uniprot P27707
- HPRT Uniprot P00492
- purine antimetabolites such as 6MP and 6TG
- GGH Uniprot Q92820
- resistance to drugs can be conferred immune cells by overexpressing a drug resistance gene as an additional optional step of the present method of sequential gene editing.
- DHFR dihydrofolate reductase
- IMPDH2 inosine monophosphate dehydrogenase 2
- calcineurin Uniprot Q96LZ3, P63098 P48454, P16298 and Q08209
- MGMT methylguanine transferase
- the engineering immune cells are made resistant to drugs purine nucleotide analogs (PNA) chemotherapy drugs, such a clorofarabine et fludarabine, as part of the gene editing step.
- PNA purine nucleotide analogs
- the first gene editing step is preferably performed on a locus encoding or regulating a surface antigen, so that sorting of the engineered cells can be carried out based on the presence/absence of said surface antigen
- the second or ultimate gene editing step can be one conferring resistance of the cells to a compound, preferably a chemotherapy drug or an immune suppressive agent.
- the double or triple gene edited cells can be selected and enriched by a culture step that takes place after the second or ultimate gene editing step.
- the present method provides a first gene editing step into at least one gene encoding a T-Cell Receptor (TCR) component, in particular TCRalpha (Uniprot P01848) and TCRbeta (Uniprot P01850) and sequentially a second gene editing step into a gene expressing DCK, HPRT or GGH, to confer respectively resistance to PNA compounds, purine antimetabolites and antifolate compounds.
- TCR T-Cell Receptor
- triple gene edited cells can be obtained for therapeutic treatments, said cells having loci modified to reduce or inactivate the expression of:
- the engineering immune cells are made resistant to immune-depletion treatments, such as those involving glucocorticoids or antibodies directed against immune cells surface proteins.
- immune-depletion treatments such as those involving glucocorticoids or antibodies directed against immune cells surface proteins.
- the antibody Alemtuzumab is used to deplete CD52 positive immune cells as in many pre-cancer treatments.
- the method of the invention can comprise a gene editing step with respect to the genes encoding or regulating the expression of CD52 (Uniprot P31358) and/or GR (Glucocorticoids receptor also referred to as NR3C1—Uniprot P04150), optionally in combination with a gene editing step leading to a reduction of the inactivation of the TCR.
- This approach was previously described by Poirot, L. et al. (Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies (2013) Cancer. Res. 75:3853), but as part of a method where the different loci were simultaneously gene edited.
- Preferred engineered immune cells are those triple or quadruple gene edited cells detailed herein, in which CD52 and or GR are additionally inactivated.
- the present method allows introducing successive gene editing modifications into immune primary cells in a time frame that limits the impact of the gene editing steps on the subsequent expansion of these cells i.e. without reducing significantly production yields.
- the present invention solves the problem of producing immune cells that express recombinant receptors, such as chimeric antigen receptors (CAR), which are triply gene edited.
- CAR chimeric antigen receptors
- Representative examples of such cells obtainable according to the invention display the following phenotypes:
- [TCR] neg designate cells in which the expression of a component of the T-Cell receptor, such as TCRbeta or TCRalpha, has been reduced or impaired.
- One preferred aspect of the present invention further concerns the problem of immune cells that express chimeric antigen receptors (CAR), which target surface molecules that are also present at the surface of said very immune cells.
- CAR chimeric antigen receptors
- X can be, for instance any of the antigen listed in table 4.
- Negative impact has been observed, for instance with respect to T-cells expressing antigens CS1, CD38 or CD22 endowed with CARs targeting same: [anti-CS1 CAR] pos , [CS1] pos , [anti-CD38 CAR] pos [CD38] pos or [anti-CD70 CAR] pos [CD70] pos .
- the CAR positive primary immune cells can attack each other resulting into immune cell depletion. This is observed even when such cells were TCR negative [TCR] neg
- the present invention provides with a technical solution to this problem by providing a method, wherein gene editing steps are sequentially performed as outlined below:
- the method results into a population of engineered [antigen X CAR] pos [antigen X] neg [TCR] neg immune cells.
- Preferred engineered immune primary cells are triple gene edited cells, such as the following ones:
- the immune cells according to the present invention can be activated or expanded, even if they can activate or proliferate independently of antigen binding mechanisms.
- T-cells in particular, can be activated and expanded using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005.
- T cells can be expanded in vitro or in vivo.
- T cells are generally expanded by contact with an agent that stimulates a CD3 TCR complex and a co-stimulatory molecule on the surface of the T cells to create an activation signal for the T-cell.
- an agent that stimulates a CD3 TCR complex and a co-stimulatory molecule on the surface of the T cells to create an activation signal for the T-cell.
- chemicals such as calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), or mitogenic lectins like phytohemagglutinin (PHA) can be used to create an activation signal for the T-cell.
- PMA phorbol 12-myristate 13-acetate
- PHA phytohemagglutinin
- T cell populations may be stimulated in vitro such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore.
- a protein kinase C activator e.g., bryostatin
- a ligand that binds the accessory molecule is used for co-stimulation of an accessory molecule on the surface of the T cells.
- a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells.
- Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or, X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-g, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGF ⁇ , and TNF- or any other additives for the growth of cells known to the skilled artisan.
- Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol.
- Media can include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells.
- Antibiotics e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject.
- the target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% C02).
- T-cells that have been exposed to varied stimulation times may exhibit different characteristics
- said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded in vivo, for example in the subject's blood after administrating said cell into the subject.
- the method of the present invention described above allows producing engineered primary immune cells within a limited time frame of about 15 to 30 days, preferably between 15 and 20 days, and most preferably between 18 and 20 days so that they keep their full immune therapeutic potential, especially with respect to their cytotoxic activity.
- These cells can form or be members of populations of cells, which preferably originate from a single donor or patient. These populations of cells can be expanded under closed culture recipients to comply with highest manufacturing practices requirements and can be frozen prior to infusion into a patient, thereby providing “off the shelf” or “ready to use” therapeutic compositions.
- PBMC comprises several types of cells: granulocytes, monocytes and lymphocytes, among which from 30 to 60% of T-cells, which generally represents between 10 8 to 10 9 of primary T-cells from one donor.
- the method of the present invention generally ends up with a population of engineered cells that reaches generally more than about 10 8 T-cells, more generally more than about 10 9 T-cells, even more generally more than about 10 10 T-cells, and usually more than 10 11 T-cells.
- the T-cells are gene edited at least at two different loci.
- compositions or populations of cells can therefore be used as a medicament, especially for treating cancer, particularly for the treatment of lymphoma, but also for solid tumors such as melanomas, neuroblastomas, gliomas or carcinomas such as lung, breast, colon, prostate or ovary tumors in a patient in need thereof.
- solid tumors such as melanomas, neuroblastomas, gliomas or carcinomas such as lung, breast, colon, prostate or ovary tumors in a patient in need thereof.
- the invention is more particularly drawn to populations of primary TCR negative T-cells originating from a single donor, wherein at least 20%, preferably 30%, more preferably 50% of the cells in said population have been modified using sequence-specific reagents in at least two, preferably three different loci.
- the present invention relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:
- said populations of cells mainly comprises CD4 and CD8 positive immune cells, such as T-cells, which can undergo robust in vivo T cell expansion and can persist for an extended amount of time in-vitro and in-vivo.
- the treatments involving the engineered primary immune cells according to the present invention can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment.
- autologous it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor.
- HLA Human Leucocyte Antigen
- allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.
- said isolated cell according to the invention or cell line derived from said isolated cell can be used for the treatment of liquid tumors, and preferably of T-cell acute lymphoblastic leukemia.
- the treatment with the engineered immune cells according to the invention may be in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.
- said treatment can be administrated into patients undergoing an immunosuppressive treatment.
- the present invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent.
- the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.
- the administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation.
- the compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally.
- the cell compositions of the present invention are preferably administered by intravenous injection.
- the administration of the cells or population of cells can consist of the administration of 10 4 -10 9 cells per kg body weight, preferably 105 to 10 6 cells/kg body weight including all integer values of cell numbers within those ranges.
- the present invention thus can provide more than 10, generally more than 50, more generally more than 100 and usually more than 1000 doses comprising between 10 6 to 10 8 gene edited cells originating from a single donor's or patient's sampling.
- the cells or population of cells can be administrated in one or more doses.
- said effective amount of cells are administrated as a single dose.
- said effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient.
- the cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art.
- An effective amount means an amount which provides a therapeutic or prophylactic benefit.
- the dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
- said effective amount of cells or composition comprising those cells are administrated parenterally.
- Said administration can be an intravenous administration.
- Said administration can be directly done by injection within a tumor.
- cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients.
- agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients.
- the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycoplienolic acid, steroids, FR901228, cytokines, and irradiation.
- immunosuppressive agents such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies
- immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies
- cytoxin fludaribine
- cyclosporin FK506, rapamycin
- mycoplienolic acid steroids
- steroids FR901228
- cytokines irradiation
- the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH,
- the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan.
- subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation.
- subjects receive an infusion of the expanded immune cells of the present invention.
- expanded cells are administered before or following surgery.
- the present invention encompasses a whole range of double, triple or quadruple gene edited cells now available for therapeutic use, including any of those illustrated herein, which could not be obtained by the prior art methods. Especially, those cells are engineered with a reduced risk of unwanted recombination or translocation at the different gene edited loci, making them safer for therapeutic use.
- the primary immune cells from the donor or patient can be made less-alloreactive by performing a first gene editing step into a TCR gene or any gene implicated in the self/non-selfrecognition, and then after an expansion step, the population can be split into two subpopulations, which respectively undergo a second gene editing step that will target distinct loci in said subpopulations.
- CD4+ positive and CD8+ positive immune cells can be (see FIG. 8 ) treated separately before being pooled together at a desired ratio to increase potency of the therapeutic compositions. This method will result into subpopulations of engineered primary immune cells that will not display exactly the same properties.
- compositions of populations of primary TCR negative T-cells resulting from a single donor comprising at least two subpopulations of T-cells, said subpopulations comprising, for instance different gene edited immune checkpoint genes.
- Such sub-populations of cells can be selected, for instance, from:
- the resulting cells can be optionally transformed to express chimeric antigen receptor to provide allogeneic CAR T Cells with various specificities, in particular as part of sub-populations expressing chimeric receptors respectively directed to different surface molecules.
- Such sub-populations can be used separately or in combination with each other into compositions for therapeutic treatments, in the same way as previously described with a single population of cells.
- Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 10 base pairs (bp) in length, more preferably of 14-55 bp.
- Rare-cutting endonucleases significantly increase homologous recombination by inducing DNA double-strand breaks (DSBs) at a defined locus thereby allowing gene repair or gene insertion therapies (Pingoud, A. and G. H. Silva (2007). Precision genome surgery. Nat. Biotechnol. 25(7): 743-4.).
- Example 1 Simultaneous Vs. Sequential Electroporation of TRAC and CD52 TALE-Nucleases into T Cells
- PBMCs frozen human PBMCs (AllCells) were thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (Dynabeads, Life Technologies, Carlsbad, Calif., United States) for 3 days. After magnetic beads removal (Day 4), 5 ⁇ 106 activated T cells were transfected with 10 ⁇ g of both mRNA encoding TALEN either simultaneously or sequentially with a 6 hour, 20 hour or 40 hour intervals by using AgilePulse electroporator (BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388) protocols.
- AgilePulse electroporator BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388
- Electroporated T cells were platted back in tissue culture vessels in Xvivo hematopoietic medium (Lonza, CH-4002 Basel, Switzerland) supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 12 days. Cells were passaged every 2 or 3 days for numeration and media renewal.
- TCR and CD52 protein were measured by cytometry using specific monoclonal antibodies and a Macsquant cytometer (Miltenyi) at D10 post activation. Furthermore, T cells growth was monitored from D4 to D12, by Trypan blue exclusion cell numeration.
- FIG. 9 are presented the percentage of TCR+, CD52+, double positive TCR/CD52+ and double negative TCR/CD52 ⁇ cells measured 6 days after electroporation according to the electroporation schedule.
- the data show that 70 to 80% of TCR KO and 65 to 75% of CD52 KO is achievable whatever the electroporation conditions, sequential or simultaneous.
- the percentage of double negative cells is comparable for all the tested conditions. This validates the finding that sequential electroporation does not reduce the rate of gene editing success.
- Example 2 Simultaneous or Sequential Electroporation of mRNA Encoding TRAC and PD1 TALE-Nucleases into T Cells
- Frequency of off-site cleavage is defined by the frequency of mutated sequences (either nucleotide deletion or addition) that are generated after endonucleases cleavage and unfaithful religation of broken ends.
- the amino acid sequences used in this experiment encoding the various TALEN® heterodimers for TRAC (SEQ ID NO. 1 and 2) and PD1 (SEQ ID NO. 5 and 6) are given in Table 3)
- Potential off-site hits can be identified in silico with an algorithm according to several parameters including mainly TALE-nuclease DNA binding sequences, number of mismatches and position of those, length of the spacer between the 2 binding domains.
- TALE-nuclease DNA binding sequences numerous potential off-site targets have been identified in the human genome for TRAC and PD1 TALEN® combination.
- the 15 first target sequences with the highest score have been verified experimentally by PCR and Deep Sequencing.
- One out of the 15, “Off-Site 3” has been found to be a true off-site target since about 1% of mutagenesis events (or Insertion/deletion, InDels events) was observed when T cell were transfected simultaneously with TRAC and PD1 TALEN®.
- PBMCs frozen human PBMCs (AllCells) were thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (Dynabeads, LifeTech) for 3 days. 5 ⁇ 10 6 activated T cells were transfected with 10 ⁇ g of both TALEN mRNA either simultaneously or sequentially with a 6 hour, 20 hour or 40 hour intervals by using AgilePulse electroporator (BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388) protocols.
- AgilePulse electroporator BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388
- Electroporated T cells were platted back in tissue culture vessels in Xvivo (Lonza) media supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 6 days. Cells were passaged every 2 or 3 days for numeration and media renewal. At the end of the 6 day period, genomic DNA was extracted from transfected T cells and subjected to PCR amplification using specific primers allowing the amplification of TRAC and PD1 “On-Site” genomic targets and 5 “Off-Site” targets including “Off-Site 3”. PCR products are then purified and modified for subsequent deep sequencing analysis using the Illumina technology. About 80,000 reads for each samples were computed.
- Example 3 Simultaneous or Sequential Electroporation of CD38, TRAC and CD52 TALEN into T Cells
- frozen human PBMCs (AllCells) are thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (TransAct, Miltenyi) for 3 days.
- 10 ⁇ 106 activated T cells are transfected with 10 ⁇ g of both TALEN mRNA either simultaneously or sequentially with a 24 hour (Day 5) or 48 hour (Day 6) intervals using Cellectis proprietary AgilPulse electroporator and protocols. The following conditions have been tested and compared in terms of KO efficiency and cell growth.
- Electroporated T cells are platted back in tissue culture vessels in Xvivo (Lonza) media supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 15 days. Cells are passaged every 2 or 3 days for numeration and media renewal.
- TCR, 0038 and 0052 protein Surface expression of TCR, 0038 and 0052 protein is measured by cytometry using specific antibodies and a Canto10 cytometer (Becton-Dickinson) at 013 post thawing. Furthermore, T cells growth is monitored from Day 5 to Day 15 by Trypan blue exclusion cell numeration.
- Table 2 presents the percentage of single negative T cells (CD38-, TCR- and CD52-) and the percentage of triple negative T cells (CD38-TCR-CD52-), according to the electroporation scheduling. These data show that 65 to 74% of TCR KO, 57 to 70% of 0052 KO, thus comparable among conditions.
- the best results is obtained when 0038 and TRAC TALEN are transfected 48h prior to CD52 TALEN transfection (Table 2, row E and FIG. 12 , row E).
- the best results are obtained when CD38 and TRAC TALEN are transfected 48h prior to CD52 TALEN transfection, as for TCR and CD52 (Table 4, row E and FIG. 12 , row E).
- all tested conditions show little variation in the % of triple negative T cells ranging from 27% to 40%.
- the best percentage of triple knock out efficiency is obtained with sequential electroporation of CD38 and TRAC TALEN 48h prior to CD52 TALEN.
- T cell growth curves for all sequential electroporation conditions are comparable with best results for conditions where a 48 h interval is performed between the two electroporation shocks (conditions C, E and G of Table 4 and FIG. 12 ).
- T-cells were cultured from PBMC and activated as described in Example 1, in order to produce [TCR] neg [PD1] neg [ ⁇ 2M] neg therapeutic immune cells endowed with a CAR directed against CD22 antigen.
- the cells were edited either simultaneously or sequentially with TALEN specific for TRAC gene (SEQ ID NO. 1 and 2), PD-1 (SEQ ID NO. 9 and 6) and B2M (beta-2-microglobulin, SEQ ID NO. 10 and 11).
- the sequential protocol is illustrated in FIG. 13 .
- T-cells were transduced with lentiviral particles for the expression of CAR targeting the antigen CD22 (SEQ ID NO. 12).
- TALEN mRNA were generated from linearized plasmid DNA encoding each TALEN arm of interest.
- An in vitro RNA synthesis kit for RNA generation was used (Invitrogen #AMB1345-5). RNA was purified using the Qiagen RNAeasy Kit (#74106) and eluted into T solution from BTX (47-0002).
- T cells were electroporated with a dose response of mRNAs encoding TRAC TALEN (10 ⁇ g), PD-1 TALEN (from 30 ⁇ g to 70 ⁇ g) and B2M TALEN (from 30 ⁇ g to 70 ⁇ g) either simultaneously or sequentially with a 48 hour intervals using Cellectis proprietary AgilPulse electroporator and protocols. After each electroporation step cells were incubated for 15 minutes at 30° C. and then incubated at 37° C. Thirteen days post thawing positive T-cells were analyzed for triple KO efficacy by first re-stimulating a portion of T cells with TransACT to induce PD-1 expression.
- Triple KO T-cells were then enriched using a biotin and column based negative purification system for TCR and B2M dKO cells (Miltenyi; biotin-TCR #130-098-219, bitoin-HLA-ABC #130-101-463, Biotin beads #130-090-485, MS columns #130-042-201). Under this purification scheme, only TCR and B2M positive cells bind the MS column, and the TCR/B2M dKO cells of interest are enriched in the flowthrough fraction with 97% or greater purity. Triple KO CAR-T cells enriched for TCR/B2M dKO were further incubated for an additional two days before assessing CAR-T cells activity.
- FIG. 15 demonstrates that triple KO CD22 CAR T were as active as their wild type counter part (non gene edited T-cells endowed with the same CAR CD22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.
Description
- This application is a division of pending U.S. application Ser. No. 17/817,877, filed on Aug. 5, 2022, which is a continuation of U.S. application Ser. No. 16/314,697, filed on Jan. 2, 2019, which is a U.S. National Stage Entry under 35 U.S.C. § 371 of PCT/EP2017/066355, filed on Jun. 30, 2017, which itself claims the benefit under 35 U.S.C. 119(e) of Denmark Patent Application No. PA201670503, filed on Jul. 6, 2016, the contents of each of which are incorporated herein by reference in their entireties for all purposes.
- The instant application contains a Sequence Listing which has been submitted electronically in xml format and is hereby incorporated by reference in its entirety. Said xml copy, created on Aug. 5, 2022, is named 116983-5073-US01sequencelisting.xml and is 26,560 bytes in size.
- The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.
- The potential of gene editing in various therapies has long been envisioned by the applicant (WO2004067753), especially in the field of cell therapy, where immune cells can be genetically modified ex-vivo and then reintroduced into patients, as already described, for instance, in U.S. Pat. No. 8,921,332.
- Since the emergence of the first programmable sequence-specific reagents by the turn of the century, initially referred to as Meganucleases [Smith et al. (2006) A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucl. Acids Res. 34 (22):e149.], endonucleases reagents have rapidly evolved, offering improved specificity, safety and reliability. In particular, TALE-nucleases (WO2011072246), which are fusions of a TALE binding domain with a cleavage catalytic domain have been successfully applied to primary immune cells, in particular T-cells from peripheral blood mononuclear cells (PBMC). Such TALE-nucleases, marketed under the name TALEN®, are currently used to simultaneously inactivate gene sequences in T-cells originating from donors, in particular to produce allogeneic therapeutic T-Cells, in which the genes encoding TCR (T-cell receptor) and CD52 are disrupted. These cells can be endowed with chimeric antigen receptors (CAR) or recombinant TCR for treating cancer patients (US2013/0315884). TALE-nucleases are very specific reagents because they need to bind DNA by pairs under obligatory heterodimeric form to obtain dimerization of the cleavage domain Fok-1. Left and right heterodimer members each recognizes a different nucleic sequences of about 14 to 20 bp, together spanning target sequences of 30 to 50 bp overall specificity.
- More recently, further endonucleases reagents have been developed based on the components of the type II prokaryotic CRISPR (Clustered Regularly Interspaced Short palindromic Repeats) adaptive immune system of the bacteria S. pyogenes. This multi-component system referred to as RNA-guided nuclease system [Gasiunas, Barrangou et al. (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria; PNAS 109(39):E2579-E2586]; Doudna, J. Charpentier E. (2014) The new frontier of genome engineering with CRISPR-Cas9 Science 346 (6213):1258096], involves members of Cas9 or Cpf1 [Zetsche et al. (2015). Cpf1 is a single RNA-guided endonuclease that provides immunity in bacteria and can be adapted for genome editing in mammalian cells. Cell 163:759-771] endonuclease families coupled with a guide RNA molecules that have the ability to drive said nuclease to some specific genome sequences. Such programmable RNA-guided endonucleases are easy to produce because the cleavage specificity is determined by the sequence of the RNA guide, which can be easily designed and cheaply produced. The specificity of CRISPR/Cas9 although stands on shorter sequences than TAL-nucleases of about 10 pb, which must be located near a particular motif (PAM) in the targeted genetic sequence.
- Other endonuclease systems derived from homing endonucleases (ex: I-Onul, or I-Crel), combined or not with TAL-nuclease (ex: MegaTAL) or zing-finger nucleases have also proven specificity, but with less efficiency so far.
- Various proofs of concept of the efficiency and safety of the above specific endonuclease reagents have been reported in human cells in-vitro or ex-vivo, but the co-delivery into the same cells of sequence specific reagents acting on different loci has still to be carefully considered as a potential factor of off-site mutations, large genomic deletions and translocations inherent to the DNA repair mechanisms (Poirot et al. (2015) Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies Cancer Res. 75: 3853-64).
- In parallel, novel specificities have been conferred to immune cells through the genetic transfer of transgenic T-cell receptors or so-called chimeric antigen receptors (CARs) (Jena et al. (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 116:1035-1044). CARs are recombinant receptors comprising a targeting moiety that is associated with one or more signaling domains in a single fusion molecule. In general, the binding moiety of a CAR consists of an antigen-binding domain of a single-chain antibody (scFv), comprising the light and heavy variable fragments of a monoclonal antibody joined by a flexible linker. Binding moieties based on receptor or ligand domains have also been used successfully. The signaling domains for first generation CARs are derived from the cytoplasmic region of the CD3zeta or the Fc receptor gamma chains. First generation CARs have been shown to successfully redirect T cell cytotoxicity, however, they failed to provide prolonged expansion and anti-tumor activity in vivo. Signaling domains from co-stimulatory molecules including CD28, OX-40 (CD134), ICOS and 4-1BB (CD137) have been added alone (second generation) or in combination (third generation) to enhance survival and increase proliferation of CAR modified T cells. CARs, as well as the expression of recombinant TCRs, have successfully allowed T cells to be redirected against antigens expressed by tumor cells from various malignancies including lymphomas and solid tumors.
- Recently engineered T-cells disrupted in their T-cell receptor (TCR) using TALE-nucleases, endowed with chimeric antigen receptor (CAR) targeting CD19 malignant antigen, referred to as “UCART19” product, have shown therapeutic potential in at least two infants who had refractory leukemia (Leukaemia success heralds wave of gene-editing therapies (2015) Nature 527:146-147). To obtain such UCART19 cells, the TALE-nuclease was transiently expressed into the cells upon electroporation of capped mRNA to operate TCR gene disruption, whereas a cassette encoding the chimeric antigen receptor (CAR CD19) was introduced randomly into the genome using a retroviral vector.
- In this later approach, the steps of gene inactivation and of expressing the chimeric antigen receptor are independently performed after inducing activation of the T-Cell “ex-vivo”.
- However, engineering primary immune cells is not without any consequences on the growth/physiology of such cells. In particular one major challenge is to ovoid cells exhaustion/anergy that significantly reduces their immune reaction and life span. This is more likely to happen when the cells are artificially activated ahead of their infusion into the patient. It is also the case when a cell is endowed with a CAR that is too reactive.
- The introduction of the polynucleotides expressing recombinant receptors into those cells, through an independent step of viral transduction, also has an impact on the overall production process.
- The inventors have explored safer means for ex-vivo delivery of endonucleases reagents into primary cells with the requirements that said cells (1) are modified at different genetic loci, (2) not bearing too many translocations, (3) produced in sufficient number to enable treating at least a hundred patients, and (4) produced in a limited time frame of less than 30 days to avoid exhaustion of the cells. They came up with the invention as described herein, where sequential gene editing is performed instead of multiplexing gene editing. Surprisingly, this occurred to be less destructive to the cells, resulting into higher quality primary immune cells.
- This invention paves the way to standard and affordable adoptive immune cell therapy treatments.
- The present invention is drawn to a method of sequential gene editing aiming to improve the genetic modification of primary human cells, especially immune cells originating from individual donors or patients.
- Primary immune cells, in particular T-cells or NK cells, have a limited life span, and although they can be expanded and activated ex-vivo by methods known in the art [Rasmussen A. M. et al. (2010) Ex-vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. Journal of Immunological Methods 355:52-60], their immune reactivity tends to reduce over time. They can also get exhausted from the moment they are collected from a donor to the moment they are reintroduced in-vivo to track down and eliminate malignant or infected cells into the patient.
- Gene editing techniques using nucleotide sequence-specific reagents, such as rare-cutting endonucleases, have become the state of the art for the introduction of genetic modifications into primary cells. However, when such endonucleases are used to cleave target sequences simultaneously at different loci, the risk of inter- or intra-chromosomal translocations increases significantly, which concur to a higher risk of unwanted genetic recombination or off-site mutations.
- To overcome this drawback and minimize adverse genome effects, the inventors have applied a safer approach, where gene editing is sequentially applied, in particular through several rounds of electroporation. To their surprise, sequential gene editing resulted into cells of higher quality and even into an increase of the yield of the engineered cells modified at different loci, as compared to multiplexing gene editing (i.e. gene editing performed simultaneously at different loci).
- The present invention thus primarily concerns a method comprising one or several steps of:
-
- Providing at least one primary immune cell from a culture or a blood sample, such as from peripheral blood mononuclear cells (PBMCs);
- Subjecting said cell to a step of gene editing, where a first set of sequence-specific reagent(s) is introduced into said cell;
- Cultivating said cell to enable said first sequence-specific reagent to stably modifying its genome at a first locus,
- Subjecting said cell to at least a second gene editing step to introduce at least a second set of sequence-specific reagent(s) into said cell, and optionally
- Cultivating said cell to enable said second sequence-specific reagent to stably modifying its genome at said second locus.
- According to a preferred embodiment, the first, second and any subsequent sequence-specific reagents are introduced into said cell by electroporation, so that the method of the invention comprises:
-
- a) Subjecting the immune cells to a first electroporation to introduce at least a first sequence-specific reagent into said immune cell;
- b) cultivating said immune cell to enable said first sequence-specific reagent to modify its genome at a first locus,
- c) submitting said cell to at least a second electroporation to introduce at least a second sequence-specific reagent into said cell, and optionally
- d) cultivating said immune cell to enable said second sequence-specific reagent to modify its genome at said second locus.
- Several strategies may be applied when applying the sequential gene editing of the present invention to obtain immune cells with higher recovery, better activation, persistence or therapeutic efficiency. As an example, the first electroporation step can be performed in view of editing or modifying a gene, in such a way that the cell will better expand or get more permissive to the subsequent modification steps.
- As another example, the first step of gene editing can be performed on a receptor or surface protein, such as TCR. The TCR negative cells obtained by this first step can be purified by removal of the cells remaining TCR positive, such that said TCR negative cells can be cultivated and then subjected to a second step of gene editing, for instance to make them resistant to a chemotherapy drug. The resulting population of cells in which the second gene editing has been achieved, can then be enriched in TCR negative drug resistant cells by culture in a medium containing said chemotherapy drug.
- Several examples are developed herein showing that, although deemed more destructive, the successive gene editing steps surprisingly contribute to improve the yield and therapeutic potential of the engineered immune cells.
- The invention is drawn to the methods, but also to the new gene edited cells obtainable by these methods, especially new triple and quadruple gene inactivated immune cells, as well as the population of cells resulting thereof, which are useful for the preparation of therapeutic compositions.
- The present invention may be further summarized by the following items:
-
- 1) A method for introducing genetic modifications at different loci of a primary immune cell, comprising the sequential steps of:
- a) subjecting said primary immune cell to a first electroporation step to introduce at least a first sequence-specific reagent into said immune cell;
- b) cultivating said primary immune cell thereby enabling said first sequence-specific reagent to modify its genome at a first locus,
- c) subjecting said primary immune to at least a second electroporation step to introduce at least a second sequence-specific reagent into said cell,
- d) cultivating and expanding said primary immune thereby enabling said second sequence-specific reagent to modify its genome at said second locus.
- 1) A method for introducing genetic modifications at different loci of a primary immune cell, comprising the sequential steps of:
- 2) The method according to
item 1, wherein the primary immune cell is cultivated in step b) from 12 to 72 hours, preferably from 24 to 48 hours. - 3) The method according to
item 1, wherein a purification step is performed between step b) and c) relying on a product resulting from the expression or the deletion of the gene that is modified at least at said first locus. - 4) The method according to any one of
items 1 to 3, wherein steps a) to d) are performed within 240 hours, preferably within 120 hours, more preferably within 96 hours, even more preferably within 72 hours. - 5) The method according to any one of
items 1 to 4, wherein said method comprises at least one further step of submitting said primary immune cell to a third electroporation step to introduce at least a third sequence-specific reagent into said cell. - 6) The method according to
item 1, wherein said first and/or second sequence-specific reagent is a polynucleotide or polypeptide encoding a rare-cutting endonuclease, a subunit thereof, or a conjugate of both a polynucleotide and a polypeptide. - 7) The method according to
item 2, wherein said first and/or second sequence-specific reagent is a polynucleotide or polypeptide encoding a rare-cutting endonuclease selected from programmable RNA or DNA guided endonuclease, TALEN, ZFN or a homing endonuclease. - 8) The method according to
item 3, wherein said first and/or second sequence-specific reagent is a conjugate of RNA guide and a Cas9 or Cpf1 polypeptide. - 9) The method according to
item 1, wherein said first and/or second sequence-specific reagent is an interference RNA (RNAi) or a polynucleotide encoding same. - 10) The method according to
item 1, wherein a transduction step is introduced between b) and c) with a retroviral or lentiviral vector. - 11) The method according to
item 10, wherein said transduction step involves an integrative lentiviral or retroviral vector for stable expression of a transgene. - 12) The method according to
item 11, wherein said transgene encodes a Chimeric Antigen Receptor (CAR). - 13) The method according to
item 10, wherein said transduction step involves a non-integrative viral vector. - 14) The method according to
item 13, wherein said non integrative viral vector is used as a template for homologous recombination or NHEJ integration of said transgene into the immune cell's genome. - 15) The method according to
item 10, wherein said first sequence-specific reagent is acting on a genomic sequence that facilitates the transduction step. - 16) The method according to any one of
items 1 to 15, wherein said first sequence-specific reagent is acting on a genomic sequence that facilitates the genetic modification of step d). - 17) The method according to any one of
items 1 to 16, wherein step b) is performed below about 35° C., preferably at about 30° C. - 18) The method according to any one of
items 1 to 17, wherein said immune cell is a T-cell. - 19) The method according to item 18, comprising a preliminary step of activating the primary T-cell by signal transduction.
- 20) The method according to item 18 or 19, wherein said first sequence-specific reagent permanently reduces or prevents expression of TCR by the primary T-cell.
- 21) The method according to any one of
items 1 to 20, wherein said first or second sequence-specific reagent permanently reduces or prevents expression of at least one gene encoding an immune checkpoint. - 22) The method according to item 21, wherein said at least one gene encoding an immune checkpoint is selected from PD1, CTLA4, PPP2CA, PPP2CB, PTPN6, PTPN22, PDCD1, LAG3, HAVCR2, BTLA, CD160, TIGIT, CD96, CRTAM, LAIR1, SIGLEC7, SIGLEC9, CD244, TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7, FADD, FAS, TGFBRII, TGFRBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1, IL10RA, IL10RB, HMOX2, IL6R, IL6ST, EIF2AK4, CSK, PAG1, SIT1, FOXP3, PRDM1, BATF, GUCY1A2, GUCY1A3, GUCY1B2, GUCY1B3.
- 23) The method according to any one of
items 1 to 20, wherein said first or second sequence-specific reagent permanently confers resistance of said primary immune cell against drugs or immune depleting agents. - 24) The method according to item 23, wherein said resistance is conferred by inactivating a gene expressing CD52, dCK, GGH or HPRT.
- 25) The method according to any one of
items 1 to 24, wherein a final step of purification is performed relying on a at least one product resulting from the expression or the deletion of one gene that is modified at said first and/or second and/or third locus. - 26) A population of primary TCR negative T-cells resulting from a single donor obtainable according to the method according to any one of
items 1 to 25, comprising at least two subpopulations of T-cells selected from:- TCR negative and PD1 negative,
- TCR negative and CD52 negative,
- TCR negative and CTLA4 negative,
- TCR negative and dCK negative,
- TCR negative and GGH negative,
- TCR negative and HPRT negative, and
- TCR negative and B12m negative.
- 27) A population of primary TCR negative T-cells originating from a single donor, wherein at least 20%, preferably 30%, more preferably 50% of the cells in said population have been modified using sequence-specific reagents in at least three different loci.
- 28) A pharmaceutical composition comprising a population of primary T cells according to any one of items 26 or 27.
-
FIG. 1 : Examples of genes and cell functions which can be sequentially modified by gene editing according to the method of the present invention to produce engineered allogeneic primary immune T-cells. Arrows within the cell represents the various genetic loci that can be inactivated by the sequence specific nuclease reagent introduced into the T-cells. -
FIG. 2 : Rationale for the sequential gene editing according to the present invention versus the multiplexing gene editing from the prior art in terms of yielding primary immune cells stacking mutations at three different loci, such as genes encoding TCR, PD1 and DCK. The method of the present invention ends up with a population of immune cells where at least 80% of the cells are triple mutants. By contrast, with the same reagent efficiency, simultaneous gene editing amounts about 50% of triple mutants. Upon cell expansion, this proportion should not much increase in the population, if not be decreasing. -
FIG. 3 : Schematic representation of one embodiment of the method according to the invention, where a viral transduction step is performed between two electroporation gene editing steps. The viral transduction is preferably performed after a cell sorting step where the cells modified by the first gene editing modifications are purified. This cell sorting step reduces the overall number of cells, thereby reducing the number of viral particles to be used for the viral transduction. This can be advantageous, for instance, when TCR is first inactivated, to follow-up with stable viral transduction and expression of the CAR. Subsequent gene editing step can then be carried out to make the cells resistant to a drug. In such a situation, culturing or expanding the cells in a medium containing the drug allows the selection of the cells that are both TCR negative and drug resistant in view of their therapeutic use. -
FIG. 4 : Schematic representation of one embodiment of the method of the invention, wherein a cell sorting step is performed between the two electroporation gene editing steps. -
FIG. 5 : Schematic representation of one embodiment of the method of the invention, wherein a cell sorting step plus a viral transduction is performed between the two electroporation gene editing steps. -
FIG. 6 : Schematic representation of one embodiment of the method according to the invention, where a culture step in a selective medium is performed between two electroporation gene editing steps, to select the cells that have been made resistant to a compound as per the first gene modification. This culture step increases the number of cells that are eventually modified at multiple loci after the second gene editing step. This approach can be applied to produce drug resistant CAR positive T-cells, that are further gene edited to be more active (inactivation of a locus inhibiting T-cell activation/cytotoxicity, such as PD1 and/or CTLA4), especially in a context of an autologous treatment where the T-cells (e.g.: Tumor Infiltrating Lymphocytes (TIL)) are collected from a patient, engineered and re-infused to said patient. -
FIG. 7 : Schematic representation of one embodiment of the method according to the invention, where the first gene editing step is performed in a gene coding or regulating the expression of a surface antigen and the second gene editing step is performed in a gene coding or regulating the expression of a product that is not a surface antigen. A cell separation step is performed between the two gene editing steps to enrich the cells allowed to pass to the second gene editing step. Optionally, the second gene editing step is followed by a culture step in a selective medium to favor/select expansion of the cells bearing the second gene editing. -
FIG. 8 : Schematic representation of one embodiment wherein a cell sorting based on immune cells subtypes, for instance CD4+ and CD8+ cells is performed after the first gene editing step (ex: TCR inactivation) and before the second gene editing step. As per this embodiment, a different gene editing can be applied to the different subtypes respectively, such as for instance the inactivation of FOXP3 in CD4+ cells and the inactivation of PD1 in CD8+ cells. The gene edited cells from the separate batches (ex: CD8+ and CD4+) can be respectively mixed at a predetermined ratio (ex: 1 to 1) to produce more active therapeutic compositions. -
FIG. 9 : Diagrams displaying the % number of cells TCR negative, CD52 negative and both TCR and CD52 negative after simultaneous gene editing (TALEN CD52 and TCR together) (see Example 1). Controls are untransfected cells, which results are represented the left columns of the diagrams -
FIG. 10 : T-cell growth curve observed after the different electroporation strategies: simultaneous and sequential according to the invention (6, 20 and 40h interval between the two CD52 and TCR gene editing steps—see example 1). -
FIG. 11 : Frequency of In-deletions (Indels) for 5 off-site targets (OFS1, OFS2, OFS3, OFS4 and OFS5) and TRAC and PD-1 on-site targets after simultaneous or sequential electroporation of TRAC and PD-1 TALEN®. Red stars highlight the abrogation of off-site 3 (OFS3) target cleavage by the method according to the invention (see example 2). -
FIG. 12 : Diagrams showing the growth of the engineered cells populations overtime from Day 5 (D5) post thawing to Day 15 (D15) with respect to the different gene editing strategies detailed in Example 3 and Table 2. -
FIG. 13 : Schematic representation of workflow for the generation of triple KO CAR T cells, as carried out in example 4. -
FIG. 14 : Diagram displaying the triple KO efficacy (% number TCR/B2M and PD1 negative cells), in two different donors using indicated doses of mRNA enconding TRAC, β2m and PD-1 TALEN®s that were electroporated either simultaneously (Sim.) or sequentially (Seq.), resulting into [TCR]neg[μ2m]neg[PD1]neg therapeutically effective number of cells originating from donors, as explained in Example 4. -
FIG. 15 : Diagrams showing cytotoxic activity on Raji cells at different effector to target ratios (E:T) of CD22 CAR-T cells that were either untransfected with TALEN® reagents (WT: black) or TALEN® transfected sequentially (dark grey) or TALEN® transfected simultaneously (light grey). - Table 1: List of genes involved into immune cells inhibitory pathways
- Table 2: gene editing efficiency of various sequential gene editing strategies according to the invention as presented in Example 3 (percentage of gene edited cells based on numbers of CD38, TCR and/or CD52 negative cells; D4, D5 and D6 are the number of days after thawing frozen primary cells).
- Table 3: Sequence of TALEN® used in the examples.
- Table 4: Selection of antigen markers of various cancers found to be expressed on the surface of T-cells. The inactivation of the genes encoding these antigen markers is proposed as part of one of one of the gene editing steps according to the invention, especially when the engineered immune cells are endowed with chimeric antigen receptors targeting these very antigens.
- Unless specifically defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled artisan in the fields of gene therapy, biochemistry, genetics, and molecular biology.
- All methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, with suitable methods and materials being described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will prevail. Further, the materials, methods, and examples are illustrative only and are not intended to be limiting, unless otherwise specified.
- The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology, transgenic biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Current Protocols in Molecular Biology (Frederick M. AUSUBEL, 2000, Wiley and son Inc, Library of Congress, USA); Molecular Cloning: A Laboratory Manual, Third Edition, (Sambrook et al, 2001, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Harries & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the series, Methods In ENZYMOLOGY (J. Abelson and M. Simon, eds.-in-chief, Academic Press, Inc., New York), specifically, Vols. 154 and 155 (Wu et al. eds.) and Vol. 185, “Gene Expression Technology” (D. Goeddel, ed.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); and Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986).
- In a general aspect, the present invention relates to methods to perform genome modification in multiple loci in primary cells through sequential electroporation steps, spaced by cell culture, sorting and/or expansion phase(s).
- In particular, these methods comprise the steps of:
-
- a) subjecting the primary immune cell to a first electroporation to introduce at least a first sequence-specific reagent into said immune cell;
- b) cultivating said primary immune cell thereby enabling said first sequence-specific reagent to modify its genome at a first locus,
- c) subjecting said primary immune to at least a second electroporation to introduce at least a second sequence-specific reagent into said cell,
- d) cultivating and expanding said primary immune thereby enabling said second sequence-specific reagent to modify its genome at said second locus.
- By “primary cell” or “primary cells” are intended cells taken directly from living tissue (e.g. biopsy material) and established for growth in vitro for a limited amount of time, meaning that they can undergo a limited number of population doublings. Primary cells are opposed to continuous tumorigenic or artificially immortalized cell lines. Non-limiting examples of such cell lines are CHO-K1 cells; HEK293 cells; Caco2 cells; U2-OS cells; NIH 3T3 cells; NSO cells; SP2 cells; CHO-S cells; DG44 cells; K-562 cells, U-937 cells; MRC5 cells; IMR90 cells; Jurkat cells; HepG2 cells; HeLa cells; HT-1080 cells; HCT-116 cells; Hu-h7 cells; Huvec cells;
Molt 4 cells. Primary cells are generally used in cell therapy as they are deemed more functional and less tumorigenic. - In general, primary immune cells are provided from donors or patients through a variety of methods known in the art, as for instance by leukapheresis techniques as reviewed by Schwartz J. et al. (Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue (2013) J Clin Apher. 28(3):145-284). The primary immune cells according to the present invention can also be differentiated from stem cells, such as cord blood stem cells, progenitor cells, bone marrow stem cells, hematopoietic stem cells (HSC) and induced pluripotent stem cells (iPS).
- By “immune cell” is meant a cell of hematopoietic origin functionally involved in the initiation and/or execution of innate and/or adaptive immune response, such as typically CD3 or CD4 positive cells. The immune cell according to the present invention can be a dendritic cell, killer dendritic cell, a mast cell, a NK-cell, a B-cell or a T-cell selected from the group consisting of inflammatory T-lymphocytes, cytotoxic T-lymphocytes, regulatory T-lymphocytes or helper T-lymphocytes. Cells can be obtained from a number of non-limiting sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and from tumors, such as tumor infiltrating lymphocytes. In some embodiments, said immune cell can be derived from a healthy donor, from a patient diagnosed with cancer or from a patient diagnosed with an infection. In another embodiment, said cell is part of a mixed population of immune cells which present different phenotypic characteristics, such as comprising CD4, CD8 and CD56 positive cells.
- By “endonuclease reagent” is meant a nucleic acid molecule that contributes to an endonuclease catalytic reaction in the target cell, itself or as a subunit of a complex, preferably leading to the cleavage of a nucleic acid sequence target. The endonuclease reagents of the invention are generally sequence-specific reagents, meaning that they can induce DNA cleavage in the cells at predetermined loci, referred to by extension as “gene targets”. The nucleic acid sequence which is recognized by the sequence specific reagents is referred to as “target sequence”. Said target sequence is usually selected to be rare or unique in the cell's genome, and more extensively in the human genome, as can be determined using software and data available from human genome databases, such as http://www.ensembl.org/index.html.
- “Rare-cutting endonucleases” are sequence-specific endonuclease reagents of choice, insofar as their recognition sequences generally range from 10 to 50 successive base pairs, preferably from 12 to 30 bp, and more preferably from 14 to 20 bp.
- According to a preferred aspect of the invention, the endonuclease reagent is transiently expressed into the cells, meaning that said reagent is not supposed to integrate into the genome or persist over a long period of time, such as be the case of RNA, more particularly mRNA, proteins or complexes mixing proteins and nucleic acids (e.g.: Ribonucleoproteins). In general, 80% the endonuclease reagent is degraded by 30 hours, preferably by 24, more preferably by 20 hours after transfection.
- According to a preferred aspect of the invention, said endonuclease reagent is a nucleic acid encoding an “engineered” or “programmable” rare-cutting endonuclease, such as a homing endonuclease as described for instance by Arnould S., et al. (WO2004067736), a zing finger nuclease (ZFN) as described, for instance, by Urnov F., et al. (Highly efficient endogenous human gene correction using designed zinc-finger nucleases (2005) Nature 435:646-651), a TALE-Nuclease as described, for instance, by Mussolino et al. (A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity (2011) Nucl. Acids Res. 39(21):9283-9293), or a MegaTAL nuclease as described, for instance by Boissel et al. (MegaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering (2013) Nucleic Acids Research 42 (4):2591-2601).
- According to the invention, the endonuclease reagent is preferentially under RNA form to allow transient endonuclease activity of said reagent into the target cell and make the entire capsule biodegradable in-vivo. Even more preferably, the endonuclease reagent is under the form of a mRNA for the expression of the rare cutting endonuclease into the cells. The endonuclease under mRNA form is preferably synthetized with a cap to enhance its stability according to techniques well known in the art, as described, for instance, by Kore A. L., et al. (Locked nucleic acid (LNA)-modified dinucleotide mRNA cap analogue: synthesis, enzymatic incorporation, and utilization (2009) J Am Chem Soc. 131(18):6364-5).
- Due to their higher specificity, TALE-nuclease have proven to be particularly appropriate for therapeutic applications, especially under heterodimeric forms—i.e. working by pairs with a “right” monomer (also referred to as “5” or “forward”) and “left” monomer (also referred to as “3” or “reverse”) as reported for instance by Mussolino et al. (TALEN©facilitate targeted genome editing in human cells with high specificity and low cytotoxicity (2014) Nucl. Acids Res. 42(10): 6762-6773).
- According to another embodiment, the endonuclease reagent is a RNA-guide to be used in conjunction with a RNA guided endonuclease, such as Cas9 or Cpf1, as per, inter alia, the teaching by Doudna, J., and Chapentier, E., (The new frontier of genome engineering with CRISPR-Cas9 (2014) Science 346 (6213):1077), which is incorporated herein by reference.
- However, because engineered rare-cutting endonuclease are sequence specific unique reagents, it cannot be excluded that, in some instances, they can promote or induce some chromosomal rearrangements, especially when several gene loci need to be cleaved in the same cell.
- Rearrangements are more prompt to happen, for instance, when multiple cleavage sites get simultaneously cut on the same chromosome or when pseudo cleavage sites appear from the unexpected combinations of heterodimers not initially designed to work together.
- The inventors have more particularly sought for lowering this risk without reducing the yield of the engineered cells when treated with any of the above endonuclease reagents (i.e. maintaining high gene KO efficacy and high cellular viability).
- Sequential Steps to Produce Batches of Engineered Primary Immune Cells of Therapeutic Grade
- The present invention thus provides a method allowing stacking gene editing in mammalian cells, while preventing undesirable genome deletions or translocations.
- By “gene editing” is meant, throughout the present specification, any methods by which a genomic sequence is modified by insertion, deletion or replacement at a selected locus by using at least an enzyme that cleaves phosphodiester bond within a polynucleotide chain.
- The method of the present invention can be associated with other methods involving physical of genetic transformations, such as a viral transduction or transfection using nanoparticles, in particular for transient expression of exogenous genetic sequences.
- The invention can be applied to human immune cells, in particular activated T-cells by alternating transfection (preferably by electroporation) and culture steps. Examples of such cycles as delineated below as examples:
-
- (TNx->h->TNx)×n
- (TNx/TNx->h->TNx)×n
- (TNx->h->TNx/TNx)×n
- (TNx/TNx->h->TNx/TNx)×n
- where TNx is a Transfection (T) of a specific endonuclease reagent N, (x≥1)
- h an interval of time in hours, and (h≥1)
- n is the number of subsequent transfection (n≥1)
- The above cycle may be combined with each other depending on the number of the different endonuclease reagents to be used sequentially.
- Preferably, each gene editing step targets one locus at a time.
- On another hand, the use of sequence-specific endonuclease reagents can be combined with other types of cell transformation not involving sequence specific endonuclease reagents, such as a retroviral transduction. This is of particular interest, for instance, for the production of primary immune cells expressing a recombinant receptors, such as a chimeric antigen receptor (CAR) or a recombinant TCR. Such chimeric antigen receptors are generally encoded by exogenous sequences which are introduced into cells by means of viral vectors, in particular lentiviral vectors. It is therefore advantageous to combine the sequential gene editing steps of the present invention with viral transduction steps, such as illustrated in
FIGS. 3, 5, 6 and 7 . - Example of combinations of sequential gene editing steps and transduction steps are delineated below:
-
- Transduction->h->(TNx->h->TNx)×n;
- Transduction->h->(TNx/TNx->h->TNx)×n;
- Transduction->h->(TNx->h->TNx/TNx)×n;
- Transduction->h->(TNx/TNx->h->TNx/TNx)×n;
- (TNx->h->TNx)×n->h->Transduction)×n;
- (TNx/TNx->h->TNx)×n->h->Transduction)×n;
- (TNx->h->TNx/TNx)×n->h->Transduction;
- (TNx/TNx->h->TNx/TNx)×n->h->Transduction;
- (TNx->h->Transduction->h->TNx)×n;
- (TNx/TNx->h->Transduction->h->TNx)×n;
- (TNx->h->Transduction->h->TNx/TNx)×n;
- (TNx/TNx->h->Transduction->h->TNx/TNx)×n;
- The transduction step may also take place prior to a gene editing step, when, for instance, vector introduces a template DNA into the primary cell to be integrated at a locus during the subsequent gene editing step. The sequence-specific endonuclease reagent is then introduced into the cell to promote the integration of said exogenous DNA at said locus. One preferred aspect is a method of the present invention comprising a first gene editing step, followed by a transduction step involving an AAV vector comprising an exogenous sequence to be integrated at a predetermined locus, prior to a second gene editing step wherein the exogenous DNA comprised in the AAV vector is integrated at said predetermined locus.
- According to one aspect of the invention, the sequential gene editing method may combine single gene editing steps (TNx) with multiplexing gene editing steps (TNx/TNx). During the multiplexing gene editing step, different endonuclease reagents may be used at different/multiple loci together. Endonucleases have different types of cleavage signatures: some of them can create “blunt ends”, such as CRISPR, 5′ “cohesive ends” such as zing Finger nucleases or TALE-nucleases or 3′ “cohesive ends” by using homing endonucleases. Combinations of endonuclease reagents can be made based on the type of cleavage sought. For instance, cohesive ends are better suited for integration of exogenous DNA than blunt ends for instance. One preferred aspect of the invention is the combined use of endonuclease reagents creating different types of cleavage signatures to reduce the deletions or translocations occurring at/or between the different gene-edited loci.
- According to a preferred embodiment of the invention, the primary immune cells are cultivated for an interval of time (h) as referred to above that is more than 10 hours, preferably from 12 to 72 hours and more preferably from 12 to 48 hours.
- According to a particular embodiment of the invention, a purification step can be performed between general step b) and c), as also illustrated in
FIGS. 4, 7 and 13 . - This purification step can be performed for the sake of purity by any standard method known in the art. In the present case, the purification step can help to select the cells which have undergone the gene editing achieved in step a). The purification can thus rely on the product resulting from the first gene editing reaction, such as a product resulting from the modification or insertion of a genetic sequence at said first locus, or the absence of a gene product in case of a deletion of such genetic sequence. In a preferred embodiment, the first gene editing step may help the expression of receptors or membrane proteins, which make the immune cells more receptive to the second gene editing step. The cells can also become more receptive to viral vectors transduction if genes involved into viral transformation are modified prior to the second gene editing.
- The genes that can be targeted as part of the first gene editing step, can be genes the modification of which will facilitate viral transduction or the realization of the second gene editing step or of any subsequent transduction or transfection step. Such genes can be, for instance, genes encoding cell restriction factors, such as TRIM5a (Uniprot Q9C035), APOBEC protein family (apolipoprotein B mRNA editing enzyme), and SAMHD1 (Uniprot Q9Y3Z3). By “cell restriction factors” is meant molecules that directly and dominantly cause a significant decrease in viral infectivity. TRIM5a, for instance, is a protein known to mediate/inhibit lentiviral, such as HIV, entry into immune cells (Stremlau M, et al. “Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor” (2006) PNAS 103(14): 5514-9). The inactivation of TRIM5a, SAMHD1 or proteins of APOBEC family as part of one of the gene editing steps of the present invention can increase the infectivity of primary cells to viral vectors during subsequent transduction steps.
- According to preferred embodiments, the invention provides that steps a) to d) of the general method are performed within 240 hours, preferably within 120 hours, more preferably within 96 hours, even more preferably within 72 hours. This limited period of time allows better recovery of the primary immune cells and limits their exhaustion. Limited exhaustion can be controlled at different steps during the process by one skilled in the art by using specific exhaustion markers such as reviewed by Wherry, J. A. (T cell exhaustion (2011) Nature Immunology 12:492-499).
- According to a preferred embodiment of the invention, the transfection step T, such as steps a) and c) in the general method previously described, as well as any further steps TN (where N is the number of gene editing steps) are performed by electroporation.
- Surprisingly, successive electroporation steps were found to be less destructive and/or less genotoxic for the primary cells than any other methods performing multiplex gene editing where various endonuclease reagents are transfected in one shot.
- The method according to the present invention can comprise at least one further step of submitting the primary immune cell to a third electroporation to introduce at least a third sequence-specific reagent into said cell.
- Such electroporation steps are typically performed in closed chambers comprising parallel plate electrodes producing a pulse electric field between said parallel plate electrodes greater than 100 volts/cm and less than 5,000 volts/cm, substantially uniform throughout the treatment volume such as described in WO/2004/083379, which is incorporated by reference, especially from page 23,
line 25 to page 29,line 11. One such electroporation chamber preferably has a geometric factor (cm−1) defined by the quotient of the electrode gap squared (cm2) divided by the chamber volume (cm3), wherein the geometric factor is less than or equal to 0.1 cm−1, wherein the suspension of the cells and the sequence-specific reagent is in a medium which is adjusted such that the medium has conductivity in a range spanning 0.01 to 1.0 milliSiemens. In general, the suspension of cells undergoes one or more pulsed electric fields. With the method, the treatment volume of the suspension is scalable, and the time of treatment of the cells in the chamber is substantially uniform. - According to a preferred embodiment of the invention, the sequence specific reagent is under the form of nucleic acids, more preferably under DNA or RNA form. Under such forms, the nucleic acids can either code for a polypeptide, typically a rare cutting endonuclease a subunit thereof, or a conjugate of both a polynucleotide and a polypeptide. The reagents can also be under the form RNA or DNA guides directing guided endonucleases such as Cas9 or Cpf1 (RNA-guided endonucleases) or Argonaute (DNA-guided endonucleases) as recently respectively described by Zetsche, B. et al. (Cpf1 Is a Single RNA-Guided Endonuclease of a
Class 2 CRISPR-Cas System (2015) Cell 163(3): 759-771) and by Gao F. et al. (DNA-guided genome editing using the Natronobacterium gregoryi Argonaute (2016) Nature Biotech). According to a most preferred embodiment, the sequence-specific reagent is under mRNA form and encodes a rare-cutting endonuclease, selected from programmable RNA or DNA guided endonuclease, TALE-nuclease, Zing-finger nuclease (ZFN), a megaTAL or a homing endonuclease. - According to another aspect of the invention said first and/or second sequence-specific reagent is an interference RNA (RNAi) or a polynucleotide encoding same.
- As previously mentioned, a transduction step can be introduced between steps b) and c) of the general method, especially an integrative lentiviral or retroviral vector for stable expression of a transgene. This is particularly adapted to express chimeric antigen receptors (CAR) at the surface of the primary immune cells modified as the present invention. Such methods for CAR expression in allogeneic primary cells are described for instance in WO2013176915. Non-integrative viral vectors can also be used, as also described by the applicant in WO2015028683. Non integrative viral vector can be used, inter alia, as a template or donor DNA for homologous recombination or NHEJ integration of transgene into the immune cell's genome as part of the second gene editing step as per the present invention.
- The steps of the present method are generally performed at mammalian cells physiological temperature (37° C. for human cells), but certain steps of the method may be performed at non-physiological temperatures, between 30 and 37° C., or even lower between 25 and 35° C., during a limited period of time, from 30 minutes to 12 hours, preferably from 1 to 10 hours, more preferably from 1 to 5, and even more preferably from 30 minutes to 2 hours. For instance, it has been observed that performing the electroporation steps at lower temperature, e.g. below about 35° C., such as at about 30° C., favors transfection efficiency.
- As further illustrated in the present specification, the present method aims particularly at producing immune cells, preferably primary immune cells, genetically modified at multiple loci, especially by gene editing, for their subsequent use in cell therapy.
- Such immune cells are generally endowed with recombinant receptors, such as CAR or recombinant TCR, which confer them higher specificity toward malignant or infected cells. These recombinant receptors are generally encoded by exogenous polynucleotides which are introduced into the cell using viral vectors as per one of the transduction steps referred to previously.
- The CARs expressed by these cells specifically target antigen markers at the surface of malignant or infected cells, which further help said immune cells to destroy these cells in-vivo as reviewed by Sadelain M. et al. [“The basic principles of chimeric antigen receptor design” (2013) Cancer Discov. 3(4):388-98].
- In general, CAR polypeptides comprise an antigen binding domain, a transmembrane domain, and an intracellular domain comprising a costimulatory domain and/or a primary signaling domain, wherein said antigen binding domain binds to the tumor antigen associated with the disease.
- Many CARs have been described in the art, which can be used to carry out the present method, which can bind tumor antigen as diverse as one selected from: CD19 molecule (CD19); membrane spanning 4-domains A1 (MS4A1 also known as CD20); CD22 molecule (CD22); CD24 molecule (CD24); CD248 molecule (CD248); CD276 molecule (CD276 or B7H3); CD33 molecule (CD33); CD38 molecule (CD38); CD44v6; CD70 molecule (CD70); CD72; CD79a; CD79b; interleukin 3 receptor subunit alpha (IL3RA also known as CD123); TNF receptor superfamily member 8 (TNFRSF8 also known as CD30); KIT proto-oncogene receptor tyrosine kinase (CD117); V-set pre-B cell surrogate light chain 1 (VPREB1 or CD179a); adhesion G protein-coupled receptor E5 (ADGRE5 or CD97); TNF receptor superfamily member 17 (TNFRSF17 also known as BCMA); SLAM family member 7 (SLAMF7 also known as CS1); L1 cell adhesion molecule (L1CAM); C-type lectin domain family 12 member A (CLEC12A also known as CLL-1); tumor-specific variant of the epidermal growth factor receptor (EGFRvIII); thyroid stimulating hormone receptor (TSHR); Fms related tyrosine kinase 3 (FLT3); ganglioside GD3 (GD3); Tn antigen (Tn Ag); lymphocyte antigen 6 family member G6D (LY6G6D); Delta like canonical Notch ligand 3 (DLL3); Interleukin-13 receptor subunit alpha-2 (IL-13RA2); Interleukin 11 receptor subunit alpha (IL11RA); mesothelin (MSLN); Receptor tyrosine kinase like orphan receptor 1 (ROR1); Prostate stem cell antigen (PSCA); erb-b2 receptor tyrosine kinase 2 (ERBB2 or Her2/neu); Protease Serine 21 (PRSS21); Kinase insert domain receptor (KDR also known as VEGFR2); Lewis y antigen (LewisY); Solute carrier family 39 member 6 (SLC39A6); Fibroblast activation protein alpha (FAP); Hsp70 family chaperone (HSP70); Platelet-derived growth factor receptor beta (PDGFR-beta); Cholinergic receptor nicotinic alpha 2 subunit (CHRNA2); Stage-Specific Embryonic Antigen-4 (SSEA-4); Mucin 1, cell surface associated (MUC1); mucin 16, cell surface associated (MUC16); claudin 18 (CLDN18); claudin 6 (CLDN6); Epidermal Growth Factor Receptor (EGFR); Preferentially expressed antigen in melanoma (PRAME); Neural Cell Adhesion Molecule (NCAM); ADAM metallopeptidase domain 10 (ADAM10); Folate receptor 1 (FOLR1); Folate receptor beta (FOLR2); Carbonic Anhydrase IX (CA9); Proteasome subunit beta 9 (PSMB9 or LMP2); Ephrin receptor A2 (EphA2); Tetraspanin 10 (TSPAN10); Fucosyl GM1 (Fuc-GM1); sialyl Lewis adhesion molecule (sLe); TGS5; high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); tumor endothelial marker 7-related (TEM7R); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); ALK receptor tyrosine kinase (ALK); Polysialic acid; Placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); NY-BR-1 antigen; uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 family member K (LY6K); olfactory receptor family 51 subfamily E member 2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); ETV6-AML1 fusion protein due to 12,21 chromosomal translocation (ETV6-AML1); sperm autoantigenic protein 17 (SPA17); X Antigen Family, Member 1E (XAGE1E); TEK receptor tyrosine kinase (Tie2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; p53 mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B 1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Cytochrome P450 1B 1 (CYP1B 1); CCCTC-Binding Factor (Zinc Finger Protein)-Like (BORIS); Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES 1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); and immunoglobulin lambda-like polypeptide 1 (IGLL1).
- More preferred CARs according to the present invention are those described in the examples, which more preferably comprise an extracellular binding domain directed against one antigen selected from CD19, CD22, CD33, 5T4, ROR1, CD38, CD52, CD123, CS1, BCMA, Flt3, CD70, EGFRvIII, WT1, HSP-70 and CCL1. Even more preferred are CARs directed against CD22, CD38, 5T4, CD123, CS1, HSP-70 and CCL1. Such CARs have preferably one structure as described in WO2016120216.
- Immune cells can also express recombinant T-Cell receptors. T cells recognise MHC-peptide conjugates on target cells through the paired a and 6 chains of the TCR. This pairing confers the antigen specificity of the immune cell. One gene therapy approach has involved the molecular cloning of the TCR genes known to be specific for an antigen of choice. These chains are then introduced into T cells usually by means of a retroviral vector in a similar way as with CAR. Consequently, expression of the cloned TCRα and TCRβ genes endows the transduced immune cells with a functional specificity determined by the pairing of these new genes. Because TCRs recognize processed peptides presented on MHC, targeted antigens can be derived from the entire protein composition of the tumor cells, including intracellular proteins, whereas CARs are generally designed to recognize molecules expressed on the surface of target cells. This quality also allows TCRs to target a large number of non-surface antigens of virally infected cells and tumors associated with viral infection, such as hepatitis-associated hepatocellular carcinoma, papilloma virus-associated cervical cancer, and Epstein-Barr virus-related malignancies (Spear, T. et al. (2016). Strategies to genetically engineer T cells for cancer immunotherapy. Cancer Immunology Immunotherapy: 65(6):631-649).
- Preferred recombinant TCR to be used in the present invention are those directed against antigen specific of cancer cells, such as MART-1, MAGE-1, MAGE-2, MAGE-3 MAGE-12, BAGE, GAGE, NY-ESO-1, or overexpressed in cancer cells, such as a-Fetoprotein, Telomerase catalytic protein, G-250, MUC-1, CarcinoEmbryonic antigen (CEA), p53, Her-2/Neu and WT1 [Rosenberg S. A., (2001) Progress in human tumour immunology and immunotherapy Nature. 411(6835):380-4].
- The exogenous polynucleotide sequence encoding the recombinant receptors are generally introduced by a transduction step, which can be performed in the course of the present invention as shown for instance in
FIGS. 4, 7 and 13 by using a viral vector, such as a lentiviral vector. - Alternatively, or as part of a gene editing step, AAV vectors can be used as a DNA template for gene targeted insertion of said polyncleotide sequence encoding a recombinant receptor at a desired locus by NHEJ or homologous recombination.
- The insertion locus may be selected to disrupt an endogenous gene present at this locus, such a gene encoding a component of TCR or β2m as previously described.
- Also said exogenous polynucleotide sequence can be integrated at a locus preferably encoding TCR, HLA, β2m, HLA, PD1 or CTLA4, as part of the editing steps of the present invention.
- In particular, the inventors have significantly improved the rate of gene targeted insertion into human cells by using AAV vectors from the AAV6 family.
- According to a preferred embodiment, the method of the invention can therefore comprise a step consisting in:
-
- transducing into said cell an AAV vector comprising said exogenous nucleic acid sequence and sequences homologous to the targeted endogenous DNA sequence, and optionally,
- Inducing the expression of a sequence specific endonuclease reagent to cleave said endogenous sequence at the locus of insertion.
- The obtained insertion of the exogenous nucleic acid sequence may then result into the introduction of genetic material, correction or replacement of the endogenous sequence, more preferably “in frame” with respect to the endogenous gene sequences at that locus.
- Alloreactivity and/or engraftment of the immune cells:
- The method according to the invention is particularly adapted to prepare primary immune cells for allogeneic therapeutic use. By “allogeneic therapeutic use” is meant that the cells originate from a donor in view of being infused into patients having a different haplotype.
- Indeed, the present invention provides with an efficient method for obtaining primary cells, which can be gene edited in various gene loci involved into host-graft interaction and recognition. Other loci may also be edited in view of improving the activity, the survival or the life-time of the engineered primary cells. Such engineered immune cells are preferably primary T cells.
-
FIG. 1 maps the main cell functions that can be modified by gene editing according to the present invention to improve the efficiency of the engineered immune cells. Any gene inactivation listed under each function can be combined with another to obtain a synergistic effect on the overall therapeutic potency of the immune cells. - The present method is particularly useful for developing engineered non-alloreactive T-cells for immunotherapy and more specifically to methods for increasing the persistence and/or the engraftment of allogeneic immune cells by proceeding with at least one step of inactivation, preferably permanently, of a gene implicated in the self/non-self recognition, using preferably specific rare-cutting endonuclease.
- According to a preferred aspect of the invention, one of the gene editing steps aims to reduce host versus graft disease (GVHD) reaction or immune rejection upon introduction of the allogeneic cells into the recipient patient. For instance, one of the sequence-specific reagents used in the method can reduce or prevent the expression of TCR in primary T-cells, such as the genes encoding TCR-alpha or TCR-beta.
- As another preferred aspect, one gene editing step is to reduce or prevent the expression of the 2m protein and/or another protein involved in its regulation such as C2TA (Uniprot P33076) or in MHC recognition, such as HLA proteins. This permits the engineered immune cells to be less alloreactive when infused into patients.
- Most preferred, is the gene editing of both TCR and B12m as part of the sequential gene editing method of the present invention into T-cells or precursor cells thereof, which method can comprise the steps of introducing an exogenous polynucleotide encoding recombinant receptors, such as CARs or recombinant TCR previously mentioned, and more preferably at the TCRalpha or TCRbeta locus.
- Inhibiting checkpoint receptors and immune cells inhibitory pathways:
- According to a preferred aspect of the invention, one of the gene editing steps, aims to disrupt the expression of a protein involved in immune cells inhibitory pathways, in particular those referred to in the literature as “immune checkpoint” (Pardoll, D. M. (2012) The blockade of immune checkpoints in cancer immunotherapy, Nature Reviews Cancer, 12:252-264). In the sense of the present invention, “immune cells inhibitory pathways” means any gene expression in immune cells that leads to a reduction of the cytotoxic activity of the lymphocytes towards malignant or infected cells. This can be for instance a gene involved into the expression of FOXP3, which is known to drive the activity of Tregs upon T cells (moderating T-cell activity).
- “Immune checkpoints” are molecules in the immune system that either turn up a signal (co-stimulatory molecules) or turn down a signal of activation of an immune cell. As per the present invention, immune checkpoints more particularly designate surface proteins involved in the ligand-receptor interactions between T cells and antigen-presenting cells (APCs) that regulate the T cell response to antigen (which is mediated by peptide-major histocompatibility complex (MHC) molecule complexes that are recognized by the T cell receptor (TCR)). These interactions can occur at the initiation of T cell responses in lymph nodes (where the major APCs are dendritic cells) or in peripheral tissues or tumours (where effector responses are regulated). One important family of membrane-bound ligands that bind both co-stimulatory and inhibitory receptors is the B7 family. All of the B7 family members and their known ligands belong to the immunoglobulin superfamily. Many of the receptors for more recently identified B7 family members have not yet been identified. Tumour necrosis factor (TNF) family members that bind to cognate TNF receptor family molecules represent a second family of regulatory ligand-receptor pairs. These receptors predominantly deliver co-stimulatory signals when engaged by their cognate ligands. Another major category of signals that regulate the activation of T cells comes from soluble cytokines in the microenvironment. In other cases, activated T cells upregulate ligands, such as CD40L, that engage cognate receptors on APCs. A2aR, adenosine A2a receptor; B7RP1, B7-related
protein 1; BTLA, B and T lymphocyte attenuator; GAL9,galectin 9; HVEM, herpesvirus entry mediator; ICOS, inducible T cell co-stimulator; IL, interleukin; KIR, killer cell immunoglobulin-like receptor; LAG3,lymphocyte activation gene 3; PD1, programmedcell death protein 1; PDL, PD1 ligand; TGFβ, transforming growth factor-β; TIM3, Tcell membrane protein 3. - Examples of further genes, which expression could be reduced or suppressed to turn-up activation in the engineered immune cells according the present invention are listed in Table 1.
- For instance, one of the sequence-specific reagents used in the method can reduce or prevent the expression by the immune cell of at least one protein selected from PD1 (Uniprot Q15116), CTLA4 (Uniprot P16410), PPP2CA (Uniprot P67775), PPP2CB (Uniprot P62714), PTPN6 (Uniprot P29350), PTPN22 (Uniprot Q9Y2R2), LAG3 (Uniprot P18627), HAVCR2 (Uniprot Q8TDQ0), BTLA (Uniprot Q7Z6A9), CD160 (Uniprot 095971), TIGIT (Uniprot Q495A1), CD96 (Uniprot P40200), CRTAM (Uniprot 095727), LAIR1 (Uniprot Q6GTX8), SIGLEC7 (Uniprot Q9Y286), SIGLEC9 (Uniprot Q9Y336), CD244 (Uniprot Q9BZW8), TNFRSF10B (Uniprot 014763), TNFRSF10A (Uniprot 000220), CASP8 (Uniprot Q14790), CASP10 (Uniprot Q92851), CASP3 (Uniprot P42574), CASP6 (Uniprot P55212), CASP7 (Uniprot P55210), FADD (Uniprot Q13158), FAS (Uniprot P25445), TGFBRII (Uniprot P37173), TGFRBRI (Uniprot Q15582), SMAD2 (Uniprot Q15796), SMAD3 (Uniprot P84022), SMAD4 (Uniprot Q13485), SMAD10 (Uniprot B7ZSB5), SKI (Uniprot P12755), SKIL (Uniprot P12757), TGIF1 (Uniprot Q15583), IL10RA (Uniprot Q13651), IL10RB (Uniprot Q08334), HMOX2 (Uniprot P30519), IL6R (Uniprot P08887), IL6ST (Uniprot P40189), EIF2AK4 (Uniprot Q9P2K8), CSK (Uniprot P41240), PAG1 (Uniprot Q9NWQ8), SIT1 (Uniprot Q9Y3P8), FOXP3 (Uniprot Q9BZS1), PRDM1 (Uniprot Q60636), BATF (Uniprot Q16520), GUCY1A2 (Uniprot P33402), GUCY1A3 (Uniprot Q02108), GUCY1B2 (Uniprot Q8BXH3) and GUCY1B3 (Uniprot Q02153). The gene editing introduced in the genes encoding the above proteins is preferably combined with an inactivation of GTeR in CAR T cells.
- Preference is given to inactivation of PP1 and CTLA4, in combination with TR.
- To improve the efficiency of the engineered cells according to the present invention, the steps of the present method using sequence-specific endonuclease reagents, can be followed by a step of contacting said engineered immune cells with at least one non-endogenous immunosuppressive polypeptide, such as a PD-L1 ligand and/or CTLA-4 Ig.
-
TABLE 1 List of genes encoding immune checkpoint proteins. Genes that can be inactivated Pathway In the pathway Co-inhibitory CTLA4 (CD152) CTLA4, PPP2CA, PPP2CB, PTPN6, receptors PTPN22 PDCD1 (PD-1, CD279) PDCD1 CD223 (lag3) LAG3 HAVCR2 (tim3) HAVCR2 BTLA(cd272) BTLA CD160(by55) CD160 IgSF family TIGIT CD96 CRTAM LAIR1(cd305) LAIR1 SIGLECs SIGLEC7 SIGLEC9 CD244(2b4) CD244 Death receptors TRAIL TNFRSF10B, TNFRSF10A, CASP8, CASP10, CASP3, CASP6, CASP7 FAS FADD, FAS Cytokine signalling TGF-beta signaling TGFBRII, TGFBRI, SMAD2, SMAD3, SMAD4, SMAD10, SKI, SKIL, TGIF1 IL10 signalling IL10RA, IL10RB, HMOX2 IL6 signalling IL6R, IL6ST Prevention of TCR CSK, PAG1 signalling SIT1 Induced Treg induced Treg FOXP3 Transcription transcription factors PRDM1 factors controlling controlling exhaustion exhaustion BATF Hypoxia mediated iNOS induced guanylated GUCY1A2, GUCY1A3, GUCY1B2, tolerance cyclase GUCY1B3 - Preference is given to the production of immune cells combining gene editing, into at least the genes encoding:
-
- TCR, PD1 and LAG3;
- TCR, PD1 and FOXP3;
- TCR, CTLA4 and LAG3;
- TCR, CTLA4 and FOXP3;
- And even more preferably to the production of immune cells combining gene editing steps into at least the genes encoding:
- TCR, β2m and PD1
- TCR, β2m and CTLA4
- TCR, β2m and LAG3
- TCR, β2m and FOXP3 preferably by inhibiting or inactivating the expression of these proteins.
- Inhibiting suppressive cytokines/metabolites
- According to another aspect of the invention, the gene editing step concerns genes encoding or positively regulating suppressive cytokines or metabolites or receptors thereof, in particular TGFbeta (Uniprot P01137), IL10R (Uniprot Q13651 and/or Q08334), A2aR (Uniprot P29274), GCN2 (Uniprot P15442) and PRDM1 (Uniprot 075626).
- Preference is given to the production of immune cells combining gene editing, into at least the genes encoding:
-
- TCR, PD1 and TGFbeta;
- TCR, CTLA4 and TGFbeta;
- TCR, PD1 and IL10R;
- TCR, CTLA4 and IL10R;
- TCR, PD1 and TGFbeta;
- TCR, CTLA4 and TGFbeta;
- TCR, PD1 and GCN2;
- TCR, CTLA4 and GCN2;
- TCR, PD1 and A2aR;
- TCR, CTLA4 and A2aR;
- TCR, PD1 and PRDM1;
- TCR, CTLA4 and PRDM1;
preferably by inhibiting or inactivating the expression of these proteins.
- Resistance to chemotherapy drugs
- As a preferred embodiment of the present method, one gene editing step is performed into a locus responsible for the sensitivity of the immune cells to compounds used in standard of care treatments for cancer or infection, such as drugs purine nucleotide analogs (PNA) or 6-Mercaptopurine (6MP) and 6 thio-guanine (6TG) commonly used in chemotherapy. Reducing or inactivating the genes involved into the mode of action of such compounds (referred to as “drug sensitizing genes”) improves the resistance of the immune cells to same.
- Examples of drug sensitizing gene are those encoding DCK (Uniprot P27707) with respect to the activity of PNA, such a clorofarabine et fludarabine, HPRT (Uniprot P00492) with respect to the activity of purine antimetabolites such as 6MP and 6TG, and GGH (Uniprot Q92820) with respect to the activity of antifolate drugs, in particular methotrexate.
- According to another aspect, resistance to drugs can be conferred immune cells by overexpressing a drug resistance gene as an additional optional step of the present method of sequential gene editing. Expression of variant alleles of several genes such as dihydrofolate reductase (DHFR)(Uniprot P00374), inosine monophosphate dehydrogenase 2 (IMPDH2)(Uniprot P12268), calcineurin (Uniprot Q96LZ3, P63098 P48454, P16298 and Q08209) or methylguanine transferase (MGMT) (Uniprot P16455) have been identified to confer drug resistance to a cell according to the invention.
- According to another aspect of the present invention, the engineering immune cells are made resistant to drugs purine nucleotide analogs (PNA) chemotherapy drugs, such a clorofarabine et fludarabine, as part of the gene editing step. This enables the cells to be used after or in combination with conventional anti-cancer chemotherapies.
- While, according to the present invention, the first gene editing step is preferably performed on a locus encoding or regulating a surface antigen, so that sorting of the engineered cells can be carried out based on the presence/absence of said surface antigen, the second or ultimate gene editing step can be one conferring resistance of the cells to a compound, preferably a chemotherapy drug or an immune suppressive agent. By doing so, the double or triple gene edited cells can be selected and enriched by a culture step that takes place after the second or ultimate gene editing step. Also, the present method provides a first gene editing step into at least one gene encoding a T-Cell Receptor (TCR) component, in particular TCRalpha (Uniprot P01848) and TCRbeta (Uniprot P01850) and sequentially a second gene editing step into a gene expressing DCK, HPRT or GGH, to confer respectively resistance to PNA compounds, purine antimetabolites and antifolate compounds.
- As a result, significant populations of triple gene edited cells can be obtained for therapeutic treatments, said cells having loci modified to reduce or inactivate the expression of:
-
- TCR; β2m; DCK;
- TCR; PD1; DCK;
- TCR, CTLA4, DCK;
- TCR, LAG3, DCK;
- Resistance to immune-suppressive treatments
- According to another aspect of the present invention, the engineering immune cells are made resistant to immune-depletion treatments, such as those involving glucocorticoids or antibodies directed against immune cells surface proteins. As an example, the antibody Alemtuzumab is used to deplete CD52 positive immune cells as in many pre-cancer treatments.
- Also the method of the invention can comprise a gene editing step with respect to the genes encoding or regulating the expression of CD52 (Uniprot P31358) and/or GR (Glucocorticoids receptor also referred to as NR3C1—Uniprot P04150), optionally in combination with a gene editing step leading to a reduction of the inactivation of the TCR. This approach was previously described by Poirot, L. et al. (Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies (2013) Cancer. Res. 75:3853), but as part of a method where the different loci were simultaneously gene edited.
- Preferred engineered immune cells are those triple or quadruple gene edited cells detailed herein, in which CD52 and or GR are additionally inactivated.
- Improving CAR Positive Immune Cell Activity and Survival
- As previously stated, the present method allows introducing successive gene editing modifications into immune primary cells in a time frame that limits the impact of the gene editing steps on the subsequent expansion of these cells i.e. without reducing significantly production yields.
- As shown in the examples, the present invention solves the problem of producing immune cells that express recombinant receptors, such as chimeric antigen receptors (CAR), which are triply gene edited. Representative examples of such cells obtainable according to the invention display the following phenotypes:
-
- [CAR CS1]pos[B2m]neg[TCR]pos[PD1]neg;
- [CAR CD38]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CD70]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CD22]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR ROR1]pos[β2m]neg[TCR]pos[PD1]neg;
- [CAR CD123]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CD19]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CD33]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR 5T4]pos[β2m]neg[TCR]pos[PD1]neg;
- [CAR BCMA]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR Flt3]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR EGFRvIII]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR WT1]pos[β2m]neg[TCR]pos[PD1]neg;
- [CAR HSP70]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CLL1]pos[β2m]neg[TCR]neg[PD1]neg;
- [CAR CS1]pos[β2m]neg[TCR]pos[CTLA4]neg;
- [CAR CD38]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR CD70]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR CD22]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR ROR1]pos[β2m]neg[TCR]pos[CTLA4]neg;
- [CAR CD123]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR CD19]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR CD33]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR 5T4]pos[β2m]neg[TCR]pos[CTLA4]neg;
- [CAR BCMA]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR Flt3]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR EGFRvIII]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [CAR WT1]pos[β2m]neg[TCR]pos[CTLA4]neg;
- [CAR HSP70]pos[β2m]neg[TCR]neg[CTLA4]neg; and
- [CAR CLL1]pos[β2m]neg[TCR]neg[CTLA4]neg;
- [TCR]neg designate cells in which the expression of a component of the T-Cell receptor, such as TCRbeta or TCRalpha, has been reduced or impaired.
- One preferred aspect of the present invention further concerns the problem of immune cells that express chimeric antigen receptors (CAR), which target surface molecules that are also present at the surface of said very immune cells. Such cells are typically noted:
-
- [anti X CAR]positive (+ or pos)[X]positive (+ or pos),
- where X can be, for instance any of the antigen listed in table 4.
- Negative impact has been observed, for instance with respect to T-cells expressing antigens CS1, CD38 or CD22 endowed with CARs targeting same: [anti-CS1 CAR]pos, [CS1]pos, [anti-CD38 CAR]pos [CD38]pos or [anti-CD70 CAR]pos [CD70]pos. The CAR positive primary immune cells can attack each other resulting into immune cell depletion. This is observed even when such cells were TCR negative [TCR]neg
- The present invention provides with a technical solution to this problem by providing a method, wherein gene editing steps are sequentially performed as outlined below:
-
- a first gene editing step is performed to inactivate the expression of the surface molecule X;
- a CAR is expressed targeting said surface molecule X, preferably by viral transduction; and
- a second gene editing step is performed to inactivate the expression of TCR;
- optionally, a third gene editing step to inactivate the expression of an immune checkpoint gene, such as PD1 or CTLA4.
- The method results into a population of engineered [antigen X CAR]pos[antigen X]neg[TCR]neg immune cells. Preferred engineered immune primary cells are triple gene edited cells, such as the following ones:
-
- [CAR CS1]pos[CS1]neg[TCR]pos[PD1]neg;
- [CAR CD38]pos[CD38]neg[TCR]neg[PD1]neg;
- [CAR CD70]pos[CD70]neg[TCR]neg[PD1]neg;
- [CAR CD22]pos[CD22]neg[TCR]neg[PD1]neg;
- [CAR CS1]pos[CS1]neg[TCR]neg[CTLA4]neg;
- [CAR CD38]pos[CD38]neg[TCR]neg[CTLA4]neg;
- [CAR CD70]pos[CD70]neg[TCR]neg[CTLA4]neg;
- [CAR CD22]pos[CD22]neg[TCR]neg[CTLA4]neg;
- [CAR CS1]pos[CS1]neg[TCR]neg[β2m]neg;
- [CAR CD38]pos[CD38]neg[TCR]neg[β2m]neg;
- [CAR CD70]pos[CD70]neg[TCR]neg[β2m]neg;
- [CAR CD22]pos[CD22]neg[TCR]neg[β2m]neg;
- Activation and Expansion of T Cells
- Whether prior to or after genetic modification, the immune cells according to the present invention can be activated or expanded, even if they can activate or proliferate independently of antigen binding mechanisms. T-cells, in particular, can be activated and expanded using methods as described, for example, in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; 6,867,041; and U.S. Patent Application Publication No. 20060121005. T cells can be expanded in vitro or in vivo. T cells are generally expanded by contact with an agent that stimulates a CD3 TCR complex and a co-stimulatory molecule on the surface of the T cells to create an activation signal for the T-cell. For example, chemicals such as calcium ionophore A23187, phorbol 12-myristate 13-acetate (PMA), or mitogenic lectins like phytohemagglutinin (PHA) can be used to create an activation signal for the T-cell.
- As non-limiting examples, T cell populations may be stimulated in vitro such as by contact with an anti-CD3 antibody, or antigen-binding fragment thereof, or an anti-CD2 antibody immobilized on a surface, or by contact with a protein kinase C activator (e.g., bryostatin) in conjunction with a calcium ionophore. For co-stimulation of an accessory molecule on the surface of the T cells, a ligand that binds the accessory molecule is used. For example, a population of T cells can be contacted with an anti-CD3 antibody and an anti-CD28 antibody, under conditions appropriate for stimulating proliferation of the T cells. Conditions appropriate for T cell culture include an appropriate media (e.g., Minimal Essential Media or RPMI Media 1640 or,
X-vivo 5, (Lonza)) that may contain factors necessary for proliferation and viability, including serum (e.g., fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN-g, IL-4, IL-7, GM-CSF, IL-10, IL-12, IL-15, TGFβ, and TNF- or any other additives for the growth of cells known to the skilled artisan. Other additives for the growth of cells include, but are not limited to, surfactant, plasmanate, and reducing agents such as N-acetyl-cysteine and 2-mercaptoethanol. Media can include RPMI 1640, A1M-V, DMEM, MEM, a-MEM, F-12,X-Vivo 1, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells. Antibiotics, e.g., penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under conditions necessary to support growth, for example, an appropriate temperature (e.g., 37° C.) and atmosphere (e.g., air plus 5% C02). T-cells that have been exposed to varied stimulation times may exhibit different characteristics - In another particular embodiment, said cells can be expanded by co-culturing with tissue or cells. Said cells can also be expanded in vivo, for example in the subject's blood after administrating said cell into the subject.
- Therapeutic Compositions and Applications
- The method of the present invention described above allows producing engineered primary immune cells within a limited time frame of about 15 to 30 days, preferably between 15 and 20 days, and most preferably between 18 and 20 days so that they keep their full immune therapeutic potential, especially with respect to their cytotoxic activity.
- These cells can form or be members of populations of cells, which preferably originate from a single donor or patient. These populations of cells can be expanded under closed culture recipients to comply with highest manufacturing practices requirements and can be frozen prior to infusion into a patient, thereby providing “off the shelf” or “ready to use” therapeutic compositions.
- As per the present invention, a significant number of cells originating from the same Leukapheresis can be obtained, which is critical to obtain sufficient doses for treating a patient. Although variations between populations of cells originating from various donors may be observed, the number of immune cells procured by a leukapheresis is generally about from 108 to 1010 cells of PBMC. PBMC comprises several types of cells: granulocytes, monocytes and lymphocytes, among which from 30 to 60% of T-cells, which generally represents between 108 to 109 of primary T-cells from one donor. The method of the present invention generally ends up with a population of engineered cells that reaches generally more than about 108 T-cells, more generally more than about 109 T-cells, even more generally more than about 1010 T-cells, and usually more than 1011 T-cells. In general, the T-cells are gene edited at least at two different loci.
- Such compositions or populations of cells can therefore be used as a medicament, especially for treating cancer, particularly for the treatment of lymphoma, but also for solid tumors such as melanomas, neuroblastomas, gliomas or carcinomas such as lung, breast, colon, prostate or ovary tumors in a patient in need thereof.
- The invention is more particularly drawn to populations of primary TCR negative T-cells originating from a single donor, wherein at least 20%, preferably 30%, more preferably 50% of the cells in said population have been modified using sequence-specific reagents in at least two, preferably three different loci.
- In another aspect, the present invention relies on methods for treating patients in need thereof, said method comprising at least one of the following steps:
-
- (a) Determining specific antigen markers present at the surface of patients tumors biopsies;
- (b) providing a population of engineered primary immune cells engineered by one of the methods of the present invention previously described expressing a CAR directed against said specific antigen markers;
- (c) Administrating said engineered population of engineered primary immune cells to said patient,
- Generally, said populations of cells mainly comprises CD4 and CD8 positive immune cells, such as T-cells, which can undergo robust in vivo T cell expansion and can persist for an extended amount of time in-vitro and in-vivo.
- The treatments involving the engineered primary immune cells according to the present invention can be ameliorating, curative or prophylactic. It may be either part of an autologous immunotherapy or part of an allogenic immunotherapy treatment. By autologous, it is meant that cells, cell line or population of cells used for treating patients are originating from said patient or from a Human Leucocyte Antigen (HLA) compatible donor. By allogeneic is meant that the cells or population of cells used for treating patients are not originating from said patient but from a donor.
- In another embodiment, said isolated cell according to the invention or cell line derived from said isolated cell can be used for the treatment of liquid tumors, and preferably of T-cell acute lymphoblastic leukemia.
- Adult tumors/cancers and pediatric tumors/cancers are also included.
- The treatment with the engineered immune cells according to the invention may be in combination with one or more therapies against cancer selected from the group of antibodies therapy, chemotherapy, cytokines therapy, dendritic cell therapy, gene therapy, hormone therapy, laser light therapy and radiation therapy.
- According to a preferred embodiment of the invention, said treatment can be administrated into patients undergoing an immunosuppressive treatment. Indeed, the present invention preferably relies on cells or population of cells, which have been made resistant to at least one immunosuppressive agent due to the inactivation of a gene encoding a receptor for such immunosuppressive agent. In this aspect, the immunosuppressive treatment should help the selection and expansion of the T-cells according to the invention within the patient.
- The administration of the cells or population of cells according to the present invention may be carried out in any convenient manner, including by aerosol inhalation, injection, ingestion, transfusion, implantation or transplantation. The compositions described herein may be administered to a patient subcutaneously, intradermally, intratumorally, intranodally, intramedullary, intramuscularly, by intravenous or intralymphatic injection, or intraperitoneally. In one embodiment, the cell compositions of the present invention are preferably administered by intravenous injection.
- The administration of the cells or population of cells can consist of the administration of 104-109 cells per kg body weight, preferably 105 to 106 cells/kg body weight including all integer values of cell numbers within those ranges. The present invention thus can provide more than 10, generally more than 50, more generally more than 100 and usually more than 1000 doses comprising between 106 to 108 gene edited cells originating from a single donor's or patient's sampling.
- The cells or population of cells can be administrated in one or more doses. In another embodiment, said effective amount of cells are administrated as a single dose. In another embodiment, said effective amount of cells are administrated as more than one dose over a period time. Timing of administration is within the judgment of managing physician and depends on the clinical condition of the patient. The cells or population of cells may be obtained from any source, such as a blood bank or a donor. While individual needs vary, determination of optimal ranges of effective amounts of a given cell type for a particular disease or conditions within the skill of the art. An effective amount means an amount which provides a therapeutic or prophylactic benefit. The dosage administrated will be dependent upon the age, health and weight of the recipient, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired.
- In another embodiment, said effective amount of cells or composition comprising those cells are administrated parenterally. Said administration can be an intravenous administration. Said administration can be directly done by injection within a tumor.
- In certain embodiments of the present invention, cells are administered to a patient in conjunction with (e.g., before, simultaneously or following) any number of relevant treatment modalities, including but not limited to treatment with agents such as antiviral therapy, cidofovir and interleukin-2, Cytarabine (also known as ARA-C) or nataliziimab treatment for MS patients or efaliztimab treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the invention may be used in combination with chemotherapy, radiation, immunosuppressive agents, such as cyclosporin, azathioprine, methotrexate, mycophenolate, and FK506, antibodies, or other immunoablative agents such as CAMPATH, anti-CD3 antibodies or other antibody therapies, cytoxin, fludaribine, cyclosporin, FK506, rapamycin, mycoplienolic acid, steroids, FR901228, cytokines, and irradiation. These drugs inhibit either the calcium dependent phosphatase calcineurin (cyclosporine and FK506) or inhibit the p70S6 kinase that is important for growth factor induced signaling (rapamycin) (Henderson, Naya et al. 1991; Liu, Albers et al. 1992; Bierer, Hollander et al. 1993). In a further embodiment, the cell compositions of the present invention are administered to a patient in conjunction with (e.g., before, simultaneously or following) bone marrow transplantation, T cell ablative therapy using either chemotherapy agents such as, fludarabine, external-beam radiation therapy (XRT), cyclophosphamide, or antibodies such as OKT3 or CAMPATH, In another embodiment, the cell compositions of the present invention are administered following B-cell ablative therapy such as agents that react with CD20, e.g., Rituxan. For example, in one embodiment, subjects may undergo standard treatment with high dose chemotherapy followed by peripheral blood stem cell transplantation. In certain embodiments, following the transplant, subjects receive an infusion of the expanded immune cells of the present invention. In an additional embodiment, expanded cells are administered before or following surgery.
- Combination Therapy Involving at Least Two Sub-Populations of T Cells.
- The present invention encompasses a whole range of double, triple or quadruple gene edited cells now available for therapeutic use, including any of those illustrated herein, which could not be obtained by the prior art methods. Especially, those cells are engineered with a reduced risk of unwanted recombination or translocation at the different gene edited loci, making them safer for therapeutic use.
- As a further advantage of the present method of sequential gene editing is also the possibility to create subpopulations of primary immune cells from an initial population originating from a single donor or patient, which subpopulations are gene edited at different loci.
- As an example, the primary immune cells from the donor or patient can be made less-alloreactive by performing a first gene editing step into a TCR gene or any gene implicated in the self/non-selfrecognition, and then after an expansion step, the population can be split into two subpopulations, which respectively undergo a second gene editing step that will target distinct loci in said subpopulations. Typically, CD4+ positive and CD8+ positive immune cells can be (see
FIG. 8 ) treated separately before being pooled together at a desired ratio to increase potency of the therapeutic compositions. This method will result into subpopulations of engineered primary immune cells that will not display exactly the same properties. - Accordingly, the present invention is also drawn to compositions of populations of primary TCR negative T-cells resulting from a single donor comprising at least two subpopulations of T-cells, said subpopulations comprising, for instance different gene edited immune checkpoint genes.
- Such sub-populations of cells can be selected, for instance, from:
-
- TCR negative and PD1 negative,
- TCR negative and CD52 negative,
- TCR negative and CTLA4 negative,
- TCR negative and dCK negative,
- TCR negative and GR negative,
- TCR negative and GGH negative,
- TCR negative and HPRT negative,
- TCR negative and B12m negative.
- The resulting cells can be optionally transformed to express chimeric antigen receptor to provide allogeneic CAR T Cells with various specificities, in particular as part of sub-populations expressing chimeric receptors respectively directed to different surface molecules.
- Such sub-populations can be used separately or in combination with each other into compositions for therapeutic treatments, in the same way as previously described with a single population of cells.
- Other Definitions
-
- Amino acid residues in a polypeptide sequence are designated herein according to the one-letter code, in which, for example, Q means Gln or Glutamine residue, R means Arg or Arginine residue and D means Asp or Aspartic acid residue.
- Amino acid substitution means the replacement of one amino acid residue with another, for instance the replacement of an Arginine residue with a Glutamine residue in a peptide sequence is an amino acid substitution.
- Nucleotides are designated as follows: one-letter code is used for designating the base of a nucleoside: a is adenine, t is thymine, c is cytosine, and g is guanine. For the degenerated nucleotides, r represents g or a (purine nucleotides), k represents g or t, s represents g or c, w represents a or t, m represents a or c, y represents t or c (pyrimidine nucleotides), d represents g, a or t, v represents g, a or c, b represents g, t or c, h represents a, t or c, and n represents g, a, t or c.
- “As used herein, “nucleic acid” or “polynucleotides” refers to nucleotides and/or polynucleotides, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), oligonucleotides, fragments generated by the polymerase chain reaction (PCR), and fragments generated by any of ligation, scission, endonuclease action, and exonuclease action. Nucleic acid molecules can be composed of monomers that are naturally-occurring nucleotides (such as DNA and RNA), or analogs of naturally-occurring nucleotides (e.g., enantiomeric forms of naturally-occurring nucleotides), or a combination of both. Modified nucleotides can have alterations in sugar moieties and/or in pyrimidine or purine base moieties. Sugar modifications include, for example, replacement of one or more hydroxyl groups with halogens, alkyl groups, amines, and azido groups, or sugars can be functionalized as ethers or esters. Moreover, the entire sugar moiety can be replaced with sterically and electronically similar structures, such as aza-sugars and carbocyclic sugar analogs. Examples of modifications in a base moiety include alkylated purines and pyrimidines, acylated purines or pyrimidines, or other well-known heterocyclic substitutes. Nucleic acid monomers can be linked by phosphodiester bonds or analogs of such linkages. Nucleic acids can be either single stranded or double stranded.
- Chimeric antigen receptor (CAR) is a term that encompasses molecules which combine an extracellular binding domain against a component present on the target cell, for example an antibody-based specificity for a desired antigen (e.g., tumor antigen) with a T cell receptor-activating intracellular domain to generate a chimeric protein that exhibits a specific anti-target cellular immune activity. Generally, CAR consists of an extracellular single chain antibody (scFv), comprising the light (VL) and the heavy (VH) variable fragment of a target antigen specific monoclonal antibody joined by a flexible linker, fused to the intracellular signaling domain of the T cell antigen receptor complex zeta chain and have the ability, when expressed in immune effector cells, to redirect antigen recognition based on the monoclonal antibody's specificity. CAR can be single-chain or multi-chain as described in WO2014039523. Binding domain other than scFv can also be used for predefined targeting of lymphocytes, such as camelid or shark (VNAR) single-domain antibody fragments or receptor ligands like a vascular endothelial growth factor polypeptide, an integrin-binding peptide, heregulin or an IL-13 mutein, antibody binding domains, antibody hypervariable loops or CDRs as non-limiting examples.
- “Recombinant TCR” are artificial polypeptide constructs consisting preferably of a single amino acid strand, which like native heterodimeric TCRs bind to MHC-peptide complexes. Recombinant TCRs are preferably single-chain polypeptides, such as described by Stone J. D, et al. [A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control (2014) Cancer Immunol. Immunother. 63(11):1163-76], Such single chain TCRs generally comprise:
- an α segment constituted by a human TCR α chain variable region sequence fused to the N terminus of a human TCR α chain constant region extracellular sequence,
- a β segment constituted by a human TCR β chain variable region sequence fused to the N terminus of a human TCR β chain constant region extracellular sequence, and
- a linker sequence linking the C terminus of the α segment to the N terminus of the β segment, or vice versa, the constant region extracellular sequences of the α and β segments being linked by a disulfide bond,
the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the α and β segments are mutually orientated substantially as in native αβ T cell receptors. - The term “endonuclease” refers to any wild-type or variant enzyme capable of catalyzing the hydrolysis (cleavage) of bonds between nucleic acids within a DNA or RNA molecule, preferably a DNA molecule. Endonucleases do not cleave the DNA or RNA molecule irrespective of its sequence, but recognize and cleave the DNA or RNA molecule at specific polynucleotide sequences, further referred to as “target sequences” or “target sites”.
- Endonucleases can be classified as rare-cutting endonucleases when having typically a polynucleotide recognition site greater than 10 base pairs (bp) in length, more preferably of 14-55 bp. Rare-cutting endonucleases significantly increase homologous recombination by inducing DNA double-strand breaks (DSBs) at a defined locus thereby allowing gene repair or gene insertion therapies (Pingoud, A. and G. H. Silva (2007). Precision genome surgery. Nat. Biotechnol. 25(7): 743-4.).
-
- by “DNA target”, “DNA target sequence”, “target DNA sequence”, “nucleic acid target sequence”, “target sequence”, or “processing site” is intended a polynucleotide sequence that can be targeted and processed by a rare-cutting endonuclease according to the present invention. These terms refer to a specific DNA location, preferably a genomic location in a cell, but also a portion of genetic material that can exist independently to the main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting example. As non-limiting examples of RNA guided target sequences, are those genome sequences that can hybridize the guide RNA which directs the RNA guided endonuclease to a desired locus.
- by “mutation” is intended the substitution, deletion, insertion of up to one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, twenty, twenty five, thirty, forty, fifty, or more nucleotides/amino acids in a polynucleotide (cDNA, gene) or a polypeptide sequence. The mutation can affect the coding sequence of a gene or its regulatory sequence. It may also affect the structure of the genomic sequence or the structure/stability of the encoded mRNA.
- by “variant” is intended a catalytically active mutant of an endonuclease reagent according to the present invention.
- the term “locus” is the specific physical location of a DNA sequence (e.g. of a gene) into a genome. The term “locus” can refer to the specific physical location of a rare-cutting endonuclease target sequence on a chromosome or on an infection agent's genome sequence. Such a locus can comprise a target sequence that is recognized and/or cleaved by a sequence-specific endonuclease according to the invention. It is understood that the locus of interest of the present invention can not only qualify a nucleic acid sequence that exists in the main body of genetic material (i.e. in a chromosome) of a cell but also a portion of genetic material that can exist independently to said main body of genetic material such as plasmids, episomes, virus, transposons or in organelles such as mitochondria as non-limiting examples.
- The term “cleavage” refers to the breakage of the covalent backbone of a polynucleotide. Cleavage can be initiated by a variety of methods including, but not limited to, enzymatic or chemical hydrolysis of a phosphodiester bond. Both single-stranded cleavage and double-stranded cleavage are possible, and double-stranded cleavage can occur as a result of two distinct single-stranded cleavage events. Double stranded DNA, RNA, or DNA/RNA hybrid cleavage can result in the production of either blunt ends or staggered ends.
- “identity” refers to sequence identity between two nucleic acid molecules or polypeptides. Identity can be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base, then the molecules are identical at that position. A degree of similarity or identity between nucleic acid or amino acid sequences is a function of the number of identical or matching nucleotides at positions shared by the nucleic acid sequences. Various alignment algorithms and/or programs may be used to calculate the identity between two sequences, including FASTA, or BLAST which are available as a part of the GCG sequence analysis package (University of Wisconsin, Madison, Wis.), and can be used with, e.g., default setting. For example, polypeptides having at least 70%, 85%, 90%, 95%, 98% or 99% identity to specific polypeptides described herein and preferably exhibiting substantially the same functions, as well as polynucleotide encoding such polypeptides, are contemplated.
- The term “subject” or “patient” as used herein includes all members of the animal kingdom including non-human primates and humans.
- The above written description of the invention provides a manner and process of making and using it such that any person skilled in this art is enabled to make and use the same, this enablement being provided in particular for the subject matter of the appended claims, which make up a part of the original description.
- Where a numerical limit or range is stated herein, the endpoints are included. Also, all values and subranges within a numerical limit or range are specifically included as if explicitly written out.
- Having generally described this invention, a further understanding can be obtained by reference to certain specific examples, which are provided herein for purposes of illustration only, and are not intended to limit the scope of the claimed invention.
- In order to analyze the impact of sequential electroporation of TALE-nuclease reagents on the overall survival of T-cells and gene knock-out efficiency, we have submitted activated primary human T cells from a single donor sample to electroporation by using TALEN® reagents (Cellectis, Paris, France) specific for TRAC gene (TCR alpha chain) according to the following experimental procedure. The amino acid sequences of the various TALEN® heterodimers used in this experiment are given in Table 3):
- Briefly, frozen human PBMCs (AllCells) were thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (Dynabeads, Life Technologies, Carlsbad, Calif., United States) for 3 days. After magnetic beads removal (Day 4), 5×106 activated T cells were transfected with 10 μg of both mRNA encoding TALEN either simultaneously or sequentially with a 6 hour, 20 hour or 40 hour intervals by using AgilePulse electroporator (BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388) protocols. Electroporated T cells were platted back in tissue culture vessels in Xvivo hematopoietic medium (Lonza, CH-4002 Basel, Switzerland) supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 12 days. Cells were passaged every 2 or 3 days for numeration and media renewal.
- Surface expression of TCR and CD52 protein was measured by cytometry using specific monoclonal antibodies and a Macsquant cytometer (Miltenyi) at D10 post activation. Furthermore, T cells growth was monitored from D4 to D12, by Trypan blue exclusion cell numeration.
- On
FIG. 9 are presented the percentage of TCR+, CD52+, double positive TCR/CD52+ and double negative TCR/CD52− cells measured 6 days after electroporation according to the electroporation schedule. The data show that 70 to 80% of TCR KO and 65 to 75% of CD52 KO is achievable whatever the electroporation conditions, sequential or simultaneous. Furthermore, the percentage of double negative cells is comparable for all the tested conditions. This validates the finding that sequential electroporation does not reduce the rate of gene editing success. - Having shown that sequential electroporation does not affect the efficiency of TALE-nuclease mediated gene knock out, we sought to see if cellular growth was impaired when cells are electroporated twice within 24 or 48h intervals, by monitoring electroporation conditions, cell and growth.
- Data shown in
FIG. 10 indicated that cellular growth was similar for all tested conditions with an advantage for the T cells sequentially transfected with a 40h interval. - Altogether, these data demonstrated that sequential electroporation does not affect KO efficiency and cellular growth.
- Simultaneous electroporation of two TALE-Nuclease heterodimers was found to be highly efficient for performing simultaneous gene knock-out in Poirot et al. (Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies (2015) Cancer Res. 75: 3853-64). However, unwanted events such as off-site cleavage or translocation were found to occur in certain instances. For instance, co-transfection of mRNA encoding TRAC TALEN® and PD1 TALEN® leads to the occurring of off-site cleavage activity due to the pairing of the TRAC TALEN left arm and PD1 TALEN left arm. Frequency of off-site cleavage (as well as on-site cleavage) is defined by the frequency of mutated sequences (either nucleotide deletion or addition) that are generated after endonucleases cleavage and unfaithful religation of broken ends. The amino acid sequences used in this experiment encoding the various TALEN® heterodimers for TRAC (SEQ ID NO. 1 and 2) and PD1 (SEQ ID NO. 5 and 6) are given in Table 3)
- Potential off-site hits can be identified in silico with an algorithm according to several parameters including mainly TALE-nuclease DNA binding sequences, number of mismatches and position of those, length of the spacer between the 2 binding domains. According to this computer search, numerous potential off-site targets have been identified in the human genome for TRAC and PD1 TALEN® combination. The 15 first target sequences with the highest score have been verified experimentally by PCR and Deep Sequencing. One out of the 15, “Off-
Site 3”, has been found to be a true off-site target since about 1% of mutagenesis events (or Insertion/deletion, InDels events) was observed when T cell were transfected simultaneously with TRAC and PD1 TALEN®. - Since the data showed in example 1, demonstrated that sequential electroporation of TALEN did not affect KO efficiency and cell expansion, we sought to determine whether this sequential transfection strategy could abolish cleavage into the “Off-
Site 3”. - Briefly, frozen human PBMCs (AllCells) were thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (Dynabeads, LifeTech) for 3 days. 5×106 activated T cells were transfected with 10 μg of both TALEN mRNA either simultaneously or sequentially with a 6 hour, 20 hour or 40 hour intervals by using AgilePulse electroporator (BTX Instrument Division, Harvard Apparatus, Inc., Holliston, Mass. 01746-1388) protocols. Electroporated T cells were platted back in tissue culture vessels in Xvivo (Lonza) media supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 6 days. Cells were passaged every 2 or 3 days for numeration and media renewal. At the end of the 6 day period, genomic DNA was extracted from transfected T cells and subjected to PCR amplification using specific primers allowing the amplification of TRAC and PD1 “On-Site” genomic targets and 5 “Off-Site” targets including “Off-
Site 3”. PCR products are then purified and modified for subsequent deep sequencing analysis using the Illumina technology. About 80,000 reads for each samples were computed. - Data are presented on
FIG. 11 . As previously observed, the simultaneous transfection of TRAC and PD-1 TALEN® into T-cells induces a high level of indels at TRAC and PD-1 on-site targets respectively. About 1% of indels is also observed at the “Off-Site 3” target whereas no significant mutagenesis event is observed for the other predicted off-site targets OF1, OF2, OF4 and OF5. Sequential transfection of TRAC TALEN first and PD-1TALEN - In order to analyze the impact of sequential TALEN electroporation on overall survival of T cells and gene knock-out efficiency, we have transfected activated human T cells with TALENs specific for TRAC gene (TCR alpha chain), CD52 and CD38 (Amino acid sequences are given in Table 3) according to the following experimental procedure:
- Briefly, frozen human PBMCs (AllCells) are thawed and activated using anti CD3 and anti CD28 antibodies-coated beads (TransAct, Miltenyi) for 3 days. At
day 4 post thawing, 10×106 activated T cells are transfected with 10 μg of both TALEN mRNA either simultaneously or sequentially with a 24 hour (Day 5) or 48 hour (Day 6) intervals using Cellectis proprietary AgilPulse electroporator and protocols. The following conditions have been tested and compared in terms of KO efficiency and cell growth. -
TABLE 2 gene editing efficiency of the sequential gene editing strategies % cells in the population [CD38]− Transfection Day post thawing [TCRαβ]− D4 D5 D6 [CD38]− [TCRαβ]− [CD52]− [CD52]− A CD38/TRAC/CD52 66.1 67.8 57 35.2 B CD38 TRAC/CD52 63.2 64.6 64.6 27.1 C CD38 TRAC/CD52 63.8 68 60.6 36.7 D CD38/TRAC CD52 61.6 73.8 50.5 27.6 E CD38/TRAC CD52 67.5 72.9 69.4 40.2 F CD38/CD52 TRAC 65.7 69.4 63.2 34.7 G CD38/CD52 TRAC 65.6 73.7 61.9 35.7 H CD38 TRAC CD52 61.2 69.8 58.3 28.3 I CD38 CD52 TRAC 59.2 73.4 56.9 28.4 Untransfected 0.1 - Electroporated T cells are platted back in tissue culture vessels in Xvivo (Lonza) media supplemented with 5% human AB serum and rIL2 (100 UI/ml) for a total of 15 days. Cells are passaged every 2 or 3 days for numeration and media renewal.
- Surface expression of TCR, 0038 and 0052 protein is measured by cytometry using specific antibodies and a Canto10 cytometer (Becton-Dickinson) at 013 post thawing. Furthermore, T cells growth is monitored from
Day 5 toDay 15 by Trypan blue exclusion cell numeration. - Table 2 presents the percentage of single negative T cells (CD38-, TCR- and CD52-) and the percentage of triple negative T cells (CD38-TCR-CD52-), according to the electroporation scheduling. These data show that 65 to 74% of TCR KO, 57 to 70% of 0052 KO, thus comparable among conditions. The best results is obtained when 0038 and TRAC TALEN are transfected 48h prior to CD52 TALEN transfection (Table 2, row E and
FIG. 12 , row E). The best results are obtained when CD38 and TRAC TALEN are transfected 48h prior to CD52 TALEN transfection, as for TCR and CD52 (Table 4, row E andFIG. 12 , row E). However, all tested conditions show little variation in the % of triple negative T cells ranging from 27% to 40%. Furthermore, the best percentage of triple knock out efficiency is obtained with sequential electroporation of CD38 and TRAC TALEN 48h prior to CD52 TALEN. - Having validated that sequential electroporation does not affect the efficacy of TALEN mediated gene knock out, we sought to see if cellular growth is impaired when cells are subjected to 2 electroporation shocks within 24 or 48h intervals. According to electroporation conditions, cell growth is measured from
day 5 toDay 13 post-thawing (FIG. 12 ). - At
day 15, the best growth rate is observed when the 3 TALEN are electroporated simultaneously. T cell growth curves for all sequential electroporation conditions are comparable with best results for conditions where a 48 h interval is performed between the two electroporation shocks (conditions C, E and G of Table 4 andFIG. 12 ). - These data indicate that cellular growth is similar for all tested sequential conditions with an advantage for T cells sequentially transfected with a 48h interval.
- Altogether, these data demonstrate that sequential electroporation does not affect KO efficiency and cellular growth.
- T-cells were cultured from PBMC and activated as described in Example 1, in order to produce [TCR]neg[PD1]neg[β2M]neg therapeutic immune cells endowed with a CAR directed against CD22 antigen.
- Furthermore, in order to analyze the impact of sequential TALEN electroporation on gene knock-out efficiency and triple KO CAR T cells activity, the cells were edited either simultaneously or sequentially with TALEN specific for TRAC gene (SEQ ID NO. 1 and 2), PD-1 (SEQ ID NO. 9 and 6) and B2M (beta-2-microglobulin, SEQ ID NO. 10 and 11). The sequential protocol is illustrated in
FIG. 13 . In both cases, T-cells were transduced with lentiviral particles for the expression of CAR targeting the antigen CD22 (SEQ ID NO. 12). - TALEN mRNA were generated from linearized plasmid DNA encoding each TALEN arm of interest. An in vitro RNA synthesis kit for RNA generation was used (Invitrogen #AMB1345-5). RNA was purified using the Qiagen RNAeasy Kit (#74106) and eluted into T solution from BTX (47-0002).
- Frozen human PBMCs from two different donors are thawed at 2×106 cells per ml on day prior activation and transduction step, in complete X-Vivo media (
X-VIVO 15, Lonza #04-418Q; 5% Human serum AB, Gemini #100-318; 20 ng/mL IL-2, Miltenyi #130-097-743;). One day post thawing, cells are transduced as described in (Poirot et al. (2015) Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies Cancer Res. 75: 3853-64) with lentiviral particles allowing the expression of a Chimeric Antigen Receptor targeting CD22 antigen containing a mimotope sequence (highlighted in bold in SEQ ID NO. 12). Cells are further activated the same day using anti CD3 and anti CD28 antibodies-coated beads (TransAct, Miltenyi) according to manufacturer's protocol for 4 days. - At
day 5 post thawing, T cells were electroporated with a dose response of mRNAs encoding TRAC TALEN (10 μg), PD-1 TALEN (from 30 μg to 70 μg) and B2M TALEN (from 30 μg to 70 μg) either simultaneously or sequentially with a 48 hour intervals using Cellectis proprietary AgilPulse electroporator and protocols. After each electroporation step cells were incubated for 15 minutes at 30° C. and then incubated at 37° C. Thirteen days post thawing positive T-cells were analyzed for triple KO efficacy by first re-stimulating a portion of T cells with TransACT to induce PD-1 expression. Two days later, re-stimulated cells were labeled with antibodies at a 1:50 dilution of each antibody for 15 minutes at 4° C. (Miltenyi; TCR #130-091-236, HLA-ABC #130-101-467, PD-1 #130-099-878). For all the different donors tested sequential editing provide the best triple KO efficacy ranging from 20 up to 40% (FIG. 14 ). - Triple KO T-cells were then enriched using a biotin and column based negative purification system for TCR and B2M dKO cells (Miltenyi; biotin-TCR #130-098-219, bitoin-HLA-ABC #130-101-463, Biotin beads #130-090-485, MS columns #130-042-201). Under this purification scheme, only TCR and B2M positive cells bind the MS column, and the TCR/B2M dKO cells of interest are enriched in the flowthrough fraction with 97% or greater purity. Triple KO CAR-T cells enriched for TCR/B2M dKO were further incubated for an additional two days before assessing CAR-T cells activity. On
day 15, T cells were analyzed for CD22 CAR cytotoxicity by co-culturing T cells with CD22 expressing Raji-Luciferase+ targets at effector to target ratios of 30:1, 15:1, 5:1, and 1:1 for 5 hours before luminescence was quantified using the ONE Glo luminescence kit (Promega).FIG. 15 demonstrates that triple KO CD22 CAR T were as active as their wild type counter part (non gene edited T-cells endowed with the same CAR CD22) -
TABLE 3 Sequence of TALEN ® used in experiments. Sequence Ref. name sequence Amino acid sequence of TALEN ® used in experiments TRAC TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Left NO. 1 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLL PVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETV QRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPE QVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQAL ETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAH GLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGG GKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLC QAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIA SHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALESIVAQ LSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSELEE KKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHL GGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEEN QTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNC NGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD TRAC TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Right NO. 2 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN GGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVA IASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQ RLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQ QVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQA LETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAH GLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPEQVVAIASHDG GKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLC QAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIAS NNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALESIVAQL SRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSELEE KKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHL GGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEEN QTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNC NGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD CD52 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Left NO. 3 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASH DGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETV QRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTP EQVVAIASNIGGKQALETVQALLPVLCQAHGLTPEQVVAIASHDGGKQA LETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAH GLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIG GKQALETVQALLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVL CQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIA SNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGRPALESIVAQ LSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSELEE KKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHL GGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEEN QTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNC NGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD CD52 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Right NO. 4 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLT PEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPEQVVAIASHDGGKQ ALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQA HGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLL PVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALESI VAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKS ELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYR GKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRY VEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLN HITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD PD-1 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Left NO. 5 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASGNGGKQALETVQALLPVLCQAHGLTPEQVVAIASH DGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGL TPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASGRGG KQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLC QAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIA SNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQR LLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQ VVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGRPALE SIVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLV KSELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGY RGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQR YVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLN HITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD PD-1 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Right NO. 6 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN GGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVV AIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGL TPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGK QALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQ AHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIAS NNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNGGKQALETVQRLLP VLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVV AIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALESI VAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKS ELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYR GKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRY VEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLN HITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD CD38 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Left NO. 7 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASH DGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLL PVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVV AIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALET VQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLT PEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQ ALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQA HGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHD GGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPV LCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVA IASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALESIV AQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSE LEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRG KHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYV EENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHI TNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD CD38 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Right NO. 8 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLP VLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVV AIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALETV QRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTP EQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQ ALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQA HGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASNI GGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLP VLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVV AIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGRPALESIV AQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSE LEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRG KHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYV EENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHI TNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD PD1 TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF Left 2 NO. 9 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASKLGGKQALETVQALLPVLCQAHGLTPEQVVAIASHD GGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPV LCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAI ASHDGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQ RLLPVLCQAHGLTPQQVVAIASYKGGKQALETVQRLLPVLCQAHGLTPQ QVVAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQA LETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAH GLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNN GGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPV LCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAI ASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGRPALESIVA QLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSEL EEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVE ENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHIT NCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD B2M TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF left NO. 10 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVV AIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALET VQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTP QQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQ ALETVQRLLPVLCQAHGLTPQQVVAIASNGGGKQALETVQRLLPVLCQA HGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPQQVVAIASN GGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLL PVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQV VAIASNGGGKQALETVQRLLPVLCQAHGLTPQQVVAIASNGGGRPALES IVAQLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVK SELEEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYR GKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRY VEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLN HITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD B2M TALEN SEQ ID MGDPKKKRKVIDIADLRTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGF right NO. 11 THAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGAR ALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGA PLNLTPEQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASN NGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLP VLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPQQVV AIASNGGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHDGGKQALETV QRLLPVLCQAHGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTP EQVVAIASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNNGGKQ ALETVQRLLPVLCQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQA HGLTPEQVVAIASHDGGKQALETVQRLLPVLCQAHGLTPEQVVAIASHD GGKQALETVQRLLPVLCQAHGLTPEQVVAIASNIGGKQALETVQALLPVL CQAHGLTPQQVVAIASNNGGKQALETVQRLLPVLCQAHGLTPEQVVAI ASNIGGKQALETVQALLPVLCQAHGLTPQQVVAIASNGGGRPALESIVA QLSRPDPALAALTNDHLVALACLGGRPALDAVKKGLGDPISRSQLVKSEL EEKKSELRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGK HLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVE ENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHIT NCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKFNNGEINFAAD CD22 CAR SEQ ID MALPVTALLLPLALLLHAARPGGGGSCPYSNPSLCSGGGGSGGGGSQV NO. 12 QLQQSGPGLVKPSQTLSLTCAISGDSVSSNSAAWNWIRQSPSRGLEWL GRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVTPEDTAVYYCA REVTGDLEDAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQS PSSLSASVGDRVTITCRASQTIWSYLNWYQQRPGKAPNLLIYAASSLQSG VPSRFSGRGSGTDFTLTISSLQAEDFATYYCQQSYSIPQTFGQGTKLEIKSD PGSGGGGSCPYSNPSLCSGGGGSELPTQGTFSNVSTNVSPAKPTTTACP YSNPSLCAPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDF ACDIYIWAPLAGTCGVLLLSLVITLYCRRGRKKLLYIFKQPFMRPVQTTQE EDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREE YDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKG ERRRGKGHDGLYQGLSTATKDTYDALHMQALPPRE -
TABLE 4 Cluster of differentiation (CD) antigen markers of various cancers found to be expressed on the surface of T-cells Antigen Other Names Structure main Distribution Function CD1a T6 IgSF, MHC-like cortical thymocytes, Langerhans cells, DC antigen presentation, with beta2m CD1b T6 IgSF, MHC-like cortical thymocytes, Langerhans cells, DC antigen presentation, with beta2m CD1c T6 IgSF, MHC-like cortical thymocytes, Langerhans cells, DC, B antigen presentation, with beta2m subset CD1d IgSF, MHC-like intestinal epith, B subset, monolow, DC antigen presentation, with beta2m CD3 gamma, T3 IgSF T, thymocyte subset with TCR, TCR surface expression/signal CD3 delta transduction CD3 epsilon T3 IgSF T, thymocyte subset with TCR, TCR surface expression/signal transduction CD4 T4 IgSF thymocyte subset, T subset, mono, mac MHC class II coreceptor, HIV receptor, T cell differentiation/activation CD5 T1, Tp67 Scavenger R SF thymocytes, T, B subset, B-CLL CD72 receptor, TCR or BCR signaling, T-B interaction CD7 IgSF hematopoietic progenitors, thymocytes, T, T costimulation NK CD8a T8, Leu-2 IgSF thymocyte subset, T subset, NK MHC class I coreceptor, receptor for some mutated HIV-1, T cell differentiation/activation CD8b IgSF thymocyte subset, T subset CD9 p24, MRP-1 TM4SF pre-B, eosinophils, basophils, platelets, Tact cellular adhesion and migration CD10 CALLA, NEP, type II TM B precursors, T precursors, neutrophils zinc-binding metalloproteinase, B cell gp100 development CD11a LFA-1, integrin Integrin family lymph, gran, mono, mac CD11a/CD18 receptor for ICAM-1, -2, -3, alphaL intercellular adhesion, T costimulation CD11b Mac-1, integrin Integrin family myeloid cells, NK binds CD54, ECM, iC3b alphaM CD11c p150, 95, CR4, Integrin family DC, myeloid cells, NK, B, T subset binds CD54, fibrinogen and iC3b integrin alphaX CD13 Aminopeptidase type II TM myeloid cells zinc-binding metalloproteinase, antigen N, APN processing, receptor for corona virus strains CD14 LPS-R GPI-linked mono, mac, Langerhans cells, granlow receptor for LPS/LBP, LPS recognition CD15 Lewis-x, Lex CHO neutrophils, eosinophils, mono adhesion CD16a FcgammaRIIIA IgSF neutrophils, mac, NK component of low affinity Fc receptor, phagocytosis and ADCC CD16b FcgammaRIIIB IgSF neutrophils component of low affinity Fc receptor, phagocytosis and ADCC CD20 B1, Bp35 TM4SF B, T subset B cell activation CD21 C3DR, CR2, CCRSF B, FDC, T subset complement C3d and EBV receptor, complex EBV-R with CD19 and CD81, BCR coreceptor CD22 BL-CAM, IgSF, B adhesion, B-mono, B-T interactions Siglec-2 sialoadhesins CD23 FcepsilonRII C-type lectin B, activated mac, eosinophils, FDC, platelets CD19-CD21-CD81 receptor, IgE low affinity receptor, signal transduction CD24 BA-1 GPI-linked thymocytes, erythrocytes, peripheral lymph, binds P-selectin myeloid CD25 Tac, p55 type I TM Tact, Bact, lymph progenitors IL-2Ralpha, with IL-2Rbeta and gamma to form high affinity complex CD31 PECAM-1 IgSF mono, platelets, gran, endoth, lymph subset CD38 receptor, adhesion CD33 p67, Siglec-3 IgSF, myeloid progenitors, mono, gran, DC, mast adhesion sialoadhesins cells, Tact CD37 TM4SF B, Tlow, granlow signal transduction CD38 T10 variable levels on majority of hematopoietic ecto-ADP-ribosyl cyclase, cell activation cells, high expression on plasma cells, B and Tact CD40 TNFRSF B, mono, mac, FDC, endoth, T subset CD154 receptor, B differentiation/costimulation, isotype-switching, rescues B cells from apoptosis CD43 Leukosialin, Sialomucin, type leukocytes, except resting B, plateletslow inhibition of T cell interaction, CD54R, adhesion sialophorin I TM CD44 H-CAM, Pgp-1 hyaladherin hematopoietic and non-hematopoietic cells, binds hyaluronic acid, adhesion family except platelets, hepatocytes, testis CD45 LCA, T200, hematopoietic cells, multiple isoforms from tyrosine phosphatase, enhanced TCR & BCR B220 alternative splicing signals CD45RA B, T subset(naive), mono exon A isoforms of CD45 CD45RB T subset, B, mono, mac, gran exon B isoforms of CD45 CD45RO Tact, memory T, B subset, mono, mac, gran isoform of CD45 lacking A, B, C exons CD46 MCP CCRSF nucleated cells membrane cofactor protein, binds C3b & C4b allowing degradation by Factor I, measles virus receptor CD47 IAP IgSF hematopoietic cells, epith, endoth, fibroblasts, leukocyte adhesion, migration, activation other tissues CD48 Blast-1 IgSF broad, all leukocytes cell adhesion CD52 CAMPATH-1 thymocytes, T, B (not plasma cells), mono, mac CD53 TM4SF leukocytes, DC, osteoblasts, osteoclasts signal transduction CD55 DAF GPI-linked hematopoietic, endoth binds C3b, complement regulation CD56 NCAM IgSF NK, T subset, neurons, some large granular adhesion lymphocyte leukemias, myeloid leukemias CD57 HNK-1, Leu-7 NK subset, T subset CD58 LFA-3 IgSF hematopoietic, non-hematopoietic cells CD2 receptor, adhesion CD59 Protectin, MAC- GPI-linked hematopoietic, non-hematopoietic cells binds complement C8 and C9, blocks assembly inhibitor of membrane attack complex CD60a GD3 CHO T subset, platelets, thymic epith, astrocytes costimulation CD63 LIMP, LAMP-3 TM4SF activated platelets, mono, mac lysosomal membrane protein, moves to cell surface after activation CD68 Macrosialin, Sialomucin intracellularly in mono, mac, neutrophils, basophils, large lymph, mast cells, gp110 DC, myeloid progenitors, liver CD69 AIM C-type lectin Tact, B, NK and gran, thymocytes, platelets, signal transduction Langerhans cells CD70 Ki-24 TNFSF Bact and Tact CD27 ligand, T and B cell costimulation CD74 Ii, invariant B, mac, mono, Langerhans cells, DC, Tact MHC class II traffic and function chain CD79a Iga IgSF B component of BCR, BCR surface expression and signal transduction CD79b Igb IgSF B component of BCR, BCR surface expression and signal transduction CD81 TAPA-1 TM4SF T, B, NK, thymocytes, DC, endoth, fibroblast, complex with CD19 & CD21, signaling, T neuroblastomas, melanomas costimulation CD82 R2 TM4SF leukocytes signal transduction CD83 HB15 IgSF Bact and Tact, DC, Langerhans cells CDw84 mono, platelets, B, T subset, mac subset CD86 B70, B7-2 IgSF mono, DC, Bact and Tact binds to CD28, CD152, T costimulation CD87 UPA-R GPI-linked gran, mono, NK, Tact, endoth, fibroblasts urokinase plasminogen activator receptor, inflammatory cell invasion, metastasis CD90 Thy-1 IgSF, GPI-linked CD34+ hematopoietic subset, neurons hematopoietic stem cell and neuron differentiation CD94 KP43 C-type lectin NK, T subset complex with NKG2, inhibits NK function CD95 Apo-1, Fas TNFRSF lymph (high upon activation), mono, FasL (CD178) receptor, apoptosis neutrophils CD96 TACTILE IgSF NK, Tact adhesion of activated T and NK CD97 TM7SF Bact and Tact, mono, gran CD98 4F2 T, B, NK, gran, all human cell lines cellular activation CD99 MIC2, E2 leukocytes T cell activation, adhesion CD100 hematopoietic cells except immature bone cell adhesion, cellular activation marrow cells, RBC and platelets CD103 HML-1, alpha6, Integrin family intraepithelial lymph, lymph subset, activated with integrin beta7, binds E-cadherin, lymph integrin alphaE lymph homing/retention CD107a LAMP-1 activated platelets, T, endoth, metastatic tumors a lysosomal membrane protein CD107b LAMP-2 activated platelets, T, endoth, metastatic tumors a lysosomal membrane protein CD109 Tact and platelets, CD34+ subset, endoth CD123 IL-3R CRSF lymph subset, basophils, hematopoietic IL-3Ralpha, with CDw131 progenitors, mac, DC, megakaryocytes CD146 MUC18, S-endo IgSF endoth, melanomas, FDC, Tact adhesion CD154 CD40L, gp39, TNFSF Tact CD40 ligand, B and DC costimulation TRAP CD158a p58.1 IgSF, KIR family NK subset, T subset inhibition of NK cell cytolytic activity, MHC class-I specific NK receptor CD158b p58.2 IgSF, KIR family NK subset, T subset inhibition of NK cell cytolytic activity, MHC class-I specific NK receptor CD163 130 kD Scavenger mono, mac receptor SF CD164 MGC-24 epith, mono, hematopoietic progenitor cell-stromal cell interaction lymphlow, bone marrow stromal cells, CD34+ erythroid progenitors CD168 RHAMM mono, T subset, thymocyte subset, adhesion, tumor migration, metastasis intracellularly in breast cancer cells CD171 L1 IgSF CNS, PNS, glial cells, mono, T subset, B, DC, kidney morphogenesis, lymph node architecture, several human tumor cells T costimulation, neurohistogenesis, homotypic interaction, binds CD9, CD24, CD56, CD142, CD166, integrins CD177 NB1 neutrophil subset CD178 FasL, CD95L TNFSF Tact, testis CD95 ligand, apoptosis, immune privilege, soluble form in serum CD180 RP-105 LRRF, TLR B subset, mono, DC B cell activation, LPS signaling, with MD-1 family CD182 CXCR2, IL-8RB GPCR1 family neutrophils, basophils, NK, T subset, mono binding of IL-8 induces chemotaxis of neutrophils CD185 CXCR5, BLR1 GPCR1 family mature B and Burkitt Lymphoma cells with chemokine BLC, possible regulatory function in Burkitt Lymphomagenesis and/or B differentiation, activation of mature B CD191 CCR1, MIP- GPCR1 family T, mono, stem cell subset binds C-C type chemokines and transduces 1alphaR, signal by increasing intracellular calcium ion RANTES-R levels CD193 CCR3, CKR3 GPCR1 family eosinophils, lower expression in neutrophils binds eotaxin, eotaxin-3, MCP-3, MCP-4, and mono, T subset RANTES & MIP-1 delta, alternative coreceptor with CD4 for HIV-1 infection. CD196 CCR6, LARC GPCR1 family T subset, B, DC subset binds MIP-3alpha/LARC receptor, DRY6 CD197 CCR7 T subset, DC Subset 6Ckine and MIP-2beta receptor CD200 OX-2 thymocytes, endoth, B, Tact inhibition of immune response CD209 DC-SIGN DC subset ICAM-3 receptor, HIV-1 binding protein CD227 MUC1, EMA Mucin family, epith, stem cell subset, FDC, mono, B subset, adhesion, signaling, binds CD169, CD54, & type I TM some myelomas selectins CD231 TALLA-1, A15 TM4SF T leukemias, neuroblastomas, brain neurons marker for T cell acute lymphoblastic leukemia CD246 ALK, Ki-1 anaplastic T cell leukemias, small intestine, brain development, implicated in ALK testis, brain, not on normal lymph lymphomas CD254 TRANCE, TNFSF lymph node & BM stroma Tact binds OPG and RANK, osteoclast differentiation, RANKL, OPGL enhances DC to stimulate naïve-T proliferation CD263 TRAIL-R3, peripheral blood lymphocytes receptor for TRAIL but lacks death domain DcR1, LIT CD272 BTLA IgSF Tact, B, remains on Th1 HVEM receptor, inhibitory response CD273 B7DC, PD-L2, IgSF DC subset, mono, mac PD-1 receptor, costimulation or suppression of T PDCD1L2 proliferation CD276 B7-H3 B7 Family, ASV in vitro cultured DC and mono, Tact, mammary costimulation, T activation tissue CD277 BT3.1, B7/BT family, T, B, NK, mono, DC, endoth, CD34+ cells, T activation butyrophilin ASV tumor cell lines SF3 A1, BTF5 CD279 PD1, SLEB2 Tact and Bact B7-H1 & B7-DC receptor, autoimmune disease and peripheral tolerance CD298 Na+/K+- broad transport sodium & potassium ions across ATPase beta3 membrane subunit CD300a CMRF35H, IgSF, ASV NK, mono, neutrophils, T and B subset and unknown IRC1, IRp60 lymphocytic cell lines, AML CD300c CMRF35A, LIR IgSF mono, neutrophils, monocytic cell lines, B & T unknown subsets CD304 BDCA4, semaphorin neurons, CD4+/CD25+ Treg, DC, endothelial interacts with VEGF165 & semaphorins, co- neuropilin 1 family and tumor cells receptor with plexin, axonal guidance, angiogenesis, cell survival, migration CD305 LAIR1 IgSF, ASV NK, B, T, mono inhibitory receptor on NK and T cells CD314 NKG2D, KLR Type II lectin-like NK, CD8+ activated, NK1.1+ T, some myeloid binds MHC class I, MICA, MICB, Rae1 & receptor cells ULBP4, activates cytolysis and cytokine production, costimulation CD317 BST2, HM1.24 Type II B, T, NK, mono, DC, fibroblast cell line, pre-B cell growth, overexpressed in multiple myeloma myeloma CD319 CS1, CRACC, SLAM receptor B Cells, Dendritic Cells, NK, NKT multiple myeloma SLAMF7 family
Claims (12)
1. An mRNA molecule encoding a PD-1-targeting TALEN comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 9.
2. The mRNA molecule of claim 1 , encoding the amino acid sequence of SEQ ID NO: 5.
3. The mRNA molecule of claim 1 , encoding the amino acid sequence of SEQ ID NO: 6.
4. The mRNA molecule of claim 1 , encoding the amino acid sequence of SEQ ID NO: 9.
5. A population of gene-edited primary immune cells produced by transiently expressing a rare-cutting sequence-specific endonuclease reagent that is a PD-1-targeting TALEN in the primary immune cells, wherein the PD-1-targeting TALEN comprises the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 9.
6. A population of gene-edited primary immune cells produced by transiently expressing a pair of PD-1-targeting TALEN monomers in the primary immune cells, wherein the PD-1-targeting TALEN monomers comprise the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 9.
7. The population of gene-edited primary immune cells of claim 6 , wherein the pair of PD-1 targeting TALEN monomers comprise a TALEN monomer having the amino acid sequence of SEQ ID NO: 5 and a TALEN monomer having the amino acid sequence of SEQ ID NO: 6.
8. The population of gene-edited primary immune cells of claim 6 , wherein the pair of PD-1 targeting TALEN monomers comprise a TALEN monomer having the amino acid sequence of SEQ ID NO: 9 and a TALEN monomer having the amino acid sequence of SEQ ID NO: 6.
9. The population of gene-edited primary immune cells of claim 5 , wherein the primary immune cells are T cells.
10. The population of gene-edited primary immune cells of claim 5 , wherein the primary immune cells are NK cells.
11. The population of gene-edited primary immune cells of claim 5 , wherein the primary immune cells are obtained from a tumor.
12. The population of gene-edited primary immune cells of claim 5 , wherein the primary immune cells are tumor infiltrating lymphocytes (TILs).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/303,080 US20230287454A1 (en) | 2016-07-06 | 2023-04-19 | Sequential gene editing in primary immune cells |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201670503 | 2016-07-06 | ||
DKPA201670503 | 2016-07-06 | ||
PCT/EP2017/066355 WO2018007263A1 (en) | 2016-07-06 | 2017-06-30 | Sequential gene editing in primary immune cells |
US201916314697A | 2019-01-02 | 2019-01-02 | |
US17/817,877 US11674155B2 (en) | 2016-07-06 | 2022-08-05 | Sequential gene editing in primary immune cells |
US18/303,080 US20230287454A1 (en) | 2016-07-06 | 2023-04-19 | Sequential gene editing in primary immune cells |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/817,877 Division US11674155B2 (en) | 2016-07-06 | 2022-08-05 | Sequential gene editing in primary immune cells |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230287454A1 true US20230287454A1 (en) | 2023-09-14 |
Family
ID=56411352
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/314,697 Active 2037-09-14 US11466291B2 (en) | 2016-07-06 | 2017-06-30 | Sequential gene editing in primary immune cells |
US17/817,877 Active US11674155B2 (en) | 2016-07-06 | 2022-08-05 | Sequential gene editing in primary immune cells |
US18/303,080 Pending US20230287454A1 (en) | 2016-07-06 | 2023-04-19 | Sequential gene editing in primary immune cells |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/314,697 Active 2037-09-14 US11466291B2 (en) | 2016-07-06 | 2017-06-30 | Sequential gene editing in primary immune cells |
US17/817,877 Active US11674155B2 (en) | 2016-07-06 | 2022-08-05 | Sequential gene editing in primary immune cells |
Country Status (6)
Country | Link |
---|---|
US (3) | US11466291B2 (en) |
EP (1) | EP3481861A1 (en) |
JP (2) | JP7195154B2 (en) |
AU (1) | AU2017291851B2 (en) |
CA (1) | CA3029761A1 (en) |
WO (1) | WO2018007263A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
AU2018229351B2 (en) | 2017-02-28 | 2024-01-04 | Vor Biopharma, Inc. | Compositions and methods for inhibition of lineage specific proteins |
JP7314115B2 (en) | 2017-03-31 | 2023-07-25 | セレクティス ソシエテ アノニム | Universal anti-CD22 chimeric antigen receptor engineered immune cells |
CN113423725A (en) | 2018-08-28 | 2021-09-21 | Vor生物制药股份有限公司 | Genetically engineered hematopoietic stem cells and uses thereof |
WO2020102701A1 (en) * | 2018-11-16 | 2020-05-22 | Rapa Therapeutics, Llc | Methods for the manufacture of th1/tc1 phenotype t cells |
AU2020384951A1 (en) * | 2019-11-13 | 2022-05-19 | Crispr Therapeutics Ag | Therapy for hematopoietic cell malignancies using genetically engineered T cells targeting CD70 |
JP2023501602A (en) * | 2019-11-13 | 2023-01-18 | クリスパー セラピューティクス アクチェンゲゼルシャフト | Renal Cell Carcinoma (RCC) Therapy Using Genetically Engineered T Cells Targeting CD70 |
KR20220101128A (en) * | 2019-11-13 | 2022-07-19 | 크리스퍼 테라퓨틱스 아게 | CD70+ Solid Tumor Therapy Using Genetically Engineered T Cells Targeting CD70 |
CA3177093A1 (en) | 2020-05-06 | 2021-11-11 | Cellectis S.A. | Methods for targeted insertion of exogenous sequences in cellular genomes |
TW202305118A (en) | 2021-03-23 | 2023-02-01 | 美商艾歐凡斯生物治療公司 | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
BR112023022492A2 (en) * | 2021-04-29 | 2024-01-09 | Maxcyte Inc | SEQUENTIAL ELETROPORATION METHODS |
CA3228272A1 (en) * | 2021-08-02 | 2023-02-09 | Vor Biopharma Inc. | Compositions and methods for gene modification |
CN115171916B (en) * | 2022-07-20 | 2023-04-07 | 广州蓝勃生物科技有限公司 | Experimental method, device, computer equipment and storage medium for reagent development |
WO2024055017A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
WO2024055018A1 (en) | 2022-09-09 | 2024-03-14 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1/tigit talen double knockdown |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
DE60130435T2 (en) | 2000-02-24 | 2009-07-23 | Invitrogen Corp., Carlsbad | SIMULTANEOUS STIMULATION AND CONCENTRATION OF CELLS |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
EP1620537B1 (en) | 2003-03-14 | 2012-10-24 | Cellectis SA | Large volume ex vivo electroporation method |
AU2010327998B2 (en) | 2009-12-10 | 2015-11-12 | Iowa State University Research Foundation, Inc. | TAL effector-mediated DNA modification |
US10391126B2 (en) * | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
IN2014DN10991A (en) | 2012-05-25 | 2015-09-25 | Cellectis | |
KR102141259B1 (en) | 2012-09-04 | 2020-08-05 | 셀렉티스 | Multi-chain chimeric antigen receptor and uses thereof |
DK3309248T3 (en) | 2013-05-29 | 2021-08-02 | Cellectis | Method for manipulating T cells for immunotherapy using an RNA-guided CAS nuclease system |
EP3041940B1 (en) | 2013-09-02 | 2020-10-28 | Cellectis | Rna based method to obtain stably integrated retroviral vectors |
CA2931267C (en) * | 2013-11-22 | 2023-08-15 | Cellectis | A method of engineering allogenic and drug resistant t-cells for immunotherapy |
ES2842212T3 (en) | 2015-01-26 | 2021-07-13 | Cellectis | Anti-CLL1 Specific Single Chain Chimeric Antigen Receptors (scCAR) for Cancer Immunotherapy |
US20180171298A1 (en) * | 2015-06-30 | 2018-06-21 | Cellectis | Methods for improving functionality in nk cell by gene inactivation using specific endonuclease |
US11466291B2 (en) * | 2016-07-06 | 2022-10-11 | Cellectis | Sequential gene editing in primary immune cells |
-
2017
- 2017-06-30 US US16/314,697 patent/US11466291B2/en active Active
- 2017-06-30 WO PCT/EP2017/066355 patent/WO2018007263A1/en unknown
- 2017-06-30 CA CA3029761A patent/CA3029761A1/en active Pending
- 2017-06-30 JP JP2018568746A patent/JP7195154B2/en active Active
- 2017-06-30 AU AU2017291851A patent/AU2017291851B2/en active Active
- 2017-06-30 EP EP17740642.8A patent/EP3481861A1/en active Pending
-
2022
- 2022-08-05 US US17/817,877 patent/US11674155B2/en active Active
- 2022-08-25 JP JP2022133783A patent/JP2022169705A/en active Pending
-
2023
- 2023-04-19 US US18/303,080 patent/US20230287454A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20200208174A1 (en) | 2020-07-02 |
EP3481861A1 (en) | 2019-05-15 |
AU2017291851B2 (en) | 2022-10-13 |
AU2017291851A1 (en) | 2019-02-07 |
JP2022169705A (en) | 2022-11-09 |
US11674155B2 (en) | 2023-06-13 |
WO2018007263A1 (en) | 2018-01-11 |
CA3029761A1 (en) | 2018-01-11 |
JP2019520076A (en) | 2019-07-18 |
JP7195154B2 (en) | 2022-12-23 |
US11466291B2 (en) | 2022-10-11 |
US20230087122A1 (en) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11674155B2 (en) | Sequential gene editing in primary immune cells | |
JP6998917B2 (en) | Methods for Manipulating Allogeneic and Highly Active T Cells for Immunotherapy | |
JP6854307B2 (en) | CD19-specific chimeric antigen receptor and its use | |
JP7033453B2 (en) | How to Improve NK Cell Functionality by Gene Inactivation Using Specific Endonucleases | |
CN106103475B (en) | Method for generating T cells compatible with allogeneic transplantation | |
AU2015245469B2 (en) | Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironment | |
AU2015239069B2 (en) | CD33 specific Chimeric Antigen Receptors for cancer immunotherapy | |
WO2019089884A2 (en) | Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy | |
JP2016524464A (en) | Method for manipulating highly active T cells for immunotherapy | |
JP2017527289A (en) | Trophoblast glycoprotein (5T4, TPBG) specific chimeric antigen receptor for cancer immunotherapy | |
US20230248825A1 (en) | T-cells expressing immune cell engagers in allogenic settings | |
US11903968B2 (en) | Engineered immune cells resistant to tumor microenvironment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |